THERAPEUTIC APPLICATIONS IN THE CARDIOVASCULAR FIELD OF QUINAZOLINEDIONE DERIVATIVES A subject-matter of the invention is the use of quinazolinedione derivatives as medicaments or for manufacturing a medicament intended for the treatment and/or prevention of at least one cardiovascular disease. The invention relates more particularly to the use of quinazolinedione derivatives capable of acting as inhibitors of phosphodiesterase 7 (PDE7), indeed even, for some of these derivatives, capable of also acting as inhibitors of phosphodiesterase 8 (PDE8), it being known that it is not ruled out for these same quinazolinedione derivatives also to be capable of acting via other biological/biochemical routes on the cardiovascular system, with the aim of treating one or more cardiovascular condition(s) and/or preventing the appearance of such condition(s). Phosphodiesterases (PDEs) are intracellular enzymes responsible for the hydrolysis of cAMP (cyclic adenosine 3',5'-monophosphate) and cGMP (cyclic guanosine 3',5'-monophosphate) secondary messengers to give inactive 5'-monophosphate nucleotides. cAMP and cGMP play an essential role in cell signalling pathways and are involved in numerous physiological processes. The inhibition of phosphodiesterases is reflected by an increase in intracellular concentrations of cAMP and cGMP, resulting in the specific activation of phosphorylation pathways involved in varied functional responses. The increase in the intracellular concentrations of cAMP or of cGMP using selective inhibitors of phosphodiesterases appears to be a promising approach in the treatment of various diseases (Bender and Beavo, Pharmacol. Rev., (2006) 58, 488-520). The inhibitors of phosphodiesterases are thus of interest as therapeutic agents and as pharmacological tools. To date, eleven families of phosphodiesterases have been identified. They are distinguished by their primary structure, their substrate specificity and their sensitivity with regard to various effectors and inhibitors specific for PDEs. Each family is composed of one or more genes which are expressed in various tissues in the form of splicing variants (Bender and Beavo, Pharmacol. Rev, (2006) 58, 488-520; Lugnier, Pharmacol. Therapeut., (2006) 109, 366-398). PDE4, PDE7 and PDE8 specifically hydrolyse cAMP and PDE5, PDE6 and PDE9 specifically hydrolyse cGMP. The family PDE7 is represented by the isoforms PDE7A and PDE7B originating from two distinct genes. Human PDE7A (Michaeli et al., J. Biol. Chem, (1993) 268, 12925-12932; Han et al, J. Biol. Chem., (1997) 272, 16152-16157; Wang et al., Biochem. Biophys. Res. Commun, (2000) 276, 1271-1277) and human PDE7B (Sasaki et al, Biochem. Biophys. Res. Commun, (2000), 271, 575-583; Gardner et al, Biochem. Biophys. Res. Commun, (2000) 272, 186-192) selectively hydrolyse cAMP with Michaelis constants (Km) of 0.1 to 0.2 pM and 0.13 to 0.2 uM respectively. The catalytic part of PDE7B exhibits approximately 67% homology with that of PDE7A. Three splicing variants are known for PDE7A. PDE7A1 and PDE7A3 are expressed mainly in the cells of the immune system and of the lungs, while PDE7A2 is above all expressed in the muscles of the skeleton, the heart and the kidneys. For PDE7B, three variants have also recently been identified (Giembycz and Smith, Drugs Future, (2006)31,207-229). The tissue distribution profiles for PDE7A and PDE7B are very different, suggesting that these two isoforms have distinct functions from the physiological viewpoint. PDE7A is copiously expressed in haematopoietic cells, the lungs, the placenta, the spleen, the muscles of the skeleton, the heart, Leydig cells, the collecting tubes of the kidneys, and the adrenal glands. Strong expression of PDE7B is detected in the pancreas, the heart, the thyroid and the muscles of the skeleton (Giembycz and Smith, Drugs Future, (2006) 31, 207-229; Wang etal., Biochem. Biophys. Res. Commun. (2000), 276, 1271-1277). Coexpression of the messenger RNAs (mRNAs) of PDE7A and PDE7B is observed in some tissues. This is the case in the osteoblasts (Ahlstrom et al., Cell Mol. Biol. Lett., (2005) 10, 305-319) and in some regions of the brain: several areas of the cortex, the dentate gyrus, the majority of the components of the olfactory system, the striatum, numerous nuclei of the thalamus and the pyrimidal cells of the hippocampus (Miro et al., Synapse, (2001) 40, 201-214; Reyes-lrisarri et al., Neuroscience, (2005) 132, 1173-1185). In contrast, in some areas of the brain, only one of the two isoforms is expressed. Thus, only the mRNAs of PDE7A are present in many nuclei of the brain stem. Likewise, the mRNAs of PDE7B are present at high concentrations in the nucleus accombens and the dorsal motor nucleus of the vagus nerve, while the mRNAs of PDE7A are not detected there (Miro et al„ Synapse, (2001) 40, 201-214; Reyes-lrisarri et al., Neuroscience, (2005) 132, 1173-1185). A subject-matter of the present invention is in particular therapeutic applications of quinazolinedione derivatives, which can prove to be powerful inhibitors of PDE7, or of PDE7 and of PDE8, according to the derivatives, or which can act by other biological routes. The invention relates to the use of a compound corresponding to the following general formula (I): in which — A represents an aryl group or a heteroaryl group; — R1represents: ■ a hydrogen atom, ■ -C(O)R in which R is a hydrogen atom, a (C1-C6) alkoxy group, an aryl group, a (C3-C6) cycloalkyl group or a (C1-C6) alkyl group, the said alkyl optionally being substituted by: . one or more hydroxyl group(s), . a benzyloxy group, . a (C1-C6) alkoxy group, optionally substituted by an aryl, or . a (C3-C6) cycloalkyl group, ■ an optionally substituted (C1-C6) alkyl group; — R2 represents: ■ a hydrogen atom, ■ a halogen atom, ■ a cyano group, ■ a nitro group, ■ a (C1-C6) alkyl group optionally substituted by an -NH2 or else by an -NHC(O)Rb group, with Rb as defined below, ■ an -ORa group in which Ra represents: . a hydrogen atom, . a (C1-C6) alkyl group optionally substituted by one or more halogen atom(s), by one or more hydroxyl group(s), by an aryl group and/or by one or more cyano group(s), . a (C2-C6) alkynyl group, . an aryl group; — R3 represents: ■ a hydrogen atom, ■ a halogen atom, ■ a hydroxyl group, ■ a cyano group, ■ an -SCF3 group, ■ a nitro group, ■ an -S(O)0-2-alkyl group, an -S(O)0-2-heterocycloalkyl group, an -O-SO2-aryl group optionally substituted by one or more halogen atom(s); ■ an -alkylaminoalkyl or -cycloalkylaminoalkyl group, each optionally substituted on the end alkyl, ■ an optionally substituted sulphonamide group, ■ an aryl group or a heteroaryl group, the said group being monocyclic or polycyclic and in addition optionally being substituted by a (C1-C6) alkyi group, by one or more halogen atom(s) or by a (C1-C6) alkoxy group, ■ a heterocycloalkyl group optionally substituted by a (C1-C6) alkyl group, ■ a (C1-C6) alkyl group optionally substituted by: - one or more halogen atom(s), - an aryl group which can be substituted by one or more halogen atom(s) or by one or more hydroxyl group(s), - a heteroaryl group, - one or more hydroxyl group(s) which can be substituted by an aryl group itself optionally substituted by one or more halogen atom(s), or - a heterocycloalkyl group optionally substituted by a CO(O)Ra group or by a (C1-C6) alkyl group, Ra being as defined above, ■ a -C(O)NRbRc group, with Rb and Rc being as defined below, ■ a -C(O)ORc group or an -O-C(O)ORc group, with Rc being as defined below, ■ a (C1-C6) alkoxy group, optionally substituted by - an aminoalkyl group, - an aminocycloalkyl group, - a cycloalkyl group, - a heterocycloalkyl group, - a monocyclic or polycyclic heteroaryl group, - one or more hydroxyl group(s), - one or more halogen atom(s), - a (C1-C6) alkoxy group, - a -C(O)ORc group, with Rc being as defined below, - a -C(O)NRbRc group, with Rb and Rc being as defined below, and/or -an aryl group, itself optionally substituted by one or more halogen atom(s), a cyano group, a (C1-C6) alkoxy group, an -O-haloalkyl group and/or a haloalkyl group, ■ an -O-cycloalkyl group, an -O-aryl group or an -O-heterocycloalkyl group, each optionally substituted by -an aryl group, itself optionally substituted by one or more halogen atom(s) or by a (C1-C6) alkyl group, - one or more halogen atom(s), and/or - a (C1-C6) alkyl group, which can itself be substituted by an aryl group, ■ an -NH-CO-NH-aryl group, an -NH-CO-NH-heteroaryl group or an -NH-CO- NH-(C1-C6) alkyl group, each optionally being substituted by one or more halogen atom(s), by a cyano group, by a nitro group, by one or more hydroxyl group(s) or by a (C1-C6) alkoxy group, ■ an -N-(C1-C6) alkyl group, it being possible for the (C1-C6) alkyl group to be substituted by one or more aryl group(s) optionally substituted by one or more halogen atom(s) and/or by an SO2 group, ■ an -NH-CO-aryl group or an -NH-CO-heteroaryl group, each optionally being substituted by one or more halogen atom(s); or else R3 forms, with A, a polycyclic heteroaryl group optionally substituted by a (C1-C6) alkoxy group or a (C1-C6) alkyl group optionally substituted by an aryl group which can itself be substituted by one or more halogen atom(s); — R4 represents a hydrogen atom or a (C1-C6)alkyl group; — Rb represents: . a hydrogen atom, . a (C1-C6) alkyl group optionally substituted by one or more halogen atom(s), by one or more hydroxyl, cyano, amino, heterocycloalkyl or (C1-C6) alkoxy group(s) or by an aryl group optionally substituted by one or more halogen atom(s), . a (C3-C6) cycloalkyl group, . a (C2-C6) alkynyl group, . a (C1-C6) alkoxy group, . an aryl group optionally substituted by one or more halogen atom(s); — Rc represents a hydrogen atom or a (C1-C6) alkyl group optionally substituted by one or more halogen atom(s); or then Rb and Rc form, together with the nitrogen atom to which they are attached, a polycyclic heteroaryl group or a heterocycloalkyl group; — m and n represent, independently of one another, the value 0, 1 or 2, it being understood that m+n<3; — p and p' represent, independently of one another, the value 1, 2 or 3, it being understood that, when p is greater than or equal to 2, then the R2 groups are on separate carbon atoms and can be different from one another and, when p' is greater than or equal to 2, then the R3 groups are on separate carbon atoms and can be different from one another; — q represents the value 0 or 2, it being understood that, when q = 0, then the nitrogenous heterocyclic group attached to the nitrogen situated in the 1 position of the 2,4-dioxo-1,2,3,4-tetrahydroquinazoline ring system is no longer bridged and is of the type: with R-1, R4, m and n as defined above, — r represents the value 0 or 1, as medicament or for the preparation of a medicament which are intended to treat at least one cardiovascular disease and/or to prevent the appearance of at least one cardiovascular disease. The compounds of general formula (I) can comprise one or more asymmetric carbons. They can thus exist in the form of enantiomers or of diastereoisomers. These enantiomers or diastereoisomers, and their mixtures, including racemic mixtures, come within the invention. Due to their structure, the compounds of general formula (I) can also exist in the form of isomers of rotamer or atropisomer type. The compounds of formula (I) can also exist in the form of bases or addition salts with acids. Such addition salts come within the invention. These salts are advantageously prepared with pharmaceutical^ acceptable acids but the salts of other acids, for example of use in the purification or separation of the compounds of general formula (I) also come within the invention. The compounds of general formula (I) can also occur in the crystalline, amorphous or oily form, these forms coming within the invention. The compounds of general formula (I) can in addition occur in the form of hydrates or of solvates, namely in the form of combinations or of associations with one or more molecules of water or with a solvent. Such hydrates and solvates also come within the invention. According to the present invention, the N-oxides of the compounds comprising an amine also come within the invention. The compounds of formula (I) in accordance with the invention also comprise those in which one or more hydrogen, carbon or halogen, in particular chlorine or fluorine, atoms have been replaced by their radioactive isotopes, for example tritium, in order to replace hydrogen, or carbon-14, in order to replace carbon-12. Such labelled compounds are of use in research, metabolism or pharmacokinetic studies or in biological and pharmacological assays as tools. In the context of the invention, the following definitions apply: - in (C1.C6)' the numerical indices determine the possible number of carbon atoms present in a chain or a ring. Thus, by way of example, C1-C6 represents a carbon chain which can have from 1 to 6 carbon atoms. Likewise, by way of example, (C1-C5) represents a carbon chain which can have from 1 to 5 carbon atoms or also (C3-C6) can represent a saturated carbon ring which can have from 3 to 6 carbon atoms; -alkoxy: an -O-alkyl group comprising a saturated, linear or branched, aliphatic chain; - alkynyl: a mono- or polyunsaturated, linear or branched, aliphatic group comprising, for example, one or two acetylenic unsaturations. For example, a (C2-C6) alkynyl group can represent an ethynyl, propynyl, and the like; - alkyl: a saturated, linear or branched, aliphatic group; for example, a (C1-C6) alkyl group represents a linear or branched carbon chain of 1 to 6 carbon atoms, in particular a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl or pentyl; - aminoalkyl: an -NH(C1-C6) alkyl or also -N((C1-C6) alkyl)2 group; - aryl: an optionally substituted monocyclic aromatic system comprising from 5 to 14 members per ring, preferably from 5 to 10 members per ring. Mention may be made, as examples of monocyclic aryl groups, of phenyl or naphthyl; the aryl group can be substituted by a group which can be one or more halogen atom(s), a hydroxyl group, a cyano group, a trifluoromethylthio group, a nitro group, an alkyl group, an alkoxy group, an alkylthio group, a methylsulphonyl group, an alkylaminoalkyl group or alkylaminocycloalkyl group which is optionally substituted, an alkylaminoalkoxy or cycloalkylaminoalkoxy group or a sulphonamide group, for example: - polycyclic aryl: an optionally substituted polycyclic aromatic system comprising from 5 to 14 members per ring, preferably from 5 to 10 members per ring, and comprising from 2 to 10 rings, at least one of the rings of which is aromatic. Mention may be made, as examples of polycyclic aryl groups, of aceanthrylene, anthracene, azulene, coronene, rubicene or naphthalene; the polycyclic aryl group can be substituted by a group which can be one or more halogen atom(s), a hydroxyl group, a cyano group, a trifluoromethylthio group, a nitro group, an alkyl group, an alkoxy group, an alkylthio group, a methylsulphonyl group, an alkylaminoalkyl or alkylaminocycloalkyl group which is optionally substituted, an alkylaminoalkoxy or cycloalkylaminoalkoxy group or a sulphonamide group, for example; - a bridged ring: a bicyclic structure comprising, according to the invention, a nitrogen atom, in which at least two carbon atoms are connected via a single bond or a carbon chain which can comprise 2 carbon atoms. By way of example, the abovementioned ring is of the type: with q = 1 or 2 and with the other groups and indices as defined above; - cycloalkyl: a saturated cyclic aliphatic group comprising from 3 to 8 carbon atoms. Mention may be made, by way of example, of a cyclopropyl, methylcyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl group; - halogen: a fluorine, a chlorine, a bromine or an iodine; - haloalkyl: (C1-C6) alkyl substituted by one to three halogen atom(s); - heteroaryl: a monocyclic aromatic system comprising from 5 to 14 ring members, preferably from 5 to 10 ring members, and comprising one to several heteroatoms, such as nitrogen, oxygen or sulphur atoms. The nitrogen atoms can be in the form of N-oxides. For example, a monocyclic heterocycle can be a pyran, a pyrazine, a pyrazole, a pyridazine, a pyridine, a pyrimidine, a pyrrole, an isothiazole, an isoxazole, a furan, an imidazole, a morpholine, a thiophene, a piperazine, a diazetidine, a dihydropyrrolidine, a piperidine, an azepine, and the like; a bicyclic heterocycle can be an isoquinoline, a pteridine, a chroman, and the like; a tricyclic heterocycle can be a phenanthroline, a xanthene, and the like; - polycyclic heteroaryl: an optionally substituted polycyclic aromatic system comprising from 5 to 14 members per ring, preferably from 5 to 10 members per ring, and comprising from 2 to 10 rings, additionally comprising one to several heteroatoms, such as nitrogen, oxygen or sulphur atoms, in at least one of the rings, and at least one of the rings of which is aromatic. Mention may be made, as examples of polycyclic heteroaryl groups, of indole, benzofuran, benzimidazole, benzothiophene, benzotriazole, benzothiazole, benzoxazole, quinoline, isoquinoline, indazole, quinazoline, phthalazine, quinoxaline, naphthyridine, 2,3-dihydro-1H-indole, 2,3-dihydrobenzofuran, 2,3-dihydro- indene, tetrahydroquinoline, tetrahydroisoquinoline or tetrahydroisoquinazoline; - a heterocycloalkyl: an optionally substituted saturated ring comprising from 3 to 8 atoms and comprising one to several heteroatoms, such as nitrogen, oxygen or sulphur atoms, in at least one of the rings, or several heteroatoms which are identical to or different from one another. For example, a heterocycloalkyl can be a pyrrolidine, a morpholine, a piperazine, a diazetidine, a dihydropyrrolidine, a piperidine, a piperadine, an azepan, an imidazolidine, a thiomorpholine, a tetrahydropyran, a tetrahydrothiopyran, a piperazine, a diazepan, and the like; - hydroxyl: an -OH group; - nitro: an -N02 group; - oxo: a -C(O)- group; - sulphonamide: group corresponding to the formula SO2-N-alkyl or SO2-N-cyclo- alkyl, alkyl and cycloalkyl being as defined above; - trifluoromethylthio is defined by the formula -S-CF3. Furthermore, it is understood that, in the present description, when an atom or a group is substituted or optionally substituted by one or more defined group(s) or atom(s), the substituents can be identical to or different from one another and may be carried, if appropriate, by the same atom or different atoms. Mention may be made, among the compounds which are a subject-matter of the invention, of a group of compounds of formula (I) in which A represents an aryl group, in particular a phenyl or heteroaryl group, in particular a pyridyl group, and all the other substituents and indices are as defined in the general formula (I) defined above. Mention may be made, among the compounds in accordance with the invention, of a group of compounds of formula (I) in which q = 0, m and n each represents 1, and all the other substituents and indices are as defined in the general formula (I) defined above. Mention may be made, among the compounds in accordance with the invention, of a group of compounds of formula (I) in which R2 represents a (C1-C6) alkyl group, in particular a methyl, substituted by an -NHC(O)Rb group in which Rb and the other substituents and indices are as defined for the compound of general formula (I) defined above. Mention may be made, among the compounds in accordance with the invention, of a group of compounds of general formula (I) in which R2 represents an -ORa group, the Ra group and all the other substituents and indices being as defined in the general formula (I) defined above. Mention may be made, among the compounds in accordance with the invention, of a group of compounds of general formula (I) in which R2 is a halogen atom or a cyano or a hydrogen or a hydroxyl or a (C1-C6) alkyl optionally substituted by an -NH2, or else by an -NHC(O)Rb group, Rb and the other substituents and indices being as defined in the general formula (I) defined above. Mention may be made, among the compounds in accordance with the invention, of a group of compounds of general formula (I) in which A is a phenyl, R, is a -C(O)R group in which R represents a hydrogen atom, q is equal to 0, n and m each have the value 1, and R2 represents -ORa, Ra and the other substituents and indices being as defined in the general formula (I) defined above. Mention may be made, among the compounds in accordance with the invention, of a group of compounds of general formula (I) in which A is a phenyl, R, is a -C(O)R group in which R represents a hydrogen atom, q is equal to 0, n and m each have the value 1, p is equal to 2, one of the R2 groups is -ORa and the other of the R2 groups is a halogen atom, Ra and the other substituents and indices being as defined in the general formula (I) defined above. Mention may be made, among the compounds in accordance with the invention, of a group of compounds of general formula (I) in which A is a phenyl, R1 is a -C(O)R group in which R represents a hydrogen atom, q is equal to 0, n and m each have the value 1, p = 1 and R2 is a methyl substituted by an -NH-CO-Rb group, Rb and the other substituents and indices being as defined in the general formula (I) defined above. Advantageously, in the compounds of formula (I), the R2 group is in the 6 position of the 2,4-dioxo-1,2,3,4-tetrahydroquinazoline ring system. The compounds of formula (I) can also have an R2 group in the 7 position of the 2,4-dioxo-1,2,3,4-tetrahydroquinazoline ring system. The R2 groups in the 6 and 7 positions can be identical or different. Advantageously, in the compounds of formula (I), p is equal to 1 or 2. The compounds of general formula (I) can be in the base, hydrate or solvate form, in the form of isomers or in the form of their mixtures. In a specific form, when p' = 2, then the two R3 groups are in the 3 and 4 positions of the ring system A and can be different from one another. The combinations of the groups of compounds in accordance with the invention mentioned above also come within the invention. Mention may be made, as examples of preferred compounds in accordance with the invention, of the following compounds: No. 1: 2-{[3-(3,4-dimethoxybenzyl)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]oxy}propanenitrile No. 2: 1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-6-hydroxyquinazoline- 2,4(1 H,3H)-dione No. 3: {[1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]oxy}acetonitrile No. 4: 2-{[1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]oxy}propanenitrile No. 5: {[3-(3,4-dimethoxybenzyl)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]oxy}acetonitrile No. 11: 4-[3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo- 3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 12:1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1- (fluoromethyl)ethoxy]quinazoline-2,4(1H,3H)-dione No. 13:4-[3-(3,4-dimethoxybenzyl)-2,4-dioxo-6-(2,2,2-trifluoroethoxy)-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 14: 1-(1-acetylpiperidin-4-yl)-6-(2,2-difluoroethoxy)-3-(3,4- dimethoxybenzyl)quinazoline-2,4(1H,3H)-dione No. 16: 4-[6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 20: N-{[3-(3,4-dimethoxybenzyl)-1-(1-formylpiperidir-4--yl)-2,4dioxo-1 ,2,3,4- tetrahydroquinazolin-6-yl]methyl}acetamide No. 22: 1-(1-acetylpiperidin-4-yl)-6-(aminomethyl)-3-(3,4- dimethoxybenzyl)quinazoline-2,4(1 H,3H)-dione hydrochloride No. 23: N-{[3-(3,4-dimethoxybenzyl)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]methyl}formamide No. 24: N-{[1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]methyl}formamide No. 25: N-{[1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]methyl}acetamide No. 32:4-[6-(2,2-difluoroethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1 (2H)- yl]piperidine-1 -carbaldehyde No. 33:4-[3-(3,4-dichlorobenzyl)-6-(2,2-difluoroethoxy)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 34:4-[3-(4-chlorobenzyl)-6-(2,2-difluoroethoxy)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 35: methyl 4-{[6-(2,2-difluoroethoxy)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4- dihydroquinazolin-3(2H)-yl]methyl}benzoate No. 36: 4-{[6-(2,2-difluoroethoxy)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4- dihydroquinazolin-3(2H)-yl]methyl}benzoicacid No. 37: 4-{[6-(2,2-difluoroethoxy)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4- dihydroquinazolin-3(2H)-yl]methyl}-N-(2-methoxyethyl)benzamide No. 38: 4-t3-(3,4-dimethoxybenzyl)-6-methyl-2,4-dioxo-3,4-dihydroquinazolin-1 (2H)- yl]piperidine-1 -carbaldehyde No. 39:4-[6-(2,2-difluoroethoxy)-3-(3-hydroxy-4-methoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1 (2H)-yl]piperidine-1 -carbaldehyde No. 40:4-[6-(2,2-difluoroethoxy)-3-[3-(2-hydroxyethoxy)-4-methoxybenzyl]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 41:4-[6-(2,2-difluoroethoxy)-3-(3-ethoxy-4-methoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 42:4-[6-(2,2-difluoroethoxy)-3-[4-methoxy-3-(2-methoxyethoxy)benzyl]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 43:4-[6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]azepane-1-carbaldehyde No. 47:4-[6-(2,2-difluoroethoxy)-3-[3-(3-hydroxypropoxy)-4-methoxybenzyl]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 48: 4-[5-chloro-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1 (2H)- yl]piperidine-1 -carbaldehyde No. 49:4-{3-[3-(cyclopentyloxy)-4-methoxybenzyl]-6-(2,2-difluoroethoxy)-2,4-dioxo- 3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 50: 2-(5-{[6-(2,2-difluoroethoxy)-1 -(1-formylpiperidin-4-yl)-2,4-dioxo-1,4- dihydroquinazolin-3(2H)-yl]methyl}-2-methoxyphenoxy)acetamide No. 51: 4-[6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]-3-methylpiperidine-1-carbaldehyde No. 52:3-[6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]-8-azabicyclo[3.2.1]octane-8-carbaldehyde No. 56: 4-{3-[4-(cyclopentyloxy)-3-methoxybenzyl]-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 57: 4-[3-(3-chlorobenzyl)-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 58:4-[3-(4-chlorobenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 59: 4-{3-[3-(cyclopentyloxy)-4-methoxybenzyl]-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 72: 4-[3-(3,4-dimethoxybenzyl)-6-(2-hydroxyethoxy)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 74: 4-[3-(3,4-dichlorobenzyl)-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 76: 4-{3-[(6-chloropyridin-3-yl)methyl]-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 78: 4-[3-(3-chloro-4-methoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 79: 4-[3-(3,4-dimethoxybenzyl)-6-(2-fluoroethoxy)-2,4-dioxo-3,4- dihydroquinazolin-1 (2H)-yl]piperidine-1 -carbaldehyde No. 89:2-[5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4- dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxyphenoxy]acetamide No. 90: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-hydroxy-4-methoxybenzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 91: 4-[3-(3,4-dimethoxybenzyl)-6-ethoxy-2,4-dioxo-3,4-dihydroquinazolin-1 (2H)- yl]piperidine-1 -carbaldehyde No. 97: 4-[5,7-dichloro-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin- 1 (2H}-yl]piperidine-1 -carbaldehyde No. 102: 4-[7-chloro-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin- 1 (2H)-yl]piperidine-1 -carbaldehyde No. 108: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(3-fluoro-4-methoxybenzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 111: 4-[6-(difluoromethoxy)-3-(3,4-dimethoxybenzyl)-2l4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 112: 4-[3-(3 AdimethoxybenzyO-e-O-methylethoxy^^-dioxo-S^- dihydroquinazolin-I^HJ-yOpiperidine-l^arbaldehyde No. 114: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-methoxy-3-(1- methylethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 116:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-methoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 117: 4-{3-[3,5-bis(trifluoromethyl)benzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]- 2,4-dioxo-3>4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 118: 4-[3-(3-ethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 124:4-{3-[3-chloro-4-(2-methoxyethoxy)benzyl]-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 130:4-[3-(3,4-diethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo- 3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 131:4-[3-(4-ethoxy-3-methoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 133: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(4-methoxy-3-methylbenzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 134: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4- (trifluoromethyl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 135: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4- (trifluoromethyl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 143: 4-{3-[4-(benzyloxy)-3-methoxybenzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]- 2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 145:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-methoxy-4-nitrobenzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 155: 4-[3-(4-ethoxybenzyl)-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 158: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-t4-(morpholin-4-ylmethyl)benzylj- 2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 160: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(4-(morpholin-4-yl)benzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 165: 4-[3-(biphenyl-4-ylmethyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo- 3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 166:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(methylsulphanyl)benzyl]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 167: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyridin-3-yl)benzyl)- 3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 170: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(3-methoxy-4-methylbenzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 175: 2-[2-(cyclopentyloxy)-5-({6-t2-fluoro-1-(fluoromethyl)ethoxy]-1-(1 - formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]acetamide No. 178: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-methoxy-4-propoxybenzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 183:2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N- methylacetamide No. 184:2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N,N- dimethylacetamide No. 185:2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N- methoxy-N-methylacetamide No. 186: 4-{3-[4-(cyclopentyloxy)-3-ethoxybenzyl]-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 188: 4-{3-[4-(cyclopentyloxy)-3-(1 -methylethoxy)benzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 189: 4-{3-[4-(cyclopentyloxy)-3-propoxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 190: 4-{3-[4-(cyclopentyloxy)-3-hydroxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 193: 4-{3-[4-(difluoromethoxy)-3-methoxybenzyl]-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 194: 4-{3-[4-(difluoromethoxy)-3-ethoxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 200: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(thiophen-3-yl)- benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 201: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyridin-4-yl)benzyl)- 3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 203:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(1-methyl-1H-indol-6-yl)methyl]- 2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 206: 4-{3-[4-(cyclopropylmethoxy)-3-methoxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidin6-1-carbaldehyde No. 207: 2-[4-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4- dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxyphenoxy]-N-methylacetamide No. 212: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-[4-(1 H-pyrazol-1 - yl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 213: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyridin-2-yl)benzyl)- 3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 215: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(thiophen-2-yl)- benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 216: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(quinolin-7-ylmethyl)- 3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 218: 4-{6-t2-fluoro-1-(fluoromethyl)ethoxy]-3-[(6-methoxynaphthalen-2- yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 223: 4-{3-[4-(1 H-benzimidazol-1 -yl)benzyl]-6-[2-fluoro-1 -(fluoromethyl)ethoxy]- 2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 224: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[3-methoxy-4-(2- methylpropoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 226: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[3-methoxy-4-(tetrahydrofuran-3- yloxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 228: 4-[3-{4-[(1 -benzylpyrrolidin-3-yl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 230: 4-[3-(1-benzothiophen-5-ylmethyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 232: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4-(1- methylethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 233: 4-[3-(3,4-dimethoxybenzyl)-7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]- 2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 234: 4-[3-{4-[(1 -acetylpyrrolidin-3-yl)oxy]-3-methoxybenzyl}-6-t2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 239: 4-[3-{4-[(4-fluorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 240: 4-[3-{4-[(4-chlorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 242: 4-[3-{4-[(3-chlorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 243:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(3-(thiophen-3- yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 245: 4-[3-(4-ethoxy-3-methoxybenzyl)-6-(2-hydroxyethoxy)-2,4-dioxo-3,4- dihydroquinazolin-1 (2H)-yl]piperidine-1 -carbaldehyde No. 246: 4-[3-{4-[2-(2,3-dihydro-1 H-indol-1-yl)-2-oxoethoxy]-3-methoxybenzyl}-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 250: 4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3>4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 251:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4-(2-oxo-2-(piperidin- 1-yl)ethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 254: 4-{3-[3-ethoxy-4-(thiophen-2-ylmethoxy)benzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 258:4-[3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(hydroxymethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 263: (2R)-2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]propanoic acid No. 264:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(1-methyl-3-(thiophen-2-yl)-1H- pyrazol-5-yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 270: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(5-methyl-1,2,4-oxadiazol-3- yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 275: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyrimidin-5- yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 276: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(1-methyl-3-phenyl-1H-pyrazol-5- yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 278: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-{[6-(1H-pyrazol-1- yl)pyridin-3-yl]methyl}-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 279: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-[(2-(thiophen-2- yl)pyrimidin-5-yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 280: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(1-methyl-1H-pyrazol-3- yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 282: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(3-methyl-1,2,4-oxadiazol-5- yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 283: [2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- formylpiperidin-4-yl)-2,4-dioxo-1I4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]aceticacid No. 285: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(thieno[2,3-b]pyridin-2- ylmethyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 286: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-t(6-phenylpyridin-3- yl)methyl]-3,4-dihydroquinazoiin-1(2H)-yl}piperidine-1-carbaldehyde No. 287: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(6-(morpholin-4-yl)pyridin-3- yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 289: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[(6-(thiophen-2- yl)pyridin-3-yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 292: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(1-methyl-5-phenyl-1 H-pyrazol-3- yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 294: 4-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo- 1,4-dihydroquinazolin-3(2H)-yl}methyl)biphenyl-2-carbonitrile No. 295: (2R)-2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N- methylpropanamide No. 297: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(thiophen-2- yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 298: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[3-methoxy-4-(morpholin-4- ylmethyl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 299: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4-(piperidin-1- ylmethyl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 300: 4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydraquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 301: 2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N- ethylacetamide No. 302: (2S)-2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 - formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]propanoic acid No. 305: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(3-methoxy-4-{[(3R)-2-oxo-1- phenylpyrrolidin-3-yl]oxy}benzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 306: 4-{3-[4-(cyclobutylmethoxy)-3-methoxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 307: 4-{3-[4-(benzyloxy)-3-methoxybenzyl]-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 308: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(4-hydroxy-3- methoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 309: 4-{3-[4-(cyclopropylmethoxy)-3-methoxybenzyl]-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 310: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[3-methoxy-4- (2-methylpropoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 311: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4- (1-methylethoxy)benzyl]-2,4-dioxo-3,4-dihyclroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 312: 4-[3-(4-ethoxy-3-methoxybenzyl)-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 315: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-{[6-(3- methoxyphenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 316: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-{[6-(2- fluorophenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 317: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-{[6-(4- fluorophenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 318: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-{[6-(4- methoxyphenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 319: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-[(6-(thiophen-2- yl)pyridin-3-yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 320: 4-{3-t3-ethoxy-4-(thiophen-2-ylmethoxy)benzyl]-7-fluoro-6-t2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 321: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(1 -methyl-1 H-pyrazol- 3-yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 322:4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyrimidin-5- yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 323: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[(1 -methyl-3-(thiophen-2- yl)-1 H-pyrazol-5-yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1 (2H)-yl}piperidine-1 - carbaldehyde No. 324: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[3-methoxy-4-(2-oxo-2- (piperidin-1-yl)ethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 325: 4-[3-{4-[2-(2,3-dihydro-1 H-indol-1-yl)-2-oxoethoxy]-3-methoxybenzyl}-7- fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)- yl]piperidine-1 -carbaldehyde No. 326: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(5-methyl-1,2,4- oxadiazol-3-yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 327: 4-[3-{4-[(3-chlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-t2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 328:4-[3-{[6-(3,5-dichlorophenyl)pyridin-3-yl]methyl}-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 329:4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)- 2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)biphenyl-2-carbonitrile No. 330: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-[4-(1 H-pyrazol- 1-yl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 331: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-{[6-(3- fluorophenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 332: 3-[5-({7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 -formylpiperidin-4- yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)pyridin-2-yl]benzonitrile No. 333:4-[3-(3,4-diethoxybenzyl)-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 334: 4-[3-{4-[(4-chlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 335: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[4-(morpholin-4- ylmethyl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 336: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-{[6-(1 H-pyrazol- 1 -yl)pyridin-3-yl]methyl}-3,4-dihydroquinazolin-1 (2H)-yl}piperidine-1 -carbaldehyde No. 337: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(4-(morpholin-4-yl)- benzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 338:4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-methoxy-4- propoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 339: 4-{3-[4-(1 H-benzimidazol-1 -yl)benzyl]-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 340: 5-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)- 2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxybenzonitrile No. 341: 3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-7-carbonitrile No. 342: 4-[3-(4-bromobenzyl)-7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 343: 4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-(2-methoxyethoxy)benzyl}-7-fluoro-6- [2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 344: 4-{3-[4-(benzyloxy)benzyl]-7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 345: 4-f3-{4-[(3,4-dichlorobenzyl)oxy]-3-ethoxybenzyl}-7-fluoro-5-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 349:4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-(2-fluoroethoxy)benzyl}-7-fluoro-6-[2- fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1 (2H)-yl]piperidine-1 - carbaldehyde No. 350: 4-[3-{4-[(2-chloro-4-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 351: 4-[3-{4-[(2,4-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 352: 4-[3-{4-[(2-chloro-6-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 353: 4-[3-{4-[(2,6-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 354: 4-[3-{4-[(2-chlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 355: 4-[7-fluoro-3-{4-[(2-fluorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 357: 2-[(3,4-dichlorobenzyl)oxy]-5-({7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]- 1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)benzonitrile No. 358: 4-[3-{4-t(3,4-dichlorophenoxy)methyl]-3-methoxybenzyl}-7-fluoro-6-t2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 360:4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4-(2- phenylethyl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 362:4-[3-{4-[(4,5-dichloro-2-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 369: 4-[3-{4-[(4-chlorophenoxy)methyl]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 371:4-[3-{3-chloro-4-[(4-chlorobenzyl)oxy]-5-ethoxybenzyl}-7-fluoro-6-[2-fluoro- 1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 373: 4-[3-{3-chloro-4-[(2,4-dichlorobenzyl)oxy]-5-ethoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 375: 4-[7-fluoro-3-{4-[(4-fluorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 376: 4-[3-{4-[(3,5-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 377: 4-[3-(4-{[4-chloro-3-(trifluoromethyl)benzyl]oxy}-3-methoxybenzyl)-7- fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquina2olin-1(2H)- yl]piperidine-1 -carbaldehyde No. 379: 4-[3-{4-[(3-chlorophenoxy)methyl]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 380: 4-[3-{4-[(3,5-difluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2)4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 381:4-{3-[4-(benzyloxy)-3-methoxybenzyl]-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 382:4-[3-{4-[(3-chloro-5-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 383: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(3-methoxy-4-{[4- (trifluoromethyl)benzyl]oxy}benzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 384: 4-[3-{4-[(2,5-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 385: 4-{[4-({7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 -formylpiperidin-4- yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2- methoxyphenoxy]methyl}benzonitrile No. 386: 3-{[4-({7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 -formylpiperidin-4- yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2- methoxyphenoxy]methyl}benzonitrile No. 387: 4-[3-{4-[(4-chloro-2-fluorobenzyl)oxy]-3-methoxybenzylf7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 388:4-[3-{4-[1-(3,4-dichlorophenyl)ethoxy]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 389: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-{4-[(3-hydroxybenzyl)oxy]- 3-methoxybenzyl}-2>4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 390: 4-[7-fluoro-3-{4-[(3-fluorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 391: 4-[3-{4-[(3,4-difluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 392: 4-{3-[4-(5,6-dichloro-1H-benzimidazol-1-yl)-3-methoxybenzyl]-7-fluoro-6- [2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 393: 4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)- 2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenyl3,4-dichlorobenzenesulphonate No. 394: 4-({7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 -formylpiperidin-4-yl)- 2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxyphenyl3,4-dichloro benzene- sulphonate No. 403: 3,4-dichloro-N-[4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2- methoxyphenyl]benzamide The compounds in accordance with the invention can be prepared by the methods illustrated in the following Schemes 1 to 4. In that which follows, the term "leaving group" is understood to mean a group which can be easily substituted, with departure of an electron pair, by cleavage of a heterolytic bond. This group can thus be easily replaced by another group, for example during a substitution reaction. Such leaving groups are, for example, halogens or an activated hydroxyl group, such as a mesylate, tosylate, triflate, and the like. Examples of leaving groups and references for their preparation are given in "Advanced Organic Chemistry", J. March, 3rd Edition, Wiley Interscience, pp. 310-316. The term "protective group PG" is understood to mean a group which makes it possible to prevent the reactivity of a function group or position during a chemical reaction which may affect it and which restores the molecule after cleavage according to methods known to a person skilled in the art. The term "temporary protective group for amines or alcohols" is understood to mean the protective groups such as those described in Protective Groups in Organic Synthesis, Greene T.W. and Wuts P.G.M., published by Wiley Intersciences, 1999, and in Protecting Groups, Kocienski P.J., 1994, Georg Thieme Verlag. Mention may be made, for example, of temporary protective groups for amines: benzyls or carbamates (such as ferf-butoxycarbonyl, cleavable in an acid medium, or benzyloxycarbonyl, cleavable by hydrogenolysis), temporary protective groups for carboxylic acids: hydrogenolysable alkyl esters (such as methyl or ethyl or tert-butyl esters which can be hydrolysed in a basic or acid medium) and benzyl esters, temporary protective groups for alcohols or phenols, such as tetrahydropyranyl, methyloxymethyl or methylethoxymethyl, tert-butyl and benzyl ethers, or temporary protective groups for carbonyl derivatives, such as linear or cyclic acetals, such as, for example, 1,3-dioxan-2- yl or 1,3-dioxolan-2-yl; and reference may be made to the well known general methods described in Protective Groups, cited above. A person skilled in the art will be in the position to choose the appropriate protective groups according to the circumstances. The compounds of formula (I) can comprise precursor groups for other functional groups which are generated subsequently in one or more other stages. In the general synthetic schemes which follow, the starting compounds and the reactants, when their method of preparation is not described, are commercially available or are described in the literature or else can be prepared according to methods which are described therein or which are known to a person skilled in the art. The pure enantiomers of the compounds in accordance with the invention can be obtained from enantiomericaliy pure precursors or else by chiral phase chromatography or else, when the compounds comprise acid or amine functional groups, by selective crystallizations of diastereoisomeric salts obtained by reaction of the compounds (I) with chiral amines or chiral acids respectively. The compounds of general formula (I) can be obtained according to the following Schemes 1 to 4. Out of concern for clarity, the R4 group has been chosen as being a hydrogen, p and p' represent 1 and 2 respectively and the R2 and R3 groups have been set as indicated in the schemes. However, it is to be understood that R4 can be as defined in the general formula (I), that R2 and R3 can have the positions indicated in the general formula (I) and that p and p' can be as defined in the general formula (I). The synthetic routes described below serve solely as illustration and are under no circumstances limiting. A person skilled in the art can apply without difficulty the teaching below to the compounds of formula (I) for which R, R,, R2) R3, R». Ra, Rb, Re, m, n, p, p' and q are as defined in the general formula (I). According to Scheme 1, the compound of formula (IV) is obtained by a reductive amination reaction by reacting a compound of formula (II), in which R' represents a (C1-C6) alkyl group and R2 is as defined for the compound of formula (I) with a compound of formula (III) in an acid medium and in the presence of a reducing agent, such as sodium triacetoxyborohydride. The PG group of the compound of formula (III) is a protective group for the amine functional group which may advantageously be tert- butoxycarbonyl (boc). The compound of formula (IV) thus formed is subsequently acylated, according to methods well known to a person skilled in the art, with an alkyl or aryl chloroformate to give the compound of formula (V) in which R" represents a (Ci-Ce) alkyl group or an aryl group which is substituted. A hydrolysis reaction in a basic medium makes it possible to obtain the compounds of formula (VI) which, by a coupling reaction with a compound of formula (VII), in which R3 is as defined for the compound of formula (I), results in the compounds of formula (VIII). An intramolecular cyclization reaction in the basic medium makes it possible to obtain the quinazolinedione derivatives of formula (IX). The protective group PG for the amine functional group is subsequently cleaved, for example in acid medium when PG is a boc, to give the compounds of formula (la) which give, by an acylation reaction, the compounds of formula (lb). The compounds of formula (la) are compounds of formula (I) and can act as intermediate for other compounds of formula (I), such as the compounds of formula (lb). The compounds of formula (I) for which R2 represents -ORa, Ra being as defined for the compound of formula (I), correspond to the formula (Id). They can be obtained from the compounds of formula (X) according to the following Scheme 2. The compounds of formula (Ic), obtained by a hydrogenolysis reaction on the compounds of formula (X), are subjected, for example, to an alkylation reaction with an alkylating agent of type Ra-X, in which Ra is as defined for the compound of formula (I) and X represents a leaving group (such as a halogen atom, for example), in the presence of a base, such as caesium carbonate (Cs2C03), or also to a Mitsunobu reaction (Synthesis, 1981, 1) with an alcohol of type Ra-OH, Ra being as defined for the compound of formula (I), to give compounds of formula (Id). The compounds of formula (X) and the compounds of formula (Ic) are compounds of formula (I) and can act as intermediate for other compounds of formula (I), such as the compounds of formula (Id). Alternatively, the compounds of formula (Id) can be obtained by following the procedure described in Scheme 3. The compounds of formula (XII) are obtained by a nucleophilic aromatic substitution reaction involving a compound of formula (XI), in which R' is as defined above, and an alcohol of type Ra-OH, in which Ra is as defined for the compound of formula (I), in the presence of a base. The reduction of the nitro group of the compounds of formula (XII) results in the corresponding anilino derivatives (XIII). A reductive amination reaction with a compound of formula (III), in which PG is a protective group for amine functional groups, such as, for example, boc, results in the compounds of formula (XIV). The compounds of formula (XV) are obtained by reaction of a compound of formula (XIV) with potassium isocyanate (KNCO) in an acid medium. An intramolecular cyclization reaction in a basic medium makes it possible to obtain the compounds of formula (XVI). The protective group PG is cleaved by methods well known to a person skilled in the art to give the compounds of formula (XVII). An acylation reaction results in the compounds of formula (XVIII). Finally, the compounds of formula (Id) are obtained either by an alkylation reaction with a derivative of type (XIX), in which X represents a leaving group, such as a halogen atom, in the presence of a base, such as, for example, caesium carbonate, or also by a Mitsunobu reaction with a benzyl alcohol of type (XX). In the compounds (XIX) and (XX), R3 is as defined above. Scheme 3 The compounds of formula (le) and (If), in which R2 more particularly represents a group of type-CH2-NHC(O)Rb, Rb being defined as in the compound of formula (1), can be prepared according to the following Scheme 4. It is understood that, in Scheme 3, the R2 group illustrated is of -O-Ra type and is in the 6 position of the quinoazolinedione structure (see, for example, compound (XVIII)) but that it is also possible to have a second R2 group, as defined in the general formula (I), in the 7 position of the same quinazolinedione group. The reduction of the nitro group of the compounds of type (XXI), in which R' and PG' are as defined above, the PG' group advantageously being boc, results in the corresponding anilino derivatives (XXII) which, by a reductive amination reaction in which they react in an acid medium and advantageously in the presence of a reducing agent, such as sodium triacetoxyborohydride, with a compound of formula (III), in which PG represents a benzyloxycarbonyl protective group for amines, give compounds of formula (XXIII). An acylation reaction with an alkyl or aryl chloroformate, in which R" represents a (C1-C6) alkyl group or an aryl group which is substituted, results in the compounds of formula (XXIV). The quinazolinedione analogues of formula (XXV) can be obtained by a hydrolysis reaction in a basic medium and then by a coupling reaction with a compound of formula (VII), in which R3 is as defined for the compound of formula (I), followed by an intramolecular cyclization reaction in a basic medium. The PG' group (preferably a boc) is subsequently cleaved in an acid medium to result in the compounds of formula (XXVI) which, by acylation, give compounds of formula (XXVII), in which Rb is as defined for the compound of formula (I). The PG protective group of (XXVII) is cleaved by a hydrogenolysis reaction to give the compounds of formula (le). Finally, the compounds of formula (If) are obtained by an acylation reaction on the compounds of formula (le). It is obvious that a person skilled in the art will be in a position to choose, in the light of his knowledge and the literature, other appropriate protective groups which make possible the introduction of all the groups described in the general formula (I). When the compound of formula (I) comprises a bridged ring, it can be obtained without distinction by one of the synthetic routes described above. The following procedures and examples describe the preparation of some compounds in accordance with the invention. These procedures and examples are not limiting and serve only to illustrate the present invention. In the procedures and examples below: - the mass spectra are produced on a quadrupole spectrometer of Platform LCZ type (Waters) or of ZQ 4000 type (Waters) in positive electrospray ionization mode; - the NMR (nuclear magnetic resonance) spectra are produced on a Fourier transform spectrometer (Bruker) at a temperature of 300°C (exchangeable protons not recorded); - s = singlet, - d = doublet, - m = multiplet, - br = broad signal -1 = triplet, - q = quartet - DMSO-d6 = deuterated dimethyl sulphoxide, - CDCI3 = deuterated chloroform. The mixtures of solvents are quantified in volumetric ratios. The NMR spectra and mass spectra confirm the structures of the compounds obtained according to the examples below. In the examples which follow, the following abbreviations are used: ACN: acetonitrile AcOEt: ethyl acetate AcOH: acetic acid DBU: 1,8-diazabicyclo[5.4.0]undec-7-ene DCM: dichloromethane DCE: 1,2-dichloroethane DIAD: diisopropyl azodicarboxylate DIEA: diisopropylamine DMF: N,N-dimethylformamide EtOH: ethanol HBTU: 0-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate IBCF: isobutyl chloroformate MeOH: methanol NaBH(OAc)3: sodium triacetoxyborohydride AT: ambient temperature min: minute THF: tetrahydrofuran NEt3: triethylamine TFA: trifluoroacetic acid EXAMPLES The following examples describe the preparation of some compounds in accordance with the invention. These examples are not limiting and serve only to illustrate the present invention. The numbers of the compounds in the examples refer to those given in the table below, in which the chemical structures and the physical properties of a few compounds in accordance with the invention are illustrated. EXAMPLE 1: Compound No.°6 Preparation of {[3-(3,4-dimethoxybenzyl)-1-(1-formylpiperidin-4-yl)-2,4-dioxo- 1,2,3,4-tetrahydroquinazolin-6-yl]oxy}acetonitrile Stage 1.1: 1,1-Dimethylethyl 4-{[4-(benzyloxy)-2-(methoxycarbonyl)phenyl]ami- no}piperidine-1 -carboxylate A mixture of 2g of methyl 2-amino-5-(benzyloxy)benzoate, 3.1 g of 1,1-dimethylethyl 4-oxopiperidine-1-carboxylate and 3.29 g of NaBH(OAc)3 in 10 ml of AcOH is irradiated under a microwave field (Biotage Initiator Sixty) at 110DC for 20 min. The same reaction is repeated with two other lots of 2 g of methyl 2-amino-5- (benzyloxy)benzoate. The three reaction media are combined. The combined product is taken up in AcOEt. The organic phase is washed with water, with a saturated NH4CI solution and with a saturated NaHC03 solution, dried over Na2SO4 and filtered, and the solvent is evaporated under reduced pressure. The residue is chromatographed on silica gel, elution being carried out with an AcOEt/heptane mixture, (5/95, v/v) as far as (30/70, v/v), to give 10.2 g of the expected product. Stage 1.2: 1,1-Dimethylethyl 4-{[4-(benzyloxy)-2-(methoxycarbonyl)phenyl][(2-methyl- propoxy)carbonyl]amino}piperidine-1-carboxylate A mixture of 2g of 1,1-dimethylethyl 4-{[4-(benzyloxy)-2- (methoxycarbonyl)phenyl]amino}piperidine-1-carboxylate obtained in stage 1.1, 0.87 ml of DIEA, 1.78 ml of IBCF and 1 g of NaOH in 10 ml of DCE is irradiated under a microwave field at 80°C for 30 min. The same reaction is repeated with 4 other lots of 2 g of 1,1-dimethylethyl 4-{[4-(benzyloxy)-2-(methoxycarbonyl)phenyl]amino}piperidine-1- carboxylate. The 5 reaction media are combined. The combined product is taken up in AcOEt and filtered, and the filtrate is evaporated under reduced pressure. The residue is chromatographed on silica gel, elution being carried out with an AcOEt/heptane mixture, (10/90, v/v) as far as (50/50, v/v), to give 9.3 g of the expected product. Stage 1.3: Sodium salt of 5-(benzyloxy)-2-({1-[(1,1-dimethylethoxy)carbonyl]-piperidin- 4-yl}[(2-methylpropoxy)carbonyl]amino)benzoic acid A mixture of 9.3 g of 1,1-dimethylethyl 4-{[4-(benzyloxy)-2- (methoxycarbonyl)phenyl][(2-methylpropoxy)carbonyl]amino}piperidine-1-carboxylate obtained in stage 1.2 and 34.4 ml of 2N NaOH in 57 ml of MeOH is heated at 100°C for 3h 00. The solution is evaporated under reduced pressure and DCM is added. Drying is carried out over Na2SO4, filtration is carried out and the solvent is evaporated under reduced pressure to give 8.7 g of the expected product. Stage 1.4: 1,1-Dimethylethyl 4-[{4-(benzyloxy)-2-[(3,4-dimethoxybenzyl)carbamoyl]phe- nyl}(isobutoxycarbonyl)amino]piperidine-1-carboxylate A mixture of 6g of sodium salt of 5-(benzyloxy)-2-({1-[(1,1- dimethylethoxy)carbonyl]piperidin-4-yl}[(2-methylpropoxy)carbonyl]amino)benzoic acid obtained in stage 1.3 and 4.42 g of DIEA in 250 ml of DMF is stirred at AT for 15 min. 6.48 g of HBTU are added and the mixture is left stirring for 30 min. 2.48 g of veratrylamine are added and the reaction mixture is stirred for 48h 00. It is evaporated under reduced pressure, the residue is taken up in AcOEt, washed with a saturated NH4CI solution and with a saturated NaHC03 solution, dried over Na2SO4 and filtered, and the solvent is evaporated under reduced pressure. The residue is chromatographed on silica gel, elution being carried out with an AcOEt/heptane mixture, (20/80, v/v) as far as (60/40, v/v), to give 7.5 g of expected product. Stage 1.5: 1,1-Dimethylethyl 4-[6-(benzyloxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carboxylate A mixture of 2.5 g of 1,1-dimethylethyl 4-[{4-(benzyloxy)-2-[(3,4- dimethoxybenzyl)carbamoyl]phenyl}(isobutoxycarbonyl)amino]piperidine-1-carboxylate obtained in stage 1.4 and 7.4 g of NaOH in 18.5 ml of DCE is irradiated under a microwave field at 110°C for 30 min. The same reaction is repeated with 2 other lots of 2.5 g of 1,1-dimethylethyl 4-[{4-(benzyloxy)-2-[(3,4-dimethoxybenzyl)carbamoyl]phenyr}- (isobutoxycarbonyl)amino]piperidine-1-carboxylate. The 3 reaction media are combined. The combined product is taken up in DCM, washed with water, dried over Na2SO4 and filtered, and the solvent is evaporated under reduced pressure to give 6.6 g of expected product. Stage 1.6: A mixture of 3.5 g of 1,1-dimethylethyl 4-[6-(benzyloxy)-3-(3,4-dimethoxybenzyl)- 6-(Benzyloxy)-3-(3,4-dimethoxybenzyl)-1-(piperidin-4-yl)quinazoline- 2,4(1 H,3H)-dione 2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carboxylate obtained in stage 1.5 and 25 ml of TFA in 50 ml of DCM is stirred at AT for 2h 00. The mixture is neutralized with K2C03. It is filtered and the filtrate is evaporated under reduced pressure. The residue is taken up in DCM and washed with a saturated NaHC03 solution and then with an 8% NaOH solution. The solution is dried over Na2SO4 and filtered, and the solvent is evaporated under reduced pressure to give 2.67 g of the expected product. Stage 1.7: 4-[6-(Benzyloxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin- 1(2H)-yl]piperidine-1-carbaldehyde A mixture of 0.6 g of 6-(benzyloxy)-3-(3,4-dimethoxybenzyl)-1-(piperidin-4- yl)quinazoline-2,4(1H,3H)-dione obtained in stage 1.6 and 0.113 g of ammonium formate in 5 ml of ACN is irradiated under a microwave field at 140°C for 1h 00. The mixture is filtered and the filtrate is evaporated under reduced pressure to give 0.62 g of the expected product. Stage 1.8: Compound No. 5: 4-[3-(3,4-Dimethoxybenzyl)-6-hydroxy-2,4-dioxo-3,4-dihydroquinazolin-1(2H)- yl]pi peridine-1 -carbaidehyde A mixture of 0.618 g of 4-[6-(benzyloxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde obtained in stage 1.7, 0.44 g of ammonium formate and 0.124 g of Pd/C (10%) in 10 ml of EtOH purged beforehand with nitrogen is irradiated under a microwave field at 80°C for 2h 00. The mixture is filtered and the filtrate is evaporated under reduced pressure to give 0.513 g of the expected product. Stage 1.9: Compound No. 6 {[3-(3,4-Dimethoxybenzyl)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]oxy}acetonitrile 0.17 g of 4-[3-(3,4-dimethoxybenzyl)-6-hydroxy-2,4-dioxo-3,4-dihydroquinazolin- 1(2H)-yl]piperidine-1-carbaldehyde obtained in stage 1.8 and 0.25 g of Cs2C03 in 3 ml of DMF are stirred for 15 min at AT. 0.056 g of bromoacetonitrile is added and the reaction mixture is subsequently irradiated under a microwave field at 100°C for 15 min. It is filtered and evaporated under reduced pressure. The residue is chromatographed on silica gel, elution being carried out with an MeOH/DCM mixture, (1/99, v/v) as far as (4/96, v/v), to give 0.112 g of the expected product. EXAMPLE 2: Compound No. 3 Preparation of {[1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo- 1,2,3,4-tetrahydroquinazolin-6-yl]oxy}acetonitriie Stage 2.1: 1-(1-Acetylpiperidin-4-yl)-6-(benzyloxy)-3-(3,4-dimethoxybenzyl)quinazoline- 2,4(1 H,3H)-dione 0.14 g of acetyl chloride is added to a mixture of 0.6 g of 6-(benzyloxy)-3-(3,4- dimethoxybenzyl)-1-(piperidin-4-yl)quinazoline-2,4(1H,3H)-dione obtained according to stage 1.6 and 0.24 g of NEt3 in 10 ml of DCM cooled to 0°C. The mixture is stirred at AT overnight. It is washed twice with a saturated NH4CI solution and filtered, and then the filtrate is evaporated under reduced pressure to give 0.64 g of the expected product. Stage 2.2: Compound No. 2 1-(1-Acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-6-hydroxyquinazoline- 2,4(1 H,3H)-dione A mixture of 0.64 g of 1-(1-acetylpiperidin-4-yl)-6-(benzyloxy)-3-(3,4- dimethoxybenzyl)quinazoline-2,4(1H,3/-/)-dione obtained in stage 2.1, 0.44 g of ammonium formate and 0.125 g of Pd/C (10%) in 10 ml of EtOH purged beforehand with nitrogen is irradiated under a microwave field at 80°C for 2h 00. The mixture is filtered and the filtrate is evaporated under reduced pressure to give 0.48 g of the expected product. Stage 2.3: Compound No. 3 {[1-(1-Acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]oxy}acetonitrile 0.12 g of 1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-6-hydroxyquinazoline- 2,4(1 H,3H)-dione obtained in stage 2.2 and 0.172 g of Cs2C03 in 3 ml of DMF are stirred for 15 min at AT. 0.038 g of bromoacetonitrile is added and the reaction mixture is subsequently irradiated under a microwave field at 100°C for 15 min. It is filtered and the filtrate is evaporated under reduced pressure. The residue is chromatographed on silica gel, elution being carried out with an MeOH/DCM mixture, (1/99, v/v) as far as (4/96, v/v), to give 0.094 g of the expected product. EXAMPLE 3: Compound No. 34 Synthesis of 4-[3-(4-chlorobenzyl)-6-(2,2-difluoroethoxy)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde Stage 3.1: Methyl 5-(2,2-difluoroethoxy)-2-nitrobenzoate 8.53 g of 2,2-difluoroethanol are added to a solution of 17.31 g of methyl 5-fluoro- 2-nitrobenzoate, 9.64 g of NEt3 and 32.71 g of 2,8,9-triisobutyl-2,5,8,9-tetraaza-1- phosphabicyclo[3.3.3]undecane in 250 ml of anhydrous THF. The mixture is stirred at AT for 30 min. The solvent is evaporated under reduced pressure. Water is added and extraction is carried out with AcOEt. The extract is washed with a 1N aqueous HCI solution, with water and then with a saturated NaCI solution. It is dried over MgSO^ and filtered, and the solvent is evaporated under reduced pressure to give 21 g of the expected product. 21 g of methyl 5-(2,2-difluoroethoxy)-2-nitrobenzoate obtained in stage 3.1 and 1 g of Pd/C (10%) in a mixture of 300 ml of AcOEt, 50 ml of EtOH and 5 ml of AcOH are stirred at AT under a hydrogen atmosphere for 24h 00. The mixture is filtered and evaporated under reduced pressure to give 18.6 g of the expected product. Stage 3.3: 1,1-Dimethylethyl 4-{[4-(2,2-difluoroethoxy)-2-(methoxycarbonyl)phenyl]ami- no}pi peri di ne-1 -carboxylate A mixture of 4 g of methyl 2-amino-5-(2,2-difluoroethoxy)benzoate and 6.88 g of 1,1-dimethylethyl 4-oxopiperidine-1-carboxylate obtained in stage 3.2 in 15 ml of AcOH is heated at 90°C for 10 min. It is allowed to cool to AT and 7.3 g of NaBH(OAc)3 are added. The mixture is left stirring at AT for 12h 00. It is extracted with AcOEt and the extract is washed with a saturated K2C03 solution and then with water. It is dried over MgSO4, filtered and evaporated under reduced pressure to give 6.63 g of the expected product. Stage 3.4: 1,1 -Dimethylethyl 4-{carbamoyl[4-(2,2-difluoroethoxy)-2-(methoxycarbonyl)- phenyl]amino}piperidine-1-carboxylate 1.95 g of potassium isocyanate in solution of 4 ml of water are added to a solution of 6.63 g of 1,1-dimethylethyl 4-{[4-(2,2-difluoroethoxy)-2-(methoxycarbonyl)phenyl] amino}piperidine-1-carboxylate obtained in stage 3.3 in 40 ml of AcOH. The mixture is stirred at AT for 12h 00. It is extracted with AcOEt and the extract is washed with a saturated K2C03 solution and then with water. It is dried over MgSO4, filtered and evaporated under reduced pressure to give 6.95 g of the expected product. Stage 3.5: 1,1-Dimethylethyl 4-[6-(2,2-difluoroethoxy)-2,4-dioxo-3,4-dihydroquinazolin- 1(2H)-yl]piperidine-1-carboxylate 2.5 g of 1,1-dimethylethyl 4-{carbamoyl[4-(2,2-difluoroethoxy)-2- (methoxycarbonyl)phenyl]amino}piperidine-1-carboxylate obtained in stage 3.4 in solution in a mixture of 10 ml of dioxane and 5 ml of a 1N aqueous NaOH solution are irradiated under a microwave field at 130°C for 30 min. Extraction is carried out with AcOEt and the extract is neutralized with a 1N aqueous HCI solution, washed with water, dried over MgSO4, filtered and evaporated under reduced pressure. The residue obtained is triturated in an AcOEt/pentane mixture to give the expected product. The same reaction is reproduced with 2 other lots of 2.5 g of 1,1-dimethylethyl 4-{carbamoyl[4-(2,2- difluoroethoxy)-2-(methoxycarbonyl)phenyl]amino}piperidine-1 -carboxylate obtained in stage 3.4 to give, in total, 5.63 g of expected product. Stage 3.6: 6-(2,2-Difluoroethoxy)-1-(piperidin-4-yl)quinazoline-2,4(1H,3H)-dione A solution of 5.63 g of 1,1-dimethylethyl 4-[6-(2,2-difluoroethoxy)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carboxylate obtained in stage 3.5 in 70 ml of formic acid is stirred at AT for 2h 00. The solvent is evaporated under reduced pressure to give 6.13 g of the expected product in the form of the formic acid salt. Stage 3.7: 4-[6-(2,2-Difluoroethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2W)- yl]piperidine-1-carbaldehyde A mixture of 6.13 g of 6-(2,2-difluoroethoxy)-1-(piperidin-4-yl)quinazoline- 2,4(1 H,3H)-6\one obtained in stage 3.6 and 3.12 g of ammonium formate in 28 ml of ACN and 28 ml of dioxane is irradiated under a microwave field at 140°C for 1h 00. The reaction mixture is run into water. The mixture is filtered and the precipitate is washed with water and then with ether to give 4.47 g of the expected product. Stage 3.8: Compound No. 34 4-[3-(4-Chlorobenzyl)-6-(2,2-difluoroethoxy)-2,4-dioxo-3,4-dihydroquinazolin- 1 (2H)-y I] piperid i ne-1 -carba Idehyde A mixture of 0.15 g of 4-[6-(2,2-difluoroethoxy)-2,4-dioxo-3,4-dihydroquinazolin- 1(2H)-yl]piperidine-1-carbaldehyde obtained in stage 3.7, 0.096 g of 1-(bromomethyl)-4- chlorobenzene and 0.3 g of Cs2C03 in 3 ml of DMF is stirred at AT for 1h 00. AcOEt is added and washing is carried out with water and then with a saturated NaCI solution. The organic phase is dried over MgSO4, filtered and evaporated under reduced pressure. The residue is chromatographed on silica gel, elution being carried out with AcOEt, to give 0.116 g of the expected product. EXAMPLE 4: Compound No. 49 Synthesis of 4-{3-[3-(cyclopentyloxy)-4-methoxybenzyl]-6-(2,2-difluoro- ethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2W)-yl}piperidine-1-carbaldehyde 0.172 g of DIAD is added to a solution of 0.15 g of 4-[6-(2,2-difluoroethoxy)-2,4- dioxo-3,44-dioxo-3,4-dihydroquinazolin-1(2H)- yl]piperidine-1 -carbaldehyde No. 39:4-t6-(2,2-difluoroethoxy)-3-(3-hydroxy-4-methoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1 (2H)-yl]piperidine-1 -carbaldehyde No. 40:4-t6-(2,2-difluoroethoxy)-3-[3-(2-hydroxyethoxy)-4-methoxybenzyl]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 41:4-[6-(2,2-difluoroethoxy)-3-(3-ethoxy-4-methoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 42:4-[6-(2,2-difluoroethoxy)-3-[4-methoxy-3-(2-methoxyethoxy)benzyl]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 43:4-[6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1 (2H)-yl]azepane-1 -carbaldehyde No. 47: 4-[6-(2,2-difluoroethoxy)-3-[3-(3-hydroxypropoxy)-4-methoxybenzyl]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 48: 4-[5-chloro-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)- yl]piperidine-1-carbaldehyde No. 49: 4-{3-[3-(cyclopentyloxy)-4-methoxybenzyl]-6-(2,2-difluoroethoxy)-2,4-dioxo- 3,4-dihydroquinazolin-1 (2H)-yl}piperidine-1 -carbaldehyde No. 50: 2-(5-{[6-(2,2-difluoroethoxy)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4- dihydroquinazolin-3(2H)-yl]methyl}-2-methoxyphenoxy)acetamide No. 51:4-[6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]-3-methylpiperidine-1-carbaldehyde No. 52: 3-t6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]-8-azabicyclo[3.2.1]octane-8-carbaldehyde No. 55: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin- 1(2H)-yl}piperidine-1-carbaldehyde No. 56: 4-{3-[4-(cyclopentyloxy)-3-methoxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2I4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 57: 4-[3-(3-chlorobenzyl)-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3,4- dihydroquinazolin-1 (2H)-yl]piperidine-1 -carbaldehyde No. 58: 4-[3-(4-chlorobenzyl)-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3,4- dihydroquinazolin-1 (2H)-yl]piperidine-1 -carbaldehyde No. 59: 4-{3-[3-(cyclopentyloxy)-4-methoxybenzyl]-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 72:4-[3-(3,4-dimethoxybenzyl)-6-(2-hydroxyethoxy)-2,4-dioxo-3,4- dihydroquinazolin-1 (2H)-yl]piperidine-1 -carbaldehyde No. 74: 4-[3-(3,4-dichlorobenzyl)-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 76:4-{3-[(6-chloropyridin-3-yl)methyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 78: 4-[3-(3-chloro-4-methoxybenzyl)-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 79:4-[3-(3,4-dimethoxybenzyl)-6-(2-fluoroethoxy)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 89: 2-[5-({6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 -formylpiperidin-4-yl)-2,4- dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxyphenoxy]acetamide No. 90: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(3-hydroxy-4-methoxybenzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 91:4-[3-(3,4-dimethoxybenzyl)-6-ethoxy-2,4-dioxo-3,4-dihydroquinazolin-1(2H)- yl]piperidine-1 -carbaldehyde No. 97: 4-[5,7-dichloro-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin- 1(2H)-yl]piperidine-1-carbaldehyde No. 102: 4-[7-chloro-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin- 1(2H)-yl]piperidine-1-carbaldehyde No. 108: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(3-fluoro-4-methoxybenzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 111: 4-[6-(difluoromethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 112: 4-[3-(3,4-dimethoxybenzyl)-6-(1-methylethoxy)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 114: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-methoxy-3-(1- methylethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 116: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-methoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 117: 4-{3-[3,5-bis(trifluoromethyl)benzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]- 2,4-dioxo-3,4-dihydroquinazolin-1 (2H)-yl}piperidine-1 -carbaldehyde No. 118: 4-[3-(3-ethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 124: 4-{3-[3-chloro-4-(2-methoxyethoxy)benzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 130: 4-[3-(3,4-diethoxybenzyl)-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo- 3,4-dihydroquinazolin-1 (2H)-yl]piperidine-1 -carbaldehyde No. 131:4-[3-(4-ethoxy-3-methoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 133; 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(4-methoxy-3-methylbenzy()-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 134: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4- (trifluoromethyl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 135: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4- (trifluoromethyl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 143: 4-{3-[4-(benzyloxy)-3-methoxybenzyl]-6-[2-fluoro-1 -(fluoromethyl)ethoxy]- 2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 145: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(3-methoxy-4-nitrobenzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 155: 4-[3-(4-ethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 158; 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[4-(morpholin-4-ylmethyl)benzyl]- 2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 160:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(4-(morpholin-4-yl)benzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 165: 4-[3-(biphenyl-4-ylmethyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo- 3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 166:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(methylsulphanyl)benzyl]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1 -carbaldehyde No. 167:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyridin-3-yl)benzyl)- 3,4-dihydroquinazolin-1 (2H)-yl}piperidine-1 -carbaldehyde No. 170: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(3-methoxy-4-methylbenzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 175: 2-t2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]acetamide No. 178: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(3-methoxy-4-propoxybenzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 183: 2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 - formylpiperidin-4-yl)-2,4-ciioxo-1,4-dihyclroquinazolin-3(2H)-yl}methyl)phenoxy]-N- methylacetamide No. 184: 2-[2-(cyclopentyloxy)-5-({6-t2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 - formylpiperidin-4-yl)-2,4-dioxo-1l4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N,N- dimethylacetamide No. 185: 2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 - formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N- methoxy-N-methylacetamide No. 186: 4-{3-[4-(cyclopentyioxy)-3-ethoxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 188;4-{3-[4-(cyclopentyloxy)-3-(1-methylethoxy)benzyl]-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 189: 4-{3-[4-(cyclopentyloxy)-3-propoxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 190: 4-{3-[4-(cydopentyloxy)-3-hydroxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 193: 4-{3-[4-(difluoromethoxy)-3-methoxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 194: 4-{3-[4-(difluoromethoxy)-3-ethoxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 200: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(thiophen-3-yl)- benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 201: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyridin-4-yl)benzyl)- 34-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 203: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[(1 -methyl-1 H-indol-6-yl)methyl]- 2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 206: 4-{3-[4-(cyclopropylmethoxy)-3-methoxybenzyl]-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No.207:2-[4-<{6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2f4- dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxyphenoxy]-N-methylacetamide No. 212: 4-{6-[2-fIuoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4-(1 H-pyrazol-1 - yl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 213:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyridin-2-yl)benzyl)- 3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 215:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(thiophen-2-yl)- benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 216: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(quinolin-7-ylmethyl)- 3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 218: 4-{5-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[(6-methoxynaphthalen-2- yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 223: 4-{3-[4-(1 H-benzimidazol-1-yl)benzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]- 2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 224: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[3-methoxy-4-(2- methylpropoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 226: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[3-methoxy-4-(tetrahydrofuran-3- yloxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 228:4-[3-{4-[(1-benzylpyrrolidin-3-yl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1- (fIuoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 230: 4-[3-(1-benzothiophen-5-ylmethyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 232: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4-(1- methylethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 233: 4-[3-(3,4-dimethoxybenzyl)-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]- 2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 234:4-t3-{4-[(1-acetylpyrrolidin-3-yl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 239: 4-[3-{4-[(4-fluorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 240: 4-[3-{4-[(4-chlorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 242: 4-t3-{4-[(3-chlorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 243: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(3-(thiophen-3- yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 245: 4-[3-(4-ethoxy-3-methoxybenzyl)-6-(2-hydroxyethoxy)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 246: 4-[3-{4-[2-(2,3-dihydro-1 H-indol-1-yl)-2-oxoethoxy]-3-methoxybenzyl}-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 250: 4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-methoxybenzyl}-6-t2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 251: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[3-methoxy-4-(2-oxo-2-(piperidin- 1-yl)ethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 254: 4-{3-[3-ethoxy-4-(thiophen-2-ylmethoxy)benzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 258: 4-[3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1 -(hydroxymethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 263: (2R)-2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 - formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]propanoic acid No. 264:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(1-methyl-3-(thiophen-2-yl)-1H- pyrazol-5-yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 270: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(5-methyl-1,2,4-oxadiazol-3- yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 275: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyrimidin-5- yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 276: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(1-methyl-3-phenyl-1H-pyrazol-5- yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 278: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-{[6-(1H-pyrazol-1- yl)pyridin-3-yl]methyl}-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 279: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-[(2-(thiophen-2- yl)pyrimidin-5-yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 280: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[4-(1 -methyl-1 H-pyrazol-3- yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 282: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[4-(3-methyl-1,2,4-oxadiazol-5- yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 283: [2-(cyclopentyloxy)-5-({6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 - formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]aceticacid No. 285:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(thieno[2,3-b]pyridin-2- ylmethyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 286: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[(6-phenylpyridin-3- yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 287: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[(6-(morpholin-4-yl)pyridin-3- yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 289: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-[(6-(thiophen-2- yl)pyridin-3-yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 292: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[(1 -methyl-5-phenyl-1 H-pyrazol-3- yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 294: 4-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo- 1,4-dihydroquinazolin-3(2H)-yl}methyl)biphenyl-2-carbonitrile No. 295:(2R)-2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- formylpiperidin-4-yl)-2,4-dioxo-1,4-clihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N- methylpropanamide No. 297: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(thiophen-2- yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 298: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[3-methoxy-4-(morpholin-4- ylmethyl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 299: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4-(piperidin-1 - ylmethyl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 300:4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 301:2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N- ethylacetamide No. 302: (2S)-2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 - formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]propanoic acid No. 305:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-methoxy-4-{[(3R)-2-oxo-1- phenylpyrrolidin-3-yl]oxy}benzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 306: 4-{3-[4-(cyclobutylmethoxy)-3-methoxybenzyi]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 307: 4-{3-[4-(benzyloxy)-3-methoxybenzyl]-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 308: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(4-hydroxy-3- methoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 309: 4-{3-[4-(cyclopropylmethoxy)-3-methoxybenzyl]-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 310: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[3-methoxy-4- (2-methylpropoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 311: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4- (1-methylethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 312: 4-[3-(4-ethoxy-3-methoxybenzyl)-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 315: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-{[6-(3- methoxyphenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 316: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-{[6-(2- fluorophenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 317: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-{[6-(4- fluorophenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 318: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-{[6-(4- methoxyphenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 319:4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[(6-(thiophen-2- yl)pyridin-3-yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 320: 4-{3-[3-ethoxy-4-(thiophen-2-ylmethoxy)benzyl]-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 321: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[4-(1 -methyl-1 H-pyrazol- 3-yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 322: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyrimidin-5- yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 323: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[(1 -methyl-3-(thiophen-2- yl)-1 H-pyrazol-5-yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1 (2H)-yl}piperidine-1 - carbaldehyde No. 324: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[3-methoxy-4-(2-oxo-2- (piperidin-1-yl)ethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 325: 4-[3-{4-[2-(2,3-dihydro-1 H-indol-1 -yl)-2-oxoethoxy]-3-methoxybenzyl}-7- fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)- yl]piperidine-1 -carbaldehyde No. 326: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(5-methyl-1,2,4- oxadiazol-3-yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 327: 4-[3-{4-[(3-chlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 328: 4-[3-{[6-(3,5-dichlorophenyl)pyridin-3-yl]methyl}-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 329: 4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)- 2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)biphenyl-2-carbonitrile No. 330: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4-(1 H-pyrazol- 1-yl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 331: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-{[6-(3- fluorophenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 332: 3-[5-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4- yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)pyridin-2-yl]benzonitrile No. 333:4-[3-(3,4-diethoxybenzyl)-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 334: 4-[3-{4-[(4-chlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 335: 4-{7-fluoro-6-[2-fluoro-1 -(fluorotnethyl)ethoxy]-3-t4-(morpholin-4- ylmethyl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 336: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-{[6-(1 H-pyrazol- 1-yl)pyridin-3-yl]methyl}-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 337: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(4-(morpholin-4-yl)- benzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1 -carbaldehyde No. 338: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(3-methoxy-4- propoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 339: 4-{3-[4-(1 H-benzimidazol-1 -yl)benzyl]-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 340: 5-({7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1-formylpiperidin-4-yl)- 2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxybenzonitrile No. 341: 3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 - formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-7-carbonitrile No. 342: 4-[3-(4-bromobenzyl)-7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 343:4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-(2-methoxyethoxy)benzyl}-7-fluoro-6- [2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 344: 4-{3-[4-(benzyloxy)benzyl]-7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 345: 4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-ethoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 349:4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-(2-fluoroethoxy)benzyl}-7-fluoro-6-[2- fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1 (2H)-yl]piperidine-1 - carbaldehyde No. 350:4-[3-{4-[(2-chloro-4-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2l4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 351:4-[3-{4-[(2,4-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 352: 4-[3-{4-[(2-chloro-6-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 353: 4-[3-{4-[(2,6-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 354: 4-[3-{4-[(2-chlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-t2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 355: 4-[7-fluoro-3-{4-[(2-fluorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3>4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 357: 2-[(3,4-dichlorobenzyl)oxy]-5-({7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]- 1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)benzonitrile No. 358: 4-[3-{4-[(3,4-dichlorophenoxy)methyl]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 360: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-t4-(2- phenylethyl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 362: 4-[3-{4-[(4,5-dichloro-2-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 369: 4-[3-{4-[(4-chlorophenoxy)methyl]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 371: 4-[3-{3-chloro-4-[(4-chlorobenzyl)oxy]-5-ethoxybenzyl}-7-fluoro-6-[2-fluoro- 1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 373:4-[3-{3-chloro-4-[(2,4-dichlorobenzyl)oxy]-5-ethoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 375: 4-[7-fluoro-3-{4-[(4-fluorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 376: 4-[3-{4-[(3,5-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 377: 4-[3-(4-{[4-chloro-3-(trifluoromethyl)benzyl]oxy}-3-methoxybenzyl)-7- fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)- yl]piperidine-1-carbaldehyde No. 379: 4-[3-{4-[(3-chlorophenoxy)methyl]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 380: 4-[3-{4-[(3,5-difluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 381: 4-{3-[4-(benzyloxy)-3-methoxybenzyl]-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 382: 4-[3-{4-[(3-chloro-5-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 383: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(3-methoxy-4-{[4- (trifluoromethyl)benzyl]oxy}benzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 384: 4-[3-{4-[(2,5-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 385: 4-{[4-({7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 -formylpiperidin-4- yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2- methoxyphenoxy]methyl}benzonitrile No. 385: 3-{[4-({7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 -formylpiperidin-4- yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2- methoxyphenoxy]methyl}benzonitrile No. 387:4-[3-{4-t(4-chloro-2-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 388:4-[3-{4-[1-(3,4-dichlorophenyl)ethoxy]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 389: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-{4-[(3-hydroxybenzyl)oxy]- 3-methoxybenzyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 390: 4-[7-fluoro-3-{4-[(3-fluorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 391:4-[3-{4-[(3,4-difluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 392: 4-{3-[4-(5,6-dichloro-1 H-benzimidazol-1-yl)-3-methoxybenzyl]-7-fluoro-6- [2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 393: 4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)- 2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenyl 3,4-dichlorobenzenesulphonate No. 394: 4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)- 2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxyphenyl3,4-dichlorobenzene- sulphonate No. 403: 3,4-dichloro-N-[4-({7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 - formylpiperidin-4-yl)-2,4-dioxo-1,4-clihydroquinazolin-3(2H)-yl}nnethyl)-2- methoxyphenyl]benzamide; in the form of the base or of an addition salt with an acid. 15. Compound corresponding to the general formula (I) in which — A represents an aryl group or a heteroaryl group; — R1 represents: ■ a hydrogen atom, ■ -C(O)R in which R is a hydrogen atom, a (C1-C6) alkoxy group, an aryl group, a (C3-C6) cycloalkyl group or a (C1-C6) alkyl group, the said alkyl optionally being substituted by: . one or more hydroxyl group(s), . a benzyloxy group, . a (C1-C6) alkoxy group, optionally substituted by an aryl, or . a (C3-C6) cycloalkyl group, ■ an optionally substituted (C1-C6) alkyl group; — R2 represents: ■ a hydrogen atom, ■ a halogen atom, ■ a cyano group, ■ a nitro group, ■ a (C1-C6) alkyl group optionally substituted by an -NH2 or else by an -NHC(O)Rb group, with Rb as defined below, ■ an -ORa group in which Ra represents: . a hydrogen atom, . a (C1-C6) alkyl group optionally substituted by one or more halogen atom(s), by one or more hydroxyl group(s), by an aryl group and/or by one or more cyano group(s), . a (C2-C6) alkynyl group, . an aryl group; — R3 represents: ■ a hydrogen atom, ■ a halogen atom, ■ a hydroxyl group, ■ a cyano group, ■ an -SCF3 group, ■ a nitro group, ■ an -S(O)0-2-alkyl group, an -S(O)0-2-heterocycloalkyl group, an -O-SO2-aryl group optionally substituted by one or more halogen atom(s); ■ an -alkylaminoalkyl or -cycloalkylaminoalkyl group, each optionally substituted on the end alkyl, ■ an optionally substituted sulphonamide group, ■ an aryl group or a heteroaryl group, the said group being monocyclic or polycyclic and in addition optionally being substituted by a (C1-C6) alkyl group, by one or more halogen atom(s) or by a (C1-C6) alkoxy group, ■ a heterocycloalkyl group optionally substituted by a (C1-C6) alkyl group, ■ a (C1-C6) alkyl group optionally substituted by: - one or more halogen atom(s), - an aryl group which can be substituted by one or more halogen atom(s) or by one or more hydroxyl group(s), - a heteroaryl group, - one or more hydroxyl group(s) which can be substituted by an aryl group itself optionally substituted by one or more halogen atom(s), or - a heterocycloalkyl group optionally substituted by a CO(O)Ra group or by a (C1-C6) alkyl group, with Ra as defined above, ■ a -C(O)NRbRc group, with Rb and Rc as defined below, ■ a -C(O)ORc group or an -O-C(O)ORc group, with Rc as defined below, ■ a (C1-C6) alkoxy group, optionally substituted by - an aminoalkyl group, - an aminocycloalkyl group, - a cycloalkyl group, - a heterocycloalkyl group, - a monocyclic or polycyclic heteroaryl group, - one or more hydroxyl group(s), - one or more halogen atom(s), - a (C1-C6) alkoxy group, - a -C(O)ORc group, with RC as defined below, - a -C(O)NRbRc group, with Rb and Rc as defined below, and/or - an aryl group, itself optionally substituted by one or more halogen atom(s), a cyano group, a (C1-C6) alkoxy group, an -O-haloalkyl group and/or a haloalkyl group, ■ an -O-cycloalkyl group, an -O-aryl group or an -O-heterocycloalkyl group, each optionally substituted by - an aryl group, itself optionally substituted by one or more halogen atom(s) or by a (C1-C6) alkyl group, - one or more halogen atom(s), and/or - a (C1-C6) alkyl group, which can itself be substituted by an aryl group, ■ an -NH-CO-NH-aryl group, an -NH-CO-NH-heteroaryl group or an -NH-CO- NH-(C1-C6) alkyl group, each optionally being substituted by one or more halogen atom(s), by a cyano group, by a nitro group, by one or more hydroxyl group(s) or by a (C1-C6) alkoxy group, ■ an -N-(C1-C6) alkyl group, it being possible for the (C1-C6) alkyl group to be substituted by one or more aryl group(s) optionally substituted by one or more halogen atom(s) and/or by an SO2 group, ■ an -NH-CO-aryl group or an -NH-CO-heteroaryl group, each optionally being substituted by one or more halogen atom(s); or else R3 forms, with A, a polycyclic heteroaryl group optionally substituted by a (C1-C6) alkoxy group or a (C1-C6) alkyl group optionally substituted by an aryl group which can itself be substituted by one or more halogen atom(s); — R4 represents a hydrogen atom or a (C1-C6) alkyl group; — Rb represents: . a hydrogen atom, . a (C1-C6) alkyl group optionally substituted by one or more halogen atom(s), by one or more hydroxyl, cyano, amino, heterocycloalkyl or (C1-C6) alkoxy group(s) or by an aryl group optionally substituted by one or more halogen atom(s), . a (C3-C6) cycloalkyl group, . a (C2-C6) alkynyl group, . a (C1-C6) alkoxy group, . an aryl group optionally substituted by one or more halogen atom(s); — Rc represents a hydrogen atom or a (C1-C6) alkyl group optionally substituted by one or more halogen atom(s); or then Rb and Rc form, together with the nitrogen atom to which they are attached, a polycyclic heteroaryl group or a heterocycloalkyl group; — m and n represent, independently of one another, the value 0, 1 or 2, it being understood that m+n<3; — p and p' represent, independently of one another, the value 1, 2 or 3, it being understood that, when p is greater than or equal to 2, then the R2 groups are on separate carbon atoms and can be different from one another and, when p' is greater than or equal to 2, then the R3 groups are on separate carbon atoms and can be different from one another; — q represents the value 0 or 2, it being understood that, when q = 0, then the nitrogenous heterocyclic group attached to the nitrogen situated in the 1 position of the 2,4-dioxo-1,2,3,4-tetrahydroquinazoline ring system is no longer bridged and is of the type: with R1, R4, m and n as defined above, — r represents the value 0 or 1; in the form of bases or of addition salts with acids; intended to treat at least one cardiovascular disease and/or to prevent the appearance of at least one cardiovascular disease. 16. Compound according to the preceding claim, characterized in that the cardiovascular diseases are chosen from (i) coronary diseases, (ii) diseases of the cardiac muscle, (iii) diseases of the heart valves, (iv) diseases of the pericardium, (v) diseases of the heart rhythm and diseases of cardiac conduction, and (vi) diseases of the vessels. 17. Compound according to either one of Claims 15 and 16, characterized in that the cardiovascular disease is chosen from myocardial infarction, in particular contractile cardiac dysfunction resulting from a myocardial infarction, diseases associated with reperfusion injuries of the cardiac and/or skeletal muscle, pulmonary hypertension, hepatic fibrosis, post-angioplasty arterial restenosis, with or without fitting a stent, atherosclerosis and its complications, cardiac insufficiency, dilated cardiopathy and myocarditis of viral and/or bacterial origin. 18. Compound according to one of Claims 15 to 17, characterized in that: — A is as defined in Claim 5; — q, m and n are as defined in Claim 6; — R2 is as defined in Claim 7, Claim 8 or Claim 9. 19. Compound according to one of Claims 15 to 17, characterized in that: A is a phenyl, R1 is a -C(O)R group in which R represents a hydrogen atom, q is equal to 0, n and m each have the value 1 and R2 represents -ORa, Ra being as defined in Claim 1 or Claim 2. 20. Compound according to one of Claims 15 to 17, characterized in that: A is a phenyl, R1 is a -C(O)R group in which R represents a hydrogen atom, q is equal to 0, n and m each have the value 1, p = 1 and R2 represents a methyl substituted by an -NH-CO-Rb group, Rb being as defined in Claim 1 or Claim 2. 21. Compound according to one of Claims 15 to 17, characterized in that: A is a phenyl, R1 is a -C(O)R group in which R represents a hydrogen atom, q is equal to 0, n and m each have the value 1, p is equal to 2, one of the R2 groups is -ORa, Ra being as defined in Claim 1 or Claim 2, and the other of the R2 groups is a halogen atom. 22. Compound according to one of Claims 15 to 17, characterized in that: the R2 group is in the 6 position of the 2,4-dioxo-1,2,3,4-tetrahydroquinazoline ring system and in that there may additionally be an R2 group, identical to or different from the said R2 group mentioned above, in the 7 position of the 2,4-dioxo-1,2,3,4- tetrahydroquinazoline ring system, the said compound of formula (I) being in the base, hydrate or solvate form, in the form of isomers or in the form of their mixtures. 23. Compound according to one of Claims 15 to 17 chosen from: No. 1: 2-{[3-(3,4-dimethoxybenzyl)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]oxy}propanenitrile No. 2: 1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-6-hydroxyquinazoline- 2,4(1 H,3H)-dione No. 3: {[1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]oxy}acetonitrile No. 4: 2-{[1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]oxy}propanenitrile No. 5: {[3-(3,4-dimethoxybenzyl)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]oxy}acetonitrile No. 6: {[3-(3,4-dimethoxybenzyl)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]oxy}acetonithle No. 11: 4-[3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo- 3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 12: 1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1- (fluoromethyl)ethoxy]quinazoline-2,4(1H,3H)-dione No. 13: 4-[3-(3,4-dimethoxybenzyl)-2,4-dioxo-6-(2,2,2-trifluoroethoxy)-3,4- dihydroquinazolin-1 (2H)-yl]piperidine-1 -carbaldehyde No. 14: 1-(1-acetylpiperidin-4-yl)-6-(2,2-difluoroethoxy)-3-(3,4- dimethoxybenzyl)quinazoline-2,4(1H,3H)-dione No. 16: 4-[6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1 (2H)-yl]piperidine-1 -carbaldehyde No. 20: N-{[3-(3,4-dimethoxybenzyl)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]methyl}acetamide No. 22:1-(1-acetylpiperidin-4-yl)-6-(aminomethyl)-3-(3,4- dimethoxybenzyl)quinazoline-2,4(1 H,3H)-dione hydrochloride No. 23: N-{[3-(3,4-dimethoxybenzyl)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]methyl}formamide No. 24: N-{[1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]methyl}formamide No. 25: N-{[1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]methyl}acetamide No. 32:4-[6-(2,2-difluoroethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)- yl]piperidine-1-carbaldehyde No. 33: 4-[3-(3,4-dichlorobenzyl)-6-(2,2-difluoroethoxy)-2,4-dioxo-3,4- dihydroquinazolin-1 (2H)-yl]piperidine-1 -carbaldehyde No. 34:4-t3-(4-chlorobenzyl)-6-(2,2-difluoroethoxy)-2,4-dioxo-3,4- dihydroquinazolin-1 (2H)-yl]piperidine-1 -carbaldehyde No. 35: methyl 4-{[6-(2,2-difluoroethoxy)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4- dihydroquinazolin-3(2H)-yl]methyl}benzoate No. 36: 4-{[6-(2,2-difluoroethoxy)-1 -(1 -formylpiperidin-4-yl)-2,4-dioxo-1,4- dihydroquinazolin-3(2H)-yl]methyl}benzoicacid No. 37: 4-{[6-(2,2-difluoroethoxy)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4- dihydroquinazolin-3(2H)-yl]methyl}-N-(2-methoxyethyl)benzamide No. 38: 4-[3-(3,4-dimethoxybenzyl)-6-methyl-2,4-dioxo-3,4-dihydroquinazolin-1 (2H)- yl]piperidine-1 -carbaldehyde No. 39: 4-[6-(2,2-difluoroethoxy)-3-(3-hydroxy-4-methoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 40: 4-[6-(2,2-difluoroethoxy)-3-[3-(2-hydroxyethoxy)-4-methoxybenzyl]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 41: 4-[6-(2,2-difluoroethoxy)-3-(3-ethoxy-4-methoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yi]piperidine-1 -carbaldehyde No. 42: 4-[6-(2,2-difiuoroethoxy)-3-[4-methoxy-3-(2-methoxyethoxy)benzyl]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 43:4-[6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1 (2H)-yl]azepane-1 -carbaldehyde No. 47: 4-[6-(2,2-difluoroethoxy)-3-[3-(3-hydroxypropoxy)-4-methoxybenzyl]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 48: 4-[5-chloro-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)- yl]piperidine-1 -carbaldehyde No. 49: 4-{3-[3-(cyclopentyloxy)-4-methoxybenzyl]-6-(2,2-difluoroethoxy)-2,4-dioxo- 3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 50: 2-(5-{[6-(2,2-difluoroethoxy)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4- dihydroquinazolin-3(2H)-yl]methyl}-2-methoxyphenoxy)acetamide No. 51: 4-[6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-2(4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]-3-methylpiperidine-1-carbaldehyde No. 52:3-[6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]-8-azabicyclo[3.2.1]octane-8-carbaldehyde No. 55: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin- 1(2H)-yl}piperidine-1-carbaldehyde No. 56: 4-{3-[4-(cyclopentyloxy)-3-methoxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 57:4-[3-(3-chlorobenzyl)-6-[2-fluoro-1-{fluoromethyl)ethoxy]-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 58: 4-[3-(4-chlorobenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 59: 4-{3-[3-(cyclopentyloxy)-4-methoxybenzyl]-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 72: 4-[3-(3,4-dimethoxybenzyl)-6-(2-hydroxyethoxy)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 74: 4-[3-(3,4-dichlorobenzyl)-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 76: 4-{3-[(6-chloropyridin-3-yl)methyl]-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 78: 4-[3-(3-chloro-4-methoxybenzyl)-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 79:4-[3-(3,4-dimethoxybenzyl)-6-(2-fluoroethoxy)-2,4-dioxo-3,4- dihydroquinazolin-1 (2H)-yl]piperidine-1 -carbaldehyde No. 89: 2-[5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4- dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxyphenoxy]acetamide No. 90: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(3-hydroxy-4-methoxybenzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 91: 4-[3-(3,4-dimethoxybenzyl)-6-ethoxy-2,4-dioxo-3,4-dihydroquinazolin-1(2H)- yl]piperidine-1 -carbaldehyde No. 97: 4-[5,7-dichloro-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin- 1(2H)-yl]piperidine-1-carbaldehyde No. 102: 4-[7-chloro-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin- 1(2H)-yl]piperidine-1-carbaldehyde No. 108: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(3-fluoro-4-methoxybenzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 111: 4-[6-(difluoromethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1 -carbaldehyde No. 112: 4-[3-(3,4-dimethoxybenzyl)-6-(1-methylethoxy)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 114: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-methoxy-3-(1- methylethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 116: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-methoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 117: 4-{3-[3,5-bis(trifluoromethyl)benzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]- 2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 118: 4-[3-(3-ethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4- dihydroquinazolin-1 (2H)-yl]piperidine-1 -carbaldehyde No. 124: 4-{3-[3-chloro-4-(2-methoxyethoxy)benzyl]-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}pipericline-1 -carbaldehyde No. 130: 4-[3-(3,4-diethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo- 3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 131: 4-[3-(4-ethoxy-3-methoxybenzyl)-6-t2-fluoro-1 -(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 133: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(4-methoxy-3-methylbenzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 134: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4- (trifluoromethyl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 135: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4- (trifluoromethyl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 143: 4-{3-[4-(benzyloxy)-3-methoxybenzyl]-6-[2-fluoro-1 -(fluoromethyl)ethoxy]- 2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 145: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(3-methoxy-4-nitrobenzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 155: 4-[3-(4-ethoxybenzyl)-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 158: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[4-(morpholin-4-ylmethyl)benzyl]- 2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 160: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(4-(morpholin-4-yl)benzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 165: 4-[3-(biphenyl-4-ylmethyl)-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo- 3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 166: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[4-(methylsulphanyl)benzyl]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 167:4-{6-t2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyridin-3-yl)benzyl)- 3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 170:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-methoxy-4-methylbenzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 175:2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]acetamide No. 178: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(3-methoxy-4-propoxybenzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 183: 2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1-(1 - formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N- methylacetamide No. 184: 2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N,N- dimethylacetamide No. 185: 2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 - formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N- methoxy-N-methylacetamide No. 186: 4-{3-[4-(cyclopentyloxy)-3-ethoxybenzyl]-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 188: 4-{3-[4-(cyclopentyloxy)-3-(1-methylethoxy)benzyl]-6-t2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 189: 4-{3-[4-(cyclopentyloxy)-3-propoxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 190: 4-{3-[4-(cyclopentyloxy)-3-hydroxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 193: 4-{3-[4-(difluoromethoxy)-3-methoxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 194: 4-{3-[4-(difluoromethoxy)-3-ethoxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 200: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(thiophen-3-yl)- benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 201: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyridin-4-yl)benzyl)- 3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 203: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(1-methyl-1 H-indol-6-yl)methyl]- 2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 206: 4-{3-[4-(cyclopropylmethoxy)-3-methoxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 207:2-[4-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4- dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxyphenoxy]-N-methylacetamide No. 212:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4-(1H-pyrazol-1- yl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 213: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyridin-2-yl)benzyl)- 3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 215: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(thiophen-2-yl)- benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 216: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(quinolin-7-ylmethyl)- 3,4-dihydroquinazolin-1 (2H)-yl}piperidine-1 -carbaldehyde No. 218: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(6-methoxynaphthalen-2- yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 223: 4-{3-[4-(1 H-benzimidazol-1-yl)benzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]- 2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 224: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[3-methoxy-4-(2- methylpropoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 226: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[3-methoxy-4-(tetrahydrofuran-3- yloxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 228: 4-[3-{4-[(1 -benzylpyrrolidin-3-yl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoromethyl)6thoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 230: 4-[3-(1 -benzothiophen-5-ylmethyl)-6-[2-fluoro-1 -(fluorometrtyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 232: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4-(1 - methylethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 233: 4-[3-(3,4-dimethoxybenzyl)-7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxyj- 2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 234:4-[3-{4-[(1-acetylpyrrolidin-3-yl)oxy]-3-nriethoxybenzyl}-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 239:4-[3-{4-[(4-fluorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 240: 4-[3-{4-[(4-chlorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 242: 4-[3-{4-[(3-chlorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoramethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 243: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(3-(thiophen-3- yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 245: 4-[3-(4-ethoxy-3-methoxybenzyl)-6-(2-hydroxyethoxy)-2,4-dioxo-3,4- dihydroquinazolin-1 (2H)-yl]piperidine-1 -carbaldehyde No. 246: 4-[3-{4-[2-(2,3-dihydro-1 H-indol-1-yl)-2-oxoethoxy]-3-methoxybenzyl}-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 250: 4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 251: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4-(2-oxo-2-(piperidin- 1-yl)ethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 254: 4-{3-[3-ethoxy-4-(thiophen-2-ylmethoxy)benzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 258: 4-[3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1 -(hydroxymethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 263:(2R)-2-t2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- forrnylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]propanoic acid No. 264: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(1-methyl-3-(thiophen-2-yl)-1 H- pyrazol-5-yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 270: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(5-methyl-1,2,4-oxadiazol-3- yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 275: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyrimidin-5- yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 276: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(1-methyl-3-phenyl-1 H-pyrazol-5- yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 278:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-{[6-(1H-pyrazol-1- yl)pyridin-3-yl]methyl}-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 279:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[(2-(thiophen-2- yl)pyrimidin-5-yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 280:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(1-methyl-1H-pyrazol-3- yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 282: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(3-methyl-1,2,4-oxadiazol-5- yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 283: t2-(cyclopentyloxy)-5-({6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 - formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazoliri-3(2H)-yl}methyl)phenoxy]aceticacid No. 285: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-(thieno[2,3-blpyridin-2- ylmethyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 286: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-[(6-phenylpyridin-3- yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 287: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[(6-(morpholin-4-yl)pyridin-3- yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 289: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-[(6-(thiophen-2- yl)pyridin-3-yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 292: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(1 -methyl-5-phenyl-1 H-pyrazol-3- yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 294: 4-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo- 1,4-dihydroquinazolin-3(2H)-yl}methyl)biphenyl-2-carbonitrile No. 295: (2R)-2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 - formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N- methylpropanamide No. 297: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(thiophen-2- yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 298: 4-{6-[2-fluoro-1 -(f luoromethyl)ethoxy]-3-[3-methoxy-4-(morpholin-4- ylmethyl)benzyl]-2,4-clioxo-3,4-dihydroquinazolin-1(2H)-yl}pipericline-1-carbalclehyde No. 299: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[3-methoxy-4-(piperidin-1 - ylmethyl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 300: 4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1- (fiuoromethyl)ethoxy]-2I4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 301: 2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N- ethylacetamide No. 302: (2S)-2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 - formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]propanoic acid No. 305: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(3-methoxy-4-{[(3R)-2-oxo-1 - phenylpyrrolidin-3-yl]oxy}benzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 306: 4-{3-[4-(cyclobutylmethoxy)-3-methoxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 307: 4-{3-[4-(benzyloxy)-3-methoxybenzyl]-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 308: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(4-hydroxy-3- methoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 309: 4-{3-[4-(cyclopropylmethoxy)-3-methoxybenzyl]-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 310: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[3-methoxy-4- (2-methylpropoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 311: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4- (1-methylethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 312: 4-[3-(4-ethoxy-3-methoxybenzyl)-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 315: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-{[6-(3- methoxyphenyl)pyridin-3-yl]rnethyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 316:4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-{[6-(2- fluorophenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 317: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-{[6-(4- fluorophenyl)pyridin-3-yl]methyl}-2,4-dioxo-3I4-dihyclroquinazolin-1(2H)-yl}pipericline-1- carbaldehyde No. 318:4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-{[6-(4- methoxyphenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 319: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[(6-(thiophen-2- yl)pyridin-3-yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 320: 4-{3-[3-ethoxy-4-(thiophen-2-ylmethoxy)benzyl]-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 321: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[4-(1 -methyl-1 H-pyrazol- 3-yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 322: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyrimidin-5- yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 323: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[(1 -methyl-3-(thiophen-2- yl)-1H-pyrazol-5-yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 324: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[3-methoxy-4-(2-oxo-2- (piperidin-1 -yl)ethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1 (2H)-yl}piperidine-1 - carbaldehyde No. 325: 4-[3-{4-[2-(2,3-dihydro-1 H-indol-1 -yl)-2-oxoethoxy]-3-methoxybenzyl}-7- fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)- yl]piperidine-1-carbaldehyde No. 326: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[4-(5-methyl-1,2,4- oxadiazol-3-yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 327: 4-[3-{4-[(3-chlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 328:4-[3-{[6-(3,5-dichlorophenyl)pyridin-3-yl]methyl}-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde i No. 329: 4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)- 2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)biphenyl-2-carbonitrile No. 330: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-[4-(1 H-pyrazol- 1 -yl)benzyl]-3,4-dihydroquinazolin-1 (2H)-yl}piperidine-1 -carbaldehyde No. 331: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-{[6-(3- fluorophenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 332:3-[5-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4- yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)pyridin-2-yl]benzonitrile No. 333: 4-[3-(3,4-diethoxybenzyl)-7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 334: 4-[3-{4-[(4-chloroben2yl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 335: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(morpholin-4- ylmethyl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 336: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-{[6-(1 H-pyrazol- 1-yl)pyridin-3-yl]methyl}-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 337: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(4-(morpholin-4-yl)- benzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 338: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(3-methoxy-4- propoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 339:4-{3-[4-(1H-benzimidazol-1-yl)benzyl]-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 340: 5-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)- 2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxybenzonitrile No. 341: 3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- formylpiperidin-y4-dioxo-1.2.3.SAtetrahydroquinazoline-7-carbonitrile No. 342: 4-[3-(4-bromobenzyl)-7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 343:4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-(2-methoxyethoxy)benzyl}-7-fluoro-6- [2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 344: 4-{3-[4-(benzyloxy)benzyl]-7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 345: 4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-ethoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 349:4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-(2-fluoroethoxy)benzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 350:4-[3-{4-[(2-chloro-4-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 351: 4-[3-{4-[(2,4-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 352:4-[3-{4-[(2-chloro-6-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 353: 4-[3-{4-[(2,6-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihyclroquinazolin-1(2H)-yl]pipericline-1-carbaldehyde No. 354: 4-[3-{4-[(2-chlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 355: 4-[7-fluoro-3-{4-[(2-fluorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 357: 2-[(3,4-dichlorobenzyl)oxy]-5-({7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]- 1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)benzonitrile No. 358: 4-[3-{4-[(3,4-dich!orophenoxy)methyl]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 360: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4-(2- phenylethyl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 362: 4-[3-{4-[(4,5-dichloro-2-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 369: 4-[3-{4-[(4-chlorophenoxy)methyl]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 371: 4-[3-{3-chloro-4-[(4-chlorobenzyl)oxy]-5-ethoxybenzyl}-7-fluoro-6-[2-fluoro- 1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 373: 4-[3-{3-chloro-4-[(2,4-dichlorobenzyl)oxy]-5-ethoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 375: 4-[7-fluoro-3-{4-[(4-fluorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 376: 4-[3-{4-[(3,5-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 377: 4-[3-(4-{[4-chloro-3-(trifluoromethyl)benzyl]oxy}-3-methoxybenzyl)-7- fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)- yl]piperidine-1 -carbaldehyde No. 379: 4-[3-{4-[(3-chlorophenoxy)methyl]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 380: 4-[3-{4-f(3,5-difluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-t2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 381:4-{3-[4-(benzyloxy)-3-methoxybenzyl]-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 382:4-[3-{4-t(3-chloro-5-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2- fiuorc-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1 (2H)-y!]piperidine-1 - carbaldehyde No. 383: 4-{7-fluoro-6-[2-f!uoro-1 -(fluoromethyl)ethoxy]-3-(3-methoxy-4-{[4- (trifluoromethyl)benzyl]oxy}ben2yl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 384: 4-[3-{4-[(2,5-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-t2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 385: 4-{[4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4- yi)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2- methoxyphenoxy]methyl}benzonitrile No. 386: 3-{[4-({7-fluoro-6-[2-fluoro-1-(fiuoromethyl)ethoxy]-1-(1-formylpiperidin-4- yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2- methoxyphenoxy]methyl}benzonitrile No. 387: 4-[3-{4-[(4-chloro-2-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 388: 4-[3-{4-[1-(3,4-dichlorophenyl)ethoxy]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 389: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-{4-[(3-hydroxybenzy!)oxy]- 3-methoxybenzyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 390: 4-[7-fluoro-3-{4-t(3-fluorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fIuoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 391:4-[3-{4-[(3,4-difluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 392:4-{3-[4-(5,6-dichloro-1H-benzimidazol-1-yl)-3-methoxybenzyl]-7-fluoro-6- [2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 393:4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)- 2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenyl 3,4-dichlorobenzenesulphonate No. 394: 4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)- 2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxyphenyl 3,4-dichlorobenzene- sulphonate No. 403:3,4-dichloro-N-[4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2- methoxyphenyrjbenzamide; THERAPEUTIC APPLICATIONS IN THE CARDIOVASCULAR FIELD OF QUINAZOLINEDIONE DERIVATIVES A subject-matter of the invention is the use of quinazolinedione derivatives as medicaments or for manufacturing a medicament intended for the treatment and/or prevention of at least one cardiovascular disease. The invention relates more particularly to the use of quinazolinedione derivatives capable of acting as inhibitors of phosphodiesterase 7 (PDE7), indeed even, for some of these derivatives, capable of also acting as inhibitors of phosphodiesterase 8 (PDE8), it being known that it is not ruled out for these same quinazolinedione derivatives also to be capable of acting via other biological/biochemical routes on the cardiovascular system, with the aim of treating one or more cardiovascular condition(s) and/or preventing the appearance of such condition(s). Phosphodiesterases (PDEs) are intracellular enzymes responsible for the hydrolysis of cAMP (cyclic adenosine 3',5'-monophosphate) and cGMP (cyclic guanosine 3',5'-monophosphate) secondary messengers to give inactive 5'-monophosphate nucleotides. cAMP and cGMP play an essential role in cell signalling pathways and are involved in numerous physiological processes. The inhibition of phosphodiesterases is reflected by an increase in intracellular concentrations of cAMP and cGMP, resulting in the specific activation of phosphorylation pathways involved in varied functional responses. The increase in the intracellular concentrations of cAMP or of cGMP using selective inhibitors of phosphodiesterases appears to be a promising approach in the treatment of various diseases (Bender and Beavo, Pharmacol. Rev., (2006) 58, 488-520). The inhibitors of phosphodiesterases are thus of interest as therapeutic agents and as pharmacological tools. To date, eleven families of phosphodiesterases have been identified. They are distinguished by their primary structure, their substrate specificity and their sensitivity with regard to various effectors and inhibitors specific for PDEs. Each family is composed of one or more genes which are expressed in various tissues in the form of splicing variants (Bender and Beavo, Pharmacol. Rev, (2006) 58, 488-520; Lugnier, Pharmacol. Therapeut., (2006) 109, 366-398). PDE4, PDE7 and PDE8 specifically hydrolyse cAMP and PDE5, PDE6 and PDE9 specifically hydrolyse cGMP. The family PDE7 is represented by the isoforms PDE7A and PDE7B originating from two distinct genes. Human PDE7A (Michaeli et al., J. Biol. Chem, (1993) 268, 12925-12932; Han et al, J. Biol. Chem., (1997) 272, 16152-16157; Wang et al., Biochem. Biophys. Res. Commun, (2000) 276, 1271-1277) and human PDE7B (Sasaki et al, Biochem. Biophys. Res. Commun, (2000), 271, 575-583; Gardner et al, Biochem. Biophys. Res. Commun, (2000) 272, 186-192) selectively hydrolyse cAMP with Michaelis constants (Km) of 0.1 to 0.2 pM and 0.13 to 0.2 uM respectively. The catalytic part of PDE7B exhibits approximately 67% homology with that of PDE7A. Three splicing variants are known for PDE7A. PDE7A1 and PDE7A3 are expressed mainly in the cells of the immune system and of the lungs, while PDE7A2 is above all expressed in the muscles of the skeleton, the heart and the kidneys. For PDE7B, three variants have also recently been identified (Giembycz and Smith, Drugs Future, (2006)31,207-229). The tissue distribution profiles for PDE7A and PDE7B are very different, suggesting that these two isoforms have distinct functions from the physiological viewpoint. PDE7A is copiously expressed in haematopoietic cells, the lungs, the placenta, the spleen, the muscles of the skeleton, the heart, Leydig cells, the collecting tubes of the kidneys, and the adrenal glands. Strong expression of PDE7B is detected in the pancreas, the heart, the thyroid and the muscles of the skeleton (Giembycz and Smith, Drugs Future, (2006) 31, 207-229; Wang etal., Biochem. Biophys. Res. Commun. (2000), 276, 1271-1277). Coexpression of the messenger RNAs (mRNAs) of PDE7A and PDE7B is observed in some tissues. This is the case in the osteoblasts (Ahlstrom et al., Cell Mol. Biol. Lett., (2005) 10, 305-319) and in some regions of the brain: several areas of the cortex, the dentate gyrus, the majority of the components of the olfactory system, the striatum, numerous nuclei of the thalamus and the pyrimidal cells of the hippocampus (Miro et al., Synapse, (2001) 40, 201-214; Reyes-lrisarri et al., Neuroscience, (2005) 132, 1173-1185). In contrast, in some areas of the brain, only one of the two isoforms is expressed. Thus, only the mRNAs of PDE7A are present in many nuclei of the brain stem. Likewise, the mRNAs of PDE7B are present at high concentrations in the nucleus accombens and the dorsal motor nucleus of the vagus nerve, while the mRNAs of PDE7A are not detected there (Miro et al„ Synapse, (2001) 40, 201-214; Reyes-lrisarri et al., Neuroscience, (2005) 132, 1173-1185). A subject-matter of the present invention is in particular therapeutic applications of quinazolinedione derivatives, which can prove to be powerful inhibitors of PDE7, or of PDE7 and of PDE8, according to the derivatives, or which can act by other biological routes. The invention relates to the use of a compound corresponding to the following general formula (I): in which — A represents an aryl group or a heteroaryl group; — R1represents: ■ a hydrogen atom, ■ -C(O)R in which R is a hydrogen atom, a (C1-C6) alkoxy group, an aryl group, a (C3-C6) cycloalkyl group or a (C1-C6) alkyl group, the said alkyl optionally being substituted by: . one or more hydroxyl group(s), . a benzyloxy group, . a (C1-C6) alkoxy group, optionally substituted by an aryl, or . a (C3-C6) cycloalkyl group, ■ an optionally substituted (C1-C6) alkyl group; — R2 represents: ■ a hydrogen atom, ■ a halogen atom, ■ a cyano group, ■ a nitro group, ■ a (C1-C6) alkyl group optionally substituted by an -NH2 or else by an -NHC(O)Rb group, with Rb as defined below, ■ an -ORa group in which Ra represents: . a hydrogen atom, . a (C1-C6) alkyl group optionally substituted by one or more halogen atom(s), by one or more hydroxyl group(s), by an aryl group and/or by one or more cyano group(s), . a (C2-C6) alkynyl group, . an aryl group; — R3 represents: ■ a hydrogen atom, ■ a halogen atom, ■ a hydroxyl group, ■ a cyano group, ■ an -SCF3 group, ■ a nitro group, ■ an -S(O)0-2-alkyl group, an -S(O)0-2-heterocycloalkyl group, an -O-SO2-aryl group optionally substituted by one or more halogen atom(s); ■ an -alkylaminoalkyl or -cycloalkylaminoalkyl group, each optionally substituted on the end alkyl, ■ an optionally substituted sulphonamide group, ■ an aryl group or a heteroaryl group, the said group being monocyclic or polycyclic and in addition optionally being substituted by a (C1-C6) alkyi group, by one or more halogen atom(s) or by a (C1-C6) alkoxy group, ■ a heterocycloalkyl group optionally substituted by a (C1-C6) alkyl group, ■ a (C1-C6) alkyl group optionally substituted by: - one or more halogen atom(s), - an aryl group which can be substituted by one or more halogen atom(s) or by one or more hydroxyl group(s), - a heteroaryl group, - one or more hydroxyl group(s) which can be substituted by an aryl group itself optionally substituted by one or more halogen atom(s), or - a heterocycloalkyl group optionally substituted by a CO(O)Ra group or by a (C1-C6) alkyl group, Ra being as defined above, ■ a -C(O)NRbRc group, with Rb and Rc being as defined below, ■ a -C(O)ORc group or an -O-C(O)ORc group, with Rc being as defined below, ■ a (C1-C6) alkoxy group, optionally substituted by - an aminoalkyl group, - an aminocycloalkyl group, - a cycloalkyl group, - a heterocycloalkyl group, - a monocyclic or polycyclic heteroaryl group, - one or more hydroxyl group(s), - one or more halogen atom(s), - a (C1-C6) alkoxy group, - a -C(O)ORc group, with Rc being as defined below, - a -C(O)NRbRc group, with Rb and Rc being as defined below, and/or -an aryl group, itself optionally substituted by one or more halogen atom(s), a cyano group, a (C1-C6) alkoxy group, an -O-haloalkyl group and/or a haloalkyl group, ■ an -O-cycloalkyl group, an -O-aryl group or an -O-heterocycloalkyl group, each optionally substituted by -an aryl group, itself optionally substituted by one or more halogen atom(s) or by a (C1-C6) alkyl group, - one or more halogen atom(s), and/or - a (C1-C6) alkyl group, which can itself be substituted by an aryl group, ■ an -NH-CO-NH-aryl group, an -NH-CO-NH-heteroaryl group or an -NH-CO- NH-(C1-C6) alkyl group, each optionally being substituted by one or more halogen atom(s), by a cyano group, by a nitro group, by one or more hydroxyl group(s) or by a (C1-C6) alkoxy group, ■ an -N-(C1-C6) alkyl group, it being possible for the (C1-C6) alkyl group to be substituted by one or more aryl group(s) optionally substituted by one or more halogen atom(s) and/or by an SO2 group, ■ an -NH-CO-aryl group or an -NH-CO-heteroaryl group, each optionally being substituted by one or more halogen atom(s); or else R3 forms, with A, a polycyclic heteroaryl group optionally substituted by a (C1-C6) alkoxy group or a (C1-C6) alkyl group optionally substituted by an aryl group which can itself be substituted by one or more halogen atom(s); — R4 represents a hydrogen atom or a (C1-C6)alkyl group; — Rb represents: . a hydrogen atom, . a (C1-C6) alkyl group optionally substituted by one or more halogen atom(s), by one or more hydroxyl, cyano, amino, heterocycloalkyl or (C1-C6) alkoxy group(s) or by an aryl group optionally substituted by one or more halogen atom(s), . a (C3-C6) cycloalkyl group, . a (C2-C6) alkynyl group, . a (C1-C6) alkoxy group, . an aryl group optionally substituted by one or more halogen atom(s); — Rc represents a hydrogen atom or a (C1-C6) alkyl group optionally substituted by one or more halogen atom(s); or then Rb and Rc form, together with the nitrogen atom to which they are attached, a polycyclic heteroaryl group or a heterocycloalkyl group; — m and n represent, independently of one another, the value 0, 1 or 2, it being understood that m+n<3; — p and p' represent, independently of one another, the value 1, 2 or 3, it being understood that, when p is greater than or equal to 2, then the R2 groups are on separate carbon atoms and can be different from one another and, when p' is greater than or equal to 2, then the R3 groups are on separate carbon atoms and can be different from one another; — q represents the value 0 or 2, it being understood that, when q = 0, then the nitrogenous heterocyclic group attached to the nitrogen situated in the 1 position of the 2,4-dioxo-1,2,3,4-tetrahydroquinazoline ring system is no longer bridged and is of the type: with R-1, R4, m and n as defined above, — r represents the value 0 or 1, as medicament or for the preparation of a medicament which are intended to treat at least one cardiovascular disease and/or to prevent the appearance of at least one cardiovascular disease. The compounds of general formula (I) can comprise one or more asymmetric carbons. They can thus exist in the form of enantiomers or of diastereoisomers. These enantiomers or diastereoisomers, and their mixtures, including racemic mixtures, come within the invention. Due to their structure, the compounds of general formula (I) can also exist in the form of isomers of rotamer or atropisomer type. The compounds of formula (I) can also exist in the form of bases or addition salts with acids. Such addition salts come within the invention. These salts are advantageously prepared with pharmaceutical^ acceptable acids but the salts of other acids, for example of use in the purification or separation of the compounds of general formula (I) also come within the invention. The compounds of general formula (I) can also occur in the crystalline, amorphous or oily form, these forms coming within the invention. The compounds of general formula (I) can in addition occur in the form of hydrates or of solvates, namely in the form of combinations or of associations with one or more molecules of water or with a solvent. Such hydrates and solvates also come within the invention. According to the present invention, the N-oxides of the compounds comprising an amine also come within the invention. The compounds of formula (I) in accordance with the invention also comprise those in which one or more hydrogen, carbon or halogen, in particular chlorine or fluorine, atoms have been replaced by their radioactive isotopes, for example tritium, in order to replace hydrogen, or carbon-14, in order to replace carbon-12. Such labelled compounds are of use in research, metabolism or pharmacokinetic studies or in biological and pharmacological assays as tools. In the context of the invention, the following definitions apply: - in (C1.C6)' the numerical indices determine the possible number of carbon atoms present in a chain or a ring. Thus, by way of example, C1-C6 represents a carbon chain which can have from 1 to 6 carbon atoms. Likewise, by way of example, (C1-C5) represents a carbon chain which can have from 1 to 5 carbon atoms or also (C3-C6) can represent a saturated carbon ring which can have from 3 to 6 carbon atoms; -alkoxy: an -O-alkyl group comprising a saturated, linear or branched, aliphatic chain; - alkynyl: a mono- or polyunsaturated, linear or branched, aliphatic group comprising, for example, one or two acetylenic unsaturations. For example, a (C2-C6) alkynyl group can represent an ethynyl, propynyl, and the like; - alkyl: a saturated, linear or branched, aliphatic group; for example, a (C1-C6) alkyl group represents a linear or branched carbon chain of 1 to 6 carbon atoms, in particular a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl or pentyl; - aminoalkyl: an -NH(C1-C6) alkyl or also -N((C1-C6) alkyl)2 group; - aryl: an optionally substituted monocyclic aromatic system comprising from 5 to 14 members per ring, preferably from 5 to 10 members per ring. Mention may be made, as examples of monocyclic aryl groups, of phenyl or naphthyl; the aryl group can be substituted by a group which can be one or more halogen atom(s), a hydroxyl group, a cyano group, a trifluoromethylthio group, a nitro group, an alkyl group, an alkoxy group, an alkylthio group, a methylsulphonyl group, an alkylaminoalkyl group or alkylaminocycloalkyl group which is optionally substituted, an alkylaminoalkoxy or cycloalkylaminoalkoxy group or a sulphonamide group, for example: - polycyclic aryl: an optionally substituted polycyclic aromatic system comprising from 5 to 14 members per ring, preferably from 5 to 10 members per ring, and comprising from 2 to 10 rings, at least one of the rings of which is aromatic. Mention may be made, as examples of polycyclic aryl groups, of aceanthrylene, anthracene, azulene, coronene, rubicene or naphthalene; the polycyclic aryl group can be substituted by a group which can be one or more halogen atom(s), a hydroxyl group, a cyano group, a trifluoromethylthio group, a nitro group, an alkyl group, an alkoxy group, an alkylthio group, a methylsulphonyl group, an alkylaminoalkyl or alkylaminocycloalkyl group which is optionally substituted, an alkylaminoalkoxy or cycloalkylaminoalkoxy group or a sulphonamide group, for example; - a bridged ring: a bicyclic structure comprising, according to the invention, a nitrogen atom, in which at least two carbon atoms are connected via a single bond or a carbon chain which can comprise 2 carbon atoms. By way of example, the abovementioned ring is of the type: with q = 1 or 2 and with the other groups and indices as defined above; - cycloalkyl: a saturated cyclic aliphatic group comprising from 3 to 8 carbon atoms. Mention may be made, by way of example, of a cyclopropyl, methylcyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl group; - halogen: a fluorine, a chlorine, a bromine or an iodine; - haloalkyl: (C1-C6) alkyl substituted by one to three halogen atom(s); - heteroaryl: a monocyclic aromatic system comprising from 5 to 14 ring members, preferably from 5 to 10 ring members, and comprising one to several heteroatoms, such as nitrogen, oxygen or sulphur atoms. The nitrogen atoms can be in the form of N-oxides. For example, a monocyclic heterocycle can be a pyran, a pyrazine, a pyrazole, a pyridazine, a pyridine, a pyrimidine, a pyrrole, an isothiazole, an isoxazole, a furan, an imidazole, a morpholine, a thiophene, a piperazine, a diazetidine, a dihydropyrrolidine, a piperidine, an azepine, and the like; a bicyclic heterocycle can be an isoquinoline, a pteridine, a chroman, and the like; a tricyclic heterocycle can be a phenanthroline, a xanthene, and the like; - polycyclic heteroaryl: an optionally substituted polycyclic aromatic system comprising from 5 to 14 members per ring, preferably from 5 to 10 members per ring, and comprising from 2 to 10 rings, additionally comprising one to several heteroatoms, such as nitrogen, oxygen or sulphur atoms, in at least one of the rings, and at least one of the rings of which is aromatic. Mention may be made, as examples of polycyclic heteroaryl groups, of indole, benzofuran, benzimidazole, benzothiophene, benzotriazole, benzothiazole, benzoxazole, quinoline, isoquinoline, indazole, quinazoline, phthalazine, quinoxaline, naphthyridine, 2,3-dihydro-1H-indole, 2,3-dihydrobenzofuran, 2,3-dihydro- indene, tetrahydroquinoline, tetrahydroisoquinoline or tetrahydroisoquinazoline; - a heterocycloalkyl: an optionally substituted saturated ring comprising from 3 to 8 atoms and comprising one to several heteroatoms, such as nitrogen, oxygen or sulphur atoms, in at least one of the rings, or several heteroatoms which are identical to or different from one another. For example, a heterocycloalkyl can be a pyrrolidine, a morpholine, a piperazine, a diazetidine, a dihydropyrrolidine, a piperidine, a piperadine, an azepan, an imidazolidine, a thiomorpholine, a tetrahydropyran, a tetrahydrothiopyran, a piperazine, a diazepan, and the like; - hydroxyl: an -OH group; - nitro: an -N02 group; - oxo: a -C(O)- group; - sulphonamide: group corresponding to the formula SO2-N-alkyl or SO2-N-cyclo- alkyl, alkyl and cycloalkyl being as defined above; - trifluoromethylthio is defined by the formula -S-CF3. Furthermore, it is understood that, in the present description, when an atom or a group is substituted or optionally substituted by one or more defined group(s) or atom(s), the substituents can be identical to or different from one another and may be carried, if appropriate, by the same atom or different atoms. Mention may be made, among the compounds which are a subject-matter of the invention, of a group of compounds of formula (I) in which A represents an aryl group, in particular a phenyl or heteroaryl group, in particular a pyridyl group, and all the other substituents and indices are as defined in the general formula (I) defined above. Mention may be made, among the compounds in accordance with the invention, of a group of compounds of formula (I) in which q = 0, m and n each represents 1, and all the other substituents and indices are as defined in the general formula (I) defined above. Mention may be made, among the compounds in accordance with the invention, of a group of compounds of formula (I) in which R2 represents a (C1-C6) alkyl group, in particular a methyl, substituted by an -NHC(O)Rb group in which Rb and the other substituents and indices are as defined for the compound of general formula (I) defined above. Mention may be made, among the compounds in accordance with the invention, of a group of compounds of general formula (I) in which R2 represents an -ORa group, the Ra group and all the other substituents and indices being as defined in the general formula (I) defined above. Mention may be made, among the compounds in accordance with the invention, of a group of compounds of general formula (I) in which R2 is a halogen atom or a cyano or a hydrogen or a hydroxyl or a (C1-C6) alkyl optionally substituted by an -NH2, or else by an -NHC(O)Rb group, Rb and the other substituents and indices being as defined in the general formula (I) defined above. Mention may be made, among the compounds in accordance with the invention, of a group of compounds of general formula (I) in which A is a phenyl, R, is a -C(O)R group in which R represents a hydrogen atom, q is equal to 0, n and m each have the value 1, and R2 represents -ORa, Ra and the other substituents and indices being as defined in the general formula (I) defined above. Mention may be made, among the compounds in accordance with the invention, of a group of compounds of general formula (I) in which A is a phenyl, R, is a -C(O)R group in which R represents a hydrogen atom, q is equal to 0, n and m each have the value 1, p is equal to 2, one of the R2 groups is -ORa and the other of the R2 groups is a halogen atom, Ra and the other substituents and indices being as defined in the general formula (I) defined above. Mention may be made, among the compounds in accordance with the invention, of a group of compounds of general formula (I) in which A is a phenyl, R1 is a -C(O)R group in which R represents a hydrogen atom, q is equal to 0, n and m each have the value 1, p = 1 and R2 is a methyl substituted by an -NH-CO-Rb group, Rb and the other substituents and indices being as defined in the general formula (I) defined above. Advantageously, in the compounds of formula (I), the R2 group is in the 6 position of the 2,4-dioxo-1,2,3,4-tetrahydroquinazoline ring system. The compounds of formula (I) can also have an R2 group in the 7 position of the 2,4-dioxo-1,2,3,4-tetrahydroquinazoline ring system. The R2 groups in the 6 and 7 positions can be identical or different. Advantageously, in the compounds of formula (I), p is equal to 1 or 2. The compounds of general formula (I) can be in the base, hydrate or solvate form, in the form of isomers or in the form of their mixtures. In a specific form, when p' = 2, then the two R3 groups are in the 3 and 4 positions of the ring system A and can be different from one another. The combinations of the groups of compounds in accordance with the invention mentioned above also come within the invention. Mention may be made, as examples of preferred compounds in accordance with the invention, of the following compounds: No. 1: 2-{[3-(3,4-dimethoxybenzyl)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]oxy}propanenitrile No. 2: 1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-6-hydroxyquinazoline- 2,4(1 H,3H)-dione No. 3: {[1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]oxy}acetonitrile No. 4: 2-{[1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]oxy}propanenitrile No. 5: {[3-(3,4-dimethoxybenzyl)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]oxy}acetonitrile No. 11: 4-[3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo- 3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 12:1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1- (fluoromethyl)ethoxy]quinazoline-2,4(1H,3H)-dione No. 13:4-[3-(3,4-dimethoxybenzyl)-2,4-dioxo-6-(2,2,2-trifluoroethoxy)-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 14: 1-(1-acetylpiperidin-4-yl)-6-(2,2-difluoroethoxy)-3-(3,4- dimethoxybenzyl)quinazoline-2,4(1H,3H)-dione No. 16: 4-[6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 20: N-{[3-(3,4-dimethoxybenzyl)-1-(1-formylpiperidir-4--yl)-2,4dioxo-1 ,2,3,4- tetrahydroquinazolin-6-yl]methyl}acetamide No. 22: 1-(1-acetylpiperidin-4-yl)-6-(aminomethyl)-3-(3,4- dimethoxybenzyl)quinazoline-2,4(1 H,3H)-dione hydrochloride No. 23: N-{[3-(3,4-dimethoxybenzyl)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]methyl}formamide No. 24: N-{[1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]methyl}formamide No. 25: N-{[1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]methyl}acetamide No. 32:4-[6-(2,2-difluoroethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1 (2H)- yl]piperidine-1 -carbaldehyde No. 33:4-[3-(3,4-dichlorobenzyl)-6-(2,2-difluoroethoxy)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 34:4-[3-(4-chlorobenzyl)-6-(2,2-difluoroethoxy)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 35: methyl 4-{[6-(2,2-difluoroethoxy)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4- dihydroquinazolin-3(2H)-yl]methyl}benzoate No. 36: 4-{[6-(2,2-difluoroethoxy)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4- dihydroquinazolin-3(2H)-yl]methyl}benzoicacid No. 37: 4-{[6-(2,2-difluoroethoxy)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4- dihydroquinazolin-3(2H)-yl]methyl}-N-(2-methoxyethyl)benzamide No. 38: 4-t3-(3,4-dimethoxybenzyl)-6-methyl-2,4-dioxo-3,4-dihydroquinazolin-1 (2H)- yl]piperidine-1 -carbaldehyde No. 39:4-[6-(2,2-difluoroethoxy)-3-(3-hydroxy-4-methoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1 (2H)-yl]piperidine-1 -carbaldehyde No. 40:4-[6-(2,2-difluoroethoxy)-3-[3-(2-hydroxyethoxy)-4-methoxybenzyl]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 41:4-[6-(2,2-difluoroethoxy)-3-(3-ethoxy-4-methoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 42:4-[6-(2,2-difluoroethoxy)-3-[4-methoxy-3-(2-methoxyethoxy)benzyl]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 43:4-[6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]azepane-1-carbaldehyde No. 47:4-[6-(2,2-difluoroethoxy)-3-[3-(3-hydroxypropoxy)-4-methoxybenzyl]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 48: 4-[5-chloro-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1 (2H)- yl]piperidine-1 -carbaldehyde No. 49:4-{3-[3-(cyclopentyloxy)-4-methoxybenzyl]-6-(2,2-difluoroethoxy)-2,4-dioxo- 3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 50: 2-(5-{[6-(2,2-difluoroethoxy)-1 -(1-formylpiperidin-4-yl)-2,4-dioxo-1,4- dihydroquinazolin-3(2H)-yl]methyl}-2-methoxyphenoxy)acetamide No. 51: 4-[6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]-3-methylpiperidine-1-carbaldehyde No. 52:3-[6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]-8-azabicyclo[3.2.1]octane-8-carbaldehyde No. 56: 4-{3-[4-(cyclopentyloxy)-3-methoxybenzyl]-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 57: 4-[3-(3-chlorobenzyl)-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 58:4-[3-(4-chlorobenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 59: 4-{3-[3-(cyclopentyloxy)-4-methoxybenzyl]-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 72: 4-[3-(3,4-dimethoxybenzyl)-6-(2-hydroxyethoxy)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 74: 4-[3-(3,4-dichlorobenzyl)-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 76: 4-{3-[(6-chloropyridin-3-yl)methyl]-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 78: 4-[3-(3-chloro-4-methoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 79: 4-[3-(3,4-dimethoxybenzyl)-6-(2-fluoroethoxy)-2,4-dioxo-3,4- dihydroquinazolin-1 (2H)-yl]piperidine-1 -carbaldehyde No. 89:2-[5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4- dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxyphenoxy]acetamide No. 90: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-hydroxy-4-methoxybenzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 91: 4-[3-(3,4-dimethoxybenzyl)-6-ethoxy-2,4-dioxo-3,4-dihydroquinazolin-1 (2H)- yl]piperidine-1 -carbaldehyde No. 97: 4-[5,7-dichloro-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin- 1 (2H}-yl]piperidine-1 -carbaldehyde No. 102: 4-[7-chloro-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin- 1 (2H)-yl]piperidine-1 -carbaldehyde No. 108: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(3-fluoro-4-methoxybenzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 111: 4-[6-(difluoromethoxy)-3-(3,4-dimethoxybenzyl)-2l4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 112: 4-[3-(3 AdimethoxybenzyO-e-O-methylethoxy^^-dioxo-S^- dihydroquinazolin-I^HJ-yOpiperidine-l^arbaldehyde No. 114: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-methoxy-3-(1- methylethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 116:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-methoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 117: 4-{3-[3,5-bis(trifluoromethyl)benzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]- 2,4-dioxo-3>4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 118: 4-[3-(3-ethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 124:4-{3-[3-chloro-4-(2-methoxyethoxy)benzyl]-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 130:4-[3-(3,4-diethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo- 3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 131:4-[3-(4-ethoxy-3-methoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 133: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(4-methoxy-3-methylbenzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 134: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4- (trifluoromethyl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 135: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4- (trifluoromethyl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 143: 4-{3-[4-(benzyloxy)-3-methoxybenzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]- 2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 145:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-methoxy-4-nitrobenzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 155: 4-[3-(4-ethoxybenzyl)-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 158: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-t4-(morpholin-4-ylmethyl)benzylj- 2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 160: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(4-(morpholin-4-yl)benzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 165: 4-[3-(biphenyl-4-ylmethyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo- 3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 166:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(methylsulphanyl)benzyl]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 167: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyridin-3-yl)benzyl)- 3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 170: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(3-methoxy-4-methylbenzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 175: 2-[2-(cyclopentyloxy)-5-({6-t2-fluoro-1-(fluoromethyl)ethoxy]-1-(1 - formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]acetamide No. 178: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-methoxy-4-propoxybenzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 183:2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N- methylacetamide No. 184:2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N,N- dimethylacetamide No. 185:2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N- methoxy-N-methylacetamide No. 186: 4-{3-[4-(cyclopentyloxy)-3-ethoxybenzyl]-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 188: 4-{3-[4-(cyclopentyloxy)-3-(1 -methylethoxy)benzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 189: 4-{3-[4-(cyclopentyloxy)-3-propoxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 190: 4-{3-[4-(cyclopentyloxy)-3-hydroxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 193: 4-{3-[4-(difluoromethoxy)-3-methoxybenzyl]-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 194: 4-{3-[4-(difluoromethoxy)-3-ethoxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 200: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(thiophen-3-yl)- benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 201: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyridin-4-yl)benzyl)- 3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 203:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(1-methyl-1H-indol-6-yl)methyl]- 2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 206: 4-{3-[4-(cyclopropylmethoxy)-3-methoxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidin6-1-carbaldehyde No. 207: 2-[4-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4- dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxyphenoxy]-N-methylacetamide No. 212: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-[4-(1 H-pyrazol-1 - yl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 213: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyridin-2-yl)benzyl)- 3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 215: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(thiophen-2-yl)- benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 216: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(quinolin-7-ylmethyl)- 3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 218: 4-{6-t2-fluoro-1-(fluoromethyl)ethoxy]-3-[(6-methoxynaphthalen-2- yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 223: 4-{3-[4-(1 H-benzimidazol-1 -yl)benzyl]-6-[2-fluoro-1 -(fluoromethyl)ethoxy]- 2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 224: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[3-methoxy-4-(2- methylpropoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 226: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[3-methoxy-4-(tetrahydrofuran-3- yloxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 228: 4-[3-{4-[(1 -benzylpyrrolidin-3-yl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 230: 4-[3-(1-benzothiophen-5-ylmethyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 232: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4-(1- methylethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 233: 4-[3-(3,4-dimethoxybenzyl)-7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]- 2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 234: 4-[3-{4-[(1 -acetylpyrrolidin-3-yl)oxy]-3-methoxybenzyl}-6-t2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 239: 4-[3-{4-[(4-fluorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 240: 4-[3-{4-[(4-chlorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 242: 4-[3-{4-[(3-chlorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 243:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(3-(thiophen-3- yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 245: 4-[3-(4-ethoxy-3-methoxybenzyl)-6-(2-hydroxyethoxy)-2,4-dioxo-3,4- dihydroquinazolin-1 (2H)-yl]piperidine-1 -carbaldehyde No. 246: 4-[3-{4-[2-(2,3-dihydro-1 H-indol-1-yl)-2-oxoethoxy]-3-methoxybenzyl}-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 250: 4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3>4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 251:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4-(2-oxo-2-(piperidin- 1-yl)ethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 254: 4-{3-[3-ethoxy-4-(thiophen-2-ylmethoxy)benzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 258:4-[3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(hydroxymethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 263: (2R)-2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]propanoic acid No. 264:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(1-methyl-3-(thiophen-2-yl)-1H- pyrazol-5-yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 270: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(5-methyl-1,2,4-oxadiazol-3- yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 275: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyrimidin-5- yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 276: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(1-methyl-3-phenyl-1H-pyrazol-5- yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 278: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-{[6-(1H-pyrazol-1- yl)pyridin-3-yl]methyl}-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 279: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-[(2-(thiophen-2- yl)pyrimidin-5-yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 280: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(1-methyl-1H-pyrazol-3- yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 282: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(3-methyl-1,2,4-oxadiazol-5- yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 283: [2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- formylpiperidin-4-yl)-2,4-dioxo-1I4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]aceticacid No. 285: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(thieno[2,3-b]pyridin-2- ylmethyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 286: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-t(6-phenylpyridin-3- yl)methyl]-3,4-dihydroquinazoiin-1(2H)-yl}piperidine-1-carbaldehyde No. 287: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(6-(morpholin-4-yl)pyridin-3- yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 289: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[(6-(thiophen-2- yl)pyridin-3-yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 292: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(1-methyl-5-phenyl-1 H-pyrazol-3- yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 294: 4-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo- 1,4-dihydroquinazolin-3(2H)-yl}methyl)biphenyl-2-carbonitrile No. 295: (2R)-2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N- methylpropanamide No. 297: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(thiophen-2- yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 298: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[3-methoxy-4-(morpholin-4- ylmethyl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 299: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4-(piperidin-1- ylmethyl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 300: 4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydraquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 301: 2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N- ethylacetamide No. 302: (2S)-2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 - formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]propanoic acid No. 305: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(3-methoxy-4-{[(3R)-2-oxo-1- phenylpyrrolidin-3-yl]oxy}benzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 306: 4-{3-[4-(cyclobutylmethoxy)-3-methoxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 307: 4-{3-[4-(benzyloxy)-3-methoxybenzyl]-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 308: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(4-hydroxy-3- methoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 309: 4-{3-[4-(cyclopropylmethoxy)-3-methoxybenzyl]-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 310: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[3-methoxy-4- (2-methylpropoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 311: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4- (1-methylethoxy)benzyl]-2,4-dioxo-3,4-dihyclroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 312: 4-[3-(4-ethoxy-3-methoxybenzyl)-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 315: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-{[6-(3- methoxyphenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 316: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-{[6-(2- fluorophenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 317: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-{[6-(4- fluorophenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 318: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-{[6-(4- methoxyphenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 319: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-[(6-(thiophen-2- yl)pyridin-3-yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 320: 4-{3-t3-ethoxy-4-(thiophen-2-ylmethoxy)benzyl]-7-fluoro-6-t2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 321: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(1 -methyl-1 H-pyrazol- 3-yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 322:4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyrimidin-5- yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 323: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[(1 -methyl-3-(thiophen-2- yl)-1 H-pyrazol-5-yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1 (2H)-yl}piperidine-1 - carbaldehyde No. 324: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[3-methoxy-4-(2-oxo-2- (piperidin-1-yl)ethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 325: 4-[3-{4-[2-(2,3-dihydro-1 H-indol-1-yl)-2-oxoethoxy]-3-methoxybenzyl}-7- fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)- yl]piperidine-1 -carbaldehyde No. 326: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(5-methyl-1,2,4- oxadiazol-3-yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 327: 4-[3-{4-[(3-chlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-t2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 328:4-[3-{[6-(3,5-dichlorophenyl)pyridin-3-yl]methyl}-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 329:4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)- 2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)biphenyl-2-carbonitrile No. 330: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-[4-(1 H-pyrazol- 1-yl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 331: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-{[6-(3- fluorophenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 332: 3-[5-({7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 -formylpiperidin-4- yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)pyridin-2-yl]benzonitrile No. 333:4-[3-(3,4-diethoxybenzyl)-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 334: 4-[3-{4-[(4-chlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 335: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[4-(morpholin-4- ylmethyl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 336: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-{[6-(1 H-pyrazol- 1 -yl)pyridin-3-yl]methyl}-3,4-dihydroquinazolin-1 (2H)-yl}piperidine-1 -carbaldehyde No. 337: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(4-(morpholin-4-yl)- benzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 338:4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-methoxy-4- propoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 339: 4-{3-[4-(1 H-benzimidazol-1 -yl)benzyl]-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 340: 5-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)- 2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxybenzonitrile No. 341: 3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-7-carbonitrile No. 342: 4-[3-(4-bromobenzyl)-7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 343: 4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-(2-methoxyethoxy)benzyl}-7-fluoro-6- [2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 344: 4-{3-[4-(benzyloxy)benzyl]-7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 345: 4-f3-{4-[(3,4-dichlorobenzyl)oxy]-3-ethoxybenzyl}-7-fluoro-5-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 349:4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-(2-fluoroethoxy)benzyl}-7-fluoro-6-[2- fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1 (2H)-yl]piperidine-1 - carbaldehyde No. 350: 4-[3-{4-[(2-chloro-4-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 351: 4-[3-{4-[(2,4-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 352: 4-[3-{4-[(2-chloro-6-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 353: 4-[3-{4-[(2,6-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 354: 4-[3-{4-[(2-chlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 355: 4-[7-fluoro-3-{4-[(2-fluorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 357: 2-[(3,4-dichlorobenzyl)oxy]-5-({7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]- 1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)benzonitrile No. 358: 4-[3-{4-t(3,4-dichlorophenoxy)methyl]-3-methoxybenzyl}-7-fluoro-6-t2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 360:4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4-(2- phenylethyl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 362:4-[3-{4-[(4,5-dichloro-2-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 369: 4-[3-{4-[(4-chlorophenoxy)methyl]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 371:4-[3-{3-chloro-4-[(4-chlorobenzyl)oxy]-5-ethoxybenzyl}-7-fluoro-6-[2-fluoro- 1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 373: 4-[3-{3-chloro-4-[(2,4-dichlorobenzyl)oxy]-5-ethoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 375: 4-[7-fluoro-3-{4-[(4-fluorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 376: 4-[3-{4-[(3,5-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 377: 4-[3-(4-{[4-chloro-3-(trifluoromethyl)benzyl]oxy}-3-methoxybenzyl)-7- fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquina2olin-1(2H)- yl]piperidine-1 -carbaldehyde No. 379: 4-[3-{4-[(3-chlorophenoxy)methyl]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 380: 4-[3-{4-[(3,5-difluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2)4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 381:4-{3-[4-(benzyloxy)-3-methoxybenzyl]-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 382:4-[3-{4-[(3-chloro-5-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 383: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(3-methoxy-4-{[4- (trifluoromethyl)benzyl]oxy}benzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 384: 4-[3-{4-[(2,5-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 385: 4-{[4-({7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 -formylpiperidin-4- yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2- methoxyphenoxy]methyl}benzonitrile No. 386: 3-{[4-({7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 -formylpiperidin-4- yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2- methoxyphenoxy]methyl}benzonitrile No. 387: 4-[3-{4-[(4-chloro-2-fluorobenzyl)oxy]-3-methoxybenzylf7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 388:4-[3-{4-[1-(3,4-dichlorophenyl)ethoxy]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 389: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-{4-[(3-hydroxybenzyl)oxy]- 3-methoxybenzyl}-2>4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 390: 4-[7-fluoro-3-{4-[(3-fluorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 391: 4-[3-{4-[(3,4-difluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 392: 4-{3-[4-(5,6-dichloro-1H-benzimidazol-1-yl)-3-methoxybenzyl]-7-fluoro-6- [2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 393: 4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)- 2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenyl3,4-dichlorobenzenesulphonate No. 394: 4-({7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 -formylpiperidin-4-yl)- 2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxyphenyl3,4-dichloro benzene- sulphonate No. 403: 3,4-dichloro-N-[4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2- methoxyphenyl]benzamide The compounds in accordance with the invention can be prepared by the methods illustrated in the following Schemes 1 to 4. In that which follows, the term "leaving group" is understood to mean a group which can be easily substituted, with departure of an electron pair, by cleavage of a heterolytic bond. This group can thus be easily replaced by another group, for example during a substitution reaction. Such leaving groups are, for example, halogens or an activated hydroxyl group, such as a mesylate, tosylate, triflate, and the like. Examples of leaving groups and references for their preparation are given in "Advanced Organic Chemistry", J. March, 3rd Edition, Wiley Interscience, pp. 310-316. The term "protective group PG" is understood to mean a group which makes it possible to prevent the reactivity of a function group or position during a chemical reaction which may affect it and which restores the molecule after cleavage according to methods known to a person skilled in the art. The term "temporary protective group for amines or alcohols" is understood to mean the protective groups such as those described in Protective Groups in Organic Synthesis, Greene T.W. and Wuts P.G.M., published by Wiley Intersciences, 1999, and in Protecting Groups, Kocienski P.J., 1994, Georg Thieme Verlag. Mention may be made, for example, of temporary protective groups for amines: benzyls or carbamates (such as ferf-butoxycarbonyl, cleavable in an acid medium, or benzyloxycarbonyl, cleavable by hydrogenolysis), temporary protective groups for carboxylic acids: hydrogenolysable alkyl esters (such as methyl or ethyl or tert-butyl esters which can be hydrolysed in a basic or acid medium) and benzyl esters, temporary protective groups for alcohols or phenols, such as tetrahydropyranyl, methyloxymethyl or methylethoxymethyl, tert-butyl and benzyl ethers, or temporary protective groups for carbonyl derivatives, such as linear or cyclic acetals, such as, for example, 1,3-dioxan-2- yl or 1,3-dioxolan-2-yl; and reference may be made to the well known general methods described in Protective Groups, cited above. A person skilled in the art will be in the position to choose the appropriate protective groups according to the circumstances. The compounds of formula (I) can comprise precursor groups for other functional groups which are generated subsequently in one or more other stages. In the general synthetic schemes which follow, the starting compounds and the reactants, when their method of preparation is not described, are commercially available or are described in the literature or else can be prepared according to methods which are described therein or which are known to a person skilled in the art. The pure enantiomers of the compounds in accordance with the invention can be obtained from enantiomericaliy pure precursors or else by chiral phase chromatography or else, when the compounds comprise acid or amine functional groups, by selective crystallizations of diastereoisomeric salts obtained by reaction of the compounds (I) with chiral amines or chiral acids respectively. The compounds of general formula (I) can be obtained according to the following Schemes 1 to 4. Out of concern for clarity, the R4 group has been chosen as being a hydrogen, p and p' represent 1 and 2 respectively and the R2 and R3 groups have been set as indicated in the schemes. However, it is to be understood that R4 can be as defined in the general formula (I), that R2 and R3 can have the positions indicated in the general formula (I) and that p and p' can be as defined in the general formula (I). The synthetic routes described below serve solely as illustration and are under no circumstances limiting. A person skilled in the art can apply without difficulty the teaching below to the compounds of formula (I) for which R, R,, R2) R3, R». Ra, Rb, Re, m, n, p, p' and q are as defined in the general formula (I). According to Scheme 1, the compound of formula (IV) is obtained by a reductive amination reaction by reacting a compound of formula (II), in which R' represents a (C1-C6) alkyl group and R2 is as defined for the compound of formula (I) with a compound of formula (III) in an acid medium and in the presence of a reducing agent, such as sodium triacetoxyborohydride. The PG group of the compound of formula (III) is a protective group for the amine functional group which may advantageously be tert- butoxycarbonyl (boc). The compound of formula (IV) thus formed is subsequently acylated, according to methods well known to a person skilled in the art, with an alkyl or aryl chloroformate to give the compound of formula (V) in which R" represents a (Ci-Ce) alkyl group or an aryl group which is substituted. A hydrolysis reaction in a basic medium makes it possible to obtain the compounds of formula (VI) which, by a coupling reaction with a compound of formula (VII), in which R3 is as defined for the compound of formula (I), results in the compounds of formula (VIII). An intramolecular cyclization reaction in the basic medium makes it possible to obtain the quinazolinedione derivatives of formula (IX). The protective group PG for the amine functional group is subsequently cleaved, for example in acid medium when PG is a boc, to give the compounds of formula (la) which give, by an acylation reaction, the compounds of formula (lb). The compounds of formula (la) are compounds of formula (I) and can act as intermediate for other compounds of formula (I), such as the compounds of formula (lb). The compounds of formula (I) for which R2 represents -ORa, Ra being as defined for the compound of formula (I), correspond to the formula (Id). They can be obtained from the compounds of formula (X) according to the following Scheme 2. The compounds of formula (Ic), obtained by a hydrogenolysis reaction on the compounds of formula (X), are subjected, for example, to an alkylation reaction with an alkylating agent of type Ra-X, in which Ra is as defined for the compound of formula (I) and X represents a leaving group (such as a halogen atom, for example), in the presence of a base, such as caesium carbonate (Cs2C03), or also to a Mitsunobu reaction (Synthesis, 1981, 1) with an alcohol of type Ra-OH, Ra being as defined for the compound of formula (I), to give compounds of formula (Id). The compounds of formula (X) and the compounds of formula (Ic) are compounds of formula (I) and can act as intermediate for other compounds of formula (I), such as the compounds of formula (Id). Alternatively, the compounds of formula (Id) can be obtained by following the procedure described in Scheme 3. The compounds of formula (XII) are obtained by a nucleophilic aromatic substitution reaction involving a compound of formula (XI), in which R' is as defined above, and an alcohol of type Ra-OH, in which Ra is as defined for the compound of formula (I), in the presence of a base. The reduction of the nitro group of the compounds of formula (XII) results in the corresponding anilino derivatives (XIII). A reductive amination reaction with a compound of formula (III), in which PG is a protective group for amine functional groups, such as, for example, boc, results in the compounds of formula (XIV). The compounds of formula (XV) are obtained by reaction of a compound of formula (XIV) with potassium isocyanate (KNCO) in an acid medium. An intramolecular cyclization reaction in a basic medium makes it possible to obtain the compounds of formula (XVI). The protective group PG is cleaved by methods well known to a person skilled in the art to give the compounds of formula (XVII). An acylation reaction results in the compounds of formula (XVIII). Finally, the compounds of formula (Id) are obtained either by an alkylation reaction with a derivative of type (XIX), in which X represents a leaving group, such as a halogen atom, in the presence of a base, such as, for example, caesium carbonate, or also by a Mitsunobu reaction with a benzyl alcohol of type (XX). In the compounds (XIX) and (XX), R3 is as defined above. Scheme 3 The compounds of formula (le) and (If), in which R2 more particularly represents a group of type-CH2-NHC(O)Rb, Rb being defined as in the compound of formula (1), can be prepared according to the following Scheme 4. It is understood that, in Scheme 3, the R2 group illustrated is of -O-Ra type and is in the 6 position of the quinoazolinedione structure (see, for example, compound (XVIII)) but that it is also possible to have a second R2 group, as defined in the general formula (I), in the 7 position of the same quinazolinedione group. The reduction of the nitro group of the compounds of type (XXI), in which R' and PG' are as defined above, the PG' group advantageously being boc, results in the corresponding anilino derivatives (XXII) which, by a reductive amination reaction in which they react in an acid medium and advantageously in the presence of a reducing agent, such as sodium triacetoxyborohydride, with a compound of formula (III), in which PG represents a benzyloxycarbonyl protective group for amines, give compounds of formula (XXIII). An acylation reaction with an alkyl or aryl chloroformate, in which R" represents a (C1-C6) alkyl group or an aryl group which is substituted, results in the compounds of formula (XXIV). The quinazolinedione analogues of formula (XXV) can be obtained by a hydrolysis reaction in a basic medium and then by a coupling reaction with a compound of formula (VII), in which R3 is as defined for the compound of formula (I), followed by an intramolecular cyclization reaction in a basic medium. The PG' group (preferably a boc) is subsequently cleaved in an acid medium to result in the compounds of formula (XXVI) which, by acylation, give compounds of formula (XXVII), in which Rb is as defined for the compound of formula (I). The PG protective group of (XXVII) is cleaved by a hydrogenolysis reaction to give the compounds of formula (le). Finally, the compounds of formula (If) are obtained by an acylation reaction on the compounds of formula (le). It is obvious that a person skilled in the art will be in a position to choose, in the light of his knowledge and the literature, other appropriate protective groups which make possible the introduction of all the groups described in the general formula (I). When the compound of formula (I) comprises a bridged ring, it can be obtained without distinction by one of the synthetic routes described above. The following procedures and examples describe the preparation of some compounds in accordance with the invention. These procedures and examples are not limiting and serve only to illustrate the present invention. In the procedures and examples below: - the mass spectra are produced on a quadrupole spectrometer of Platform LCZ type (Waters) or of ZQ 4000 type (Waters) in positive electrospray ionization mode; - the NMR (nuclear magnetic resonance) spectra are produced on a Fourier transform spectrometer (Bruker) at a temperature of 300°C (exchangeable protons not recorded); - s = singlet, - d = doublet, - m = multiplet, - br = broad signal -1 = triplet, - q = quartet - DMSO-d6 = deuterated dimethyl sulphoxide, - CDCI3 = deuterated chloroform. The mixtures of solvents are quantified in volumetric ratios. The NMR spectra and mass spectra confirm the structures of the compounds obtained according to the examples below. In the examples which follow, the following abbreviations are used: ACN: acetonitrile AcOEt: ethyl acetate AcOH: acetic acid DBU: 1,8-diazabicyclo[5.4.0]undec-7-ene DCM: dichloromethane DCE: 1,2-dichloroethane DIAD: diisopropyl azodicarboxylate DIEA: diisopropylamine DMF: N,N-dimethylformamide EtOH: ethanol HBTU: 0-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate IBCF: isobutyl chloroformate MeOH: methanol NaBH(OAc)3: sodium triacetoxyborohydride AT: ambient temperature min: minute THF: tetrahydrofuran NEt3: triethylamine TFA: trifluoroacetic acid EXAMPLES The following examples describe the preparation of some compounds in accordance with the invention. These examples are not limiting and serve only to illustrate the present invention. The numbers of the compounds in the examples refer to those given in the table below, in which the chemical structures and the physical properties of a few compounds in accordance with the invention are illustrated. EXAMPLE 1: Compound No.°6 Preparation of {[3-(3,4-dimethoxybenzyl)-1-(1-formylpiperidin-4-yl)-2,4-dioxo- 1,2,3,4-tetrahydroquinazolin-6-yl]oxy}acetonitrile Stage 1.1: 1,1-Dimethylethyl 4-{[4-(benzyloxy)-2-(methoxycarbonyl)phenyl]ami- no}piperidine-1 -carboxylate A mixture of 2g of methyl 2-amino-5-(benzyloxy)benzoate, 3.1 g of 1,1-dimethylethyl 4-oxopiperidine-1-carboxylate and 3.29 g of NaBH(OAc)3 in 10 ml of AcOH is irradiated under a microwave field (Biotage Initiator Sixty) at 110DC for 20 min. The same reaction is repeated with two other lots of 2 g of methyl 2-amino-5- (benzyloxy)benzoate. The three reaction media are combined. The combined product is taken up in AcOEt. The organic phase is washed with water, with a saturated NH4CI solution and with a saturated NaHC03 solution, dried over Na2SO4 and filtered, and the solvent is evaporated under reduced pressure. The residue is chromatographed on silica gel, elution being carried out with an AcOEt/heptane mixture, (5/95, v/v) as far as (30/70, v/v), to give 10.2 g of the expected product. Stage 1.2: 1,1-Dimethylethyl 4-{[4-(benzyloxy)-2-(methoxycarbonyl)phenyl][(2-methyl- propoxy)carbonyl]amino}piperidine-1-carboxylate A mixture of 2g of 1,1-dimethylethyl 4-{[4-(benzyloxy)-2- (methoxycarbonyl)phenyl]amino}piperidine-1-carboxylate obtained in stage 1.1, 0.87 ml of DIEA, 1.78 ml of IBCF and 1 g of NaOH in 10 ml of DCE is irradiated under a microwave field at 80°C for 30 min. The same reaction is repeated with 4 other lots of 2 g of 1,1-dimethylethyl 4-{[4-(benzyloxy)-2-(methoxycarbonyl)phenyl]amino}piperidine-1- carboxylate. The 5 reaction media are combined. The combined product is taken up in AcOEt and filtered, and the filtrate is evaporated under reduced pressure. The residue is chromatographed on silica gel, elution being carried out with an AcOEt/heptane mixture, (10/90, v/v) as far as (50/50, v/v), to give 9.3 g of the expected product. Stage 1.3: Sodium salt of 5-(benzyloxy)-2-({1-[(1,1-dimethylethoxy)carbonyl]-piperidin- 4-yl}[(2-methylpropoxy)carbonyl]amino)benzoic acid A mixture of 9.3 g of 1,1-dimethylethyl 4-{[4-(benzyloxy)-2- (methoxycarbonyl)phenyl][(2-methylpropoxy)carbonyl]amino}piperidine-1-carboxylate obtained in stage 1.2 and 34.4 ml of 2N NaOH in 57 ml of MeOH is heated at 100°C for 3h 00. The solution is evaporated under reduced pressure and DCM is added. Drying is carried out over Na2SO4, filtration is carried out and the solvent is evaporated under reduced pressure to give 8.7 g of the expected product. Stage 1.4: 1,1-Dimethylethyl 4-[{4-(benzyloxy)-2-[(3,4-dimethoxybenzyl)carbamoyl]phe- nyl}(isobutoxycarbonyl)amino]piperidine-1-carboxylate A mixture of 6g of sodium salt of 5-(benzyloxy)-2-({1-[(1,1- dimethylethoxy)carbonyl]piperidin-4-yl}[(2-methylpropoxy)carbonyl]amino)benzoic acid obtained in stage 1.3 and 4.42 g of DIEA in 250 ml of DMF is stirred at AT for 15 min. 6.48 g of HBTU are added and the mixture is left stirring for 30 min. 2.48 g of veratrylamine are added and the reaction mixture is stirred for 48h 00. It is evaporated under reduced pressure, the residue is taken up in AcOEt, washed with a saturated NH4CI solution and with a saturated NaHC03 solution, dried over Na2SO4 and filtered, and the solvent is evaporated under reduced pressure. The residue is chromatographed on silica gel, elution being carried out with an AcOEt/heptane mixture, (20/80, v/v) as far as (60/40, v/v), to give 7.5 g of expected product. Stage 1.5: 1,1-Dimethylethyl 4-[6-(benzyloxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carboxylate A mixture of 2.5 g of 1,1-dimethylethyl 4-[{4-(benzyloxy)-2-[(3,4- dimethoxybenzyl)carbamoyl]phenyl}(isobutoxycarbonyl)amino]piperidine-1-carboxylate obtained in stage 1.4 and 7.4 g of NaOH in 18.5 ml of DCE is irradiated under a microwave field at 110°C for 30 min. The same reaction is repeated with 2 other lots of 2.5 g of 1,1-dimethylethyl 4-[{4-(benzyloxy)-2-[(3,4-dimethoxybenzyl)carbamoyl]phenyr}- (isobutoxycarbonyl)amino]piperidine-1-carboxylate. The 3 reaction media are combined. The combined product is taken up in DCM, washed with water, dried over Na2SO4 and filtered, and the solvent is evaporated under reduced pressure to give 6.6 g of expected product. Stage 1.6: A mixture of 3.5 g of 1,1-dimethylethyl 4-[6-(benzyloxy)-3-(3,4-dimethoxybenzyl)- 6-(Benzyloxy)-3-(3,4-dimethoxybenzyl)-1-(piperidin-4-yl)quinazoline- 2,4(1 H,3H)-dione 2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carboxylate obtained in stage 1.5 and 25 ml of TFA in 50 ml of DCM is stirred at AT for 2h 00. The mixture is neutralized with K2C03. It is filtered and the filtrate is evaporated under reduced pressure. The residue is taken up in DCM and washed with a saturated NaHC03 solution and then with an 8% NaOH solution. The solution is dried over Na2SO4 and filtered, and the solvent is evaporated under reduced pressure to give 2.67 g of the expected product. Stage 1.7: 4-[6-(Benzyloxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin- 1(2H)-yl]piperidine-1-carbaldehyde A mixture of 0.6 g of 6-(benzyloxy)-3-(3,4-dimethoxybenzyl)-1-(piperidin-4- yl)quinazoline-2,4(1H,3H)-dione obtained in stage 1.6 and 0.113 g of ammonium formate in 5 ml of ACN is irradiated under a microwave field at 140°C for 1h 00. The mixture is filtered and the filtrate is evaporated under reduced pressure to give 0.62 g of the expected product. Stage 1.8: Compound No. 5: 4-[3-(3,4-Dimethoxybenzyl)-6-hydroxy-2,4-dioxo-3,4-dihydroquinazolin-1(2H)- yl]pi peridine-1 -carbaidehyde A mixture of 0.618 g of 4-[6-(benzyloxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde obtained in stage 1.7, 0.44 g of ammonium formate and 0.124 g of Pd/C (10%) in 10 ml of EtOH purged beforehand with nitrogen is irradiated under a microwave field at 80°C for 2h 00. The mixture is filtered and the filtrate is evaporated under reduced pressure to give 0.513 g of the expected product. Stage 1.9: Compound No. 6 {[3-(3,4-Dimethoxybenzyl)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]oxy}acetonitrile 0.17 g of 4-[3-(3,4-dimethoxybenzyl)-6-hydroxy-2,4-dioxo-3,4-dihydroquinazolin- 1(2H)-yl]piperidine-1-carbaldehyde obtained in stage 1.8 and 0.25 g of Cs2C03 in 3 ml of DMF are stirred for 15 min at AT. 0.056 g of bromoacetonitrile is added and the reaction mixture is subsequently irradiated under a microwave field at 100°C for 15 min. It is filtered and evaporated under reduced pressure. The residue is chromatographed on silica gel, elution being carried out with an MeOH/DCM mixture, (1/99, v/v) as far as (4/96, v/v), to give 0.112 g of the expected product. EXAMPLE 2: Compound No. 3 Preparation of {[1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo- 1,2,3,4-tetrahydroquinazolin-6-yl]oxy}acetonitriie Stage 2.1: 1-(1-Acetylpiperidin-4-yl)-6-(benzyloxy)-3-(3,4-dimethoxybenzyl)quinazoline- 2,4(1 H,3H)-dione 0.14 g of acetyl chloride is added to a mixture of 0.6 g of 6-(benzyloxy)-3-(3,4- dimethoxybenzyl)-1-(piperidin-4-yl)quinazoline-2,4(1H,3H)-dione obtained according to stage 1.6 and 0.24 g of NEt3 in 10 ml of DCM cooled to 0°C. The mixture is stirred at AT overnight. It is washed twice with a saturated NH4CI solution and filtered, and then the filtrate is evaporated under reduced pressure to give 0.64 g of the expected product. Stage 2.2: Compound No. 2 1-(1-Acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-6-hydroxyquinazoline- 2,4(1 H,3H)-dione A mixture of 0.64 g of 1-(1-acetylpiperidin-4-yl)-6-(benzyloxy)-3-(3,4- dimethoxybenzyl)quinazoline-2,4(1H,3/-/)-dione obtained in stage 2.1, 0.44 g of ammonium formate and 0.125 g of Pd/C (10%) in 10 ml of EtOH purged beforehand with nitrogen is irradiated under a microwave field at 80°C for 2h 00. The mixture is filtered and the filtrate is evaporated under reduced pressure to give 0.48 g of the expected product. Stage 2.3: Compound No. 3 {[1-(1-Acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]oxy}acetonitrile 0.12 g of 1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-6-hydroxyquinazoline- 2,4(1 H,3H)-dione obtained in stage 2.2 and 0.172 g of Cs2C03 in 3 ml of DMF are stirred for 15 min at AT. 0.038 g of bromoacetonitrile is added and the reaction mixture is subsequently irradiated under a microwave field at 100°C for 15 min. It is filtered and the filtrate is evaporated under reduced pressure. The residue is chromatographed on silica gel, elution being carried out with an MeOH/DCM mixture, (1/99, v/v) as far as (4/96, v/v), to give 0.094 g of the expected product. EXAMPLE 3: Compound No. 34 Synthesis of 4-[3-(4-chlorobenzyl)-6-(2,2-difluoroethoxy)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde Stage 3.1: Methyl 5-(2,2-difluoroethoxy)-2-nitrobenzoate 8.53 g of 2,2-difluoroethanol are added to a solution of 17.31 g of methyl 5-fluoro- 2-nitrobenzoate, 9.64 g of NEt3 and 32.71 g of 2,8,9-triisobutyl-2,5,8,9-tetraaza-1- phosphabicyclo[3.3.3]undecane in 250 ml of anhydrous THF. The mixture is stirred at AT for 30 min. The solvent is evaporated under reduced pressure. Water is added and extraction is carried out with AcOEt. The extract is washed with a 1N aqueous HCI solution, with water and then with a saturated NaCI solution. It is dried over MgSO^ and filtered, and the solvent is evaporated under reduced pressure to give 21 g of the expected product. 21 g of methyl 5-(2,2-difluoroethoxy)-2-nitrobenzoate obtained in stage 3.1 and 1 g of Pd/C (10%) in a mixture of 300 ml of AcOEt, 50 ml of EtOH and 5 ml of AcOH are stirred at AT under a hydrogen atmosphere for 24h 00. The mixture is filtered and evaporated under reduced pressure to give 18.6 g of the expected product. Stage 3.3: 1,1-Dimethylethyl 4-{[4-(2,2-difluoroethoxy)-2-(methoxycarbonyl)phenyl]ami- no}pi peri di ne-1 -carboxylate A mixture of 4 g of methyl 2-amino-5-(2,2-difluoroethoxy)benzoate and 6.88 g of 1,1-dimethylethyl 4-oxopiperidine-1-carboxylate obtained in stage 3.2 in 15 ml of AcOH is heated at 90°C for 10 min. It is allowed to cool to AT and 7.3 g of NaBH(OAc)3 are added. The mixture is left stirring at AT for 12h 00. It is extracted with AcOEt and the extract is washed with a saturated K2C03 solution and then with water. It is dried over MgSO4, filtered and evaporated under reduced pressure to give 6.63 g of the expected product. Stage 3.4: 1,1 -Dimethylethyl 4-{carbamoyl[4-(2,2-difluoroethoxy)-2-(methoxycarbonyl)- phenyl]amino}piperidine-1-carboxylate 1.95 g of potassium isocyanate in solution of 4 ml of water are added to a solution of 6.63 g of 1,1-dimethylethyl 4-{[4-(2,2-difluoroethoxy)-2-(methoxycarbonyl)phenyl] amino}piperidine-1-carboxylate obtained in stage 3.3 in 40 ml of AcOH. The mixture is stirred at AT for 12h 00. It is extracted with AcOEt and the extract is washed with a saturated K2C03 solution and then with water. It is dried over MgSO4, filtered and evaporated under reduced pressure to give 6.95 g of the expected product. Stage 3.5: 1,1-Dimethylethyl 4-[6-(2,2-difluoroethoxy)-2,4-dioxo-3,4-dihydroquinazolin- 1(2H)-yl]piperidine-1-carboxylate 2.5 g of 1,1-dimethylethyl 4-{carbamoyl[4-(2,2-difluoroethoxy)-2- (methoxycarbonyl)phenyl]amino}piperidine-1-carboxylate obtained in stage 3.4 in solution in a mixture of 10 ml of dioxane and 5 ml of a 1N aqueous NaOH solution are irradiated under a microwave field at 130°C for 30 min. Extraction is carried out with AcOEt and the extract is neutralized with a 1N aqueous HCI solution, washed with water, dried over MgSO4, filtered and evaporated under reduced pressure. The residue obtained is triturated in an AcOEt/pentane mixture to give the expected product. The same reaction is reproduced with 2 other lots of 2.5 g of 1,1-dimethylethyl 4-{carbamoyl[4-(2,2- difluoroethoxy)-2-(methoxycarbonyl)phenyl]amino}piperidine-1 -carboxylate obtained in stage 3.4 to give, in total, 5.63 g of expected product. Stage 3.6: 6-(2,2-Difluoroethoxy)-1-(piperidin-4-yl)quinazoline-2,4(1H,3H)-dione A solution of 5.63 g of 1,1-dimethylethyl 4-[6-(2,2-difluoroethoxy)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carboxylate obtained in stage 3.5 in 70 ml of formic acid is stirred at AT for 2h 00. The solvent is evaporated under reduced pressure to give 6.13 g of the expected product in the form of the formic acid salt. Stage 3.7: 4-[6-(2,2-Difluoroethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2W)- yl]piperidine-1-carbaldehyde A mixture of 6.13 g of 6-(2,2-difluoroethoxy)-1-(piperidin-4-yl)quinazoline- 2,4(1 H,3H)-6\one obtained in stage 3.6 and 3.12 g of ammonium formate in 28 ml of ACN and 28 ml of dioxane is irradiated under a microwave field at 140°C for 1h 00. The reaction mixture is run into water. The mixture is filtered and the precipitate is washed with water and then with ether to give 4.47 g of the expected product. Stage 3.8: Compound No. 34 4-[3-(4-Chlorobenzyl)-6-(2,2-difluoroethoxy)-2,4-dioxo-3,4-dihydroquinazolin- 1 (2H)-y I] piperid i ne-1 -carba Idehyde A mixture of 0.15 g of 4-[6-(2,2-difluoroethoxy)-2,4-dioxo-3,4-dihydroquinazolin- 1(2H)-yl]piperidine-1-carbaldehyde obtained in stage 3.7, 0.096 g of 1-(bromomethyl)-4- chlorobenzene and 0.3 g of Cs2C03 in 3 ml of DMF is stirred at AT for 1h 00. AcOEt is added and washing is carried out with water and then with a saturated NaCI solution. The organic phase is dried over MgSO4, filtered and evaporated under reduced pressure. The residue is chromatographed on silica gel, elution being carried out with AcOEt, to give 0.116 g of the expected product. EXAMPLE 4: Compound No. 49 Synthesis of 4-{3-[3-(cyclopentyloxy)-4-methoxybenzyl]-6-(2,2-difluoro- ethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2W)-yl}piperidine-1-carbaldehyde 0.172 g of DIAD is added to a solution of 0.15 g of 4-[6-(2,2-difluoroethoxy)-2,4- dioxo-3,44-dioxo-3,4-dihydroquinazolin-1(2H)- yl]piperidine-1 -carbaldehyde No. 39:4-t6-(2,2-difluoroethoxy)-3-(3-hydroxy-4-methoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1 (2H)-yl]piperidine-1 -carbaldehyde No. 40:4-t6-(2,2-difluoroethoxy)-3-[3-(2-hydroxyethoxy)-4-methoxybenzyl]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 41:4-[6-(2,2-difluoroethoxy)-3-(3-ethoxy-4-methoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 42:4-[6-(2,2-difluoroethoxy)-3-[4-methoxy-3-(2-methoxyethoxy)benzyl]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 43:4-[6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1 (2H)-yl]azepane-1 -carbaldehyde No. 47: 4-[6-(2,2-difluoroethoxy)-3-[3-(3-hydroxypropoxy)-4-methoxybenzyl]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 48: 4-[5-chloro-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)- yl]piperidine-1-carbaldehyde No. 49: 4-{3-[3-(cyclopentyloxy)-4-methoxybenzyl]-6-(2,2-difluoroethoxy)-2,4-dioxo- 3,4-dihydroquinazolin-1 (2H)-yl}piperidine-1 -carbaldehyde No. 50: 2-(5-{[6-(2,2-difluoroethoxy)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4- dihydroquinazolin-3(2H)-yl]methyl}-2-methoxyphenoxy)acetamide No. 51:4-[6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]-3-methylpiperidine-1-carbaldehyde No. 52: 3-t6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]-8-azabicyclo[3.2.1]octane-8-carbaldehyde No. 55: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin- 1(2H)-yl}piperidine-1-carbaldehyde No. 56: 4-{3-[4-(cyclopentyloxy)-3-methoxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2I4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 57: 4-[3-(3-chlorobenzyl)-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3,4- dihydroquinazolin-1 (2H)-yl]piperidine-1 -carbaldehyde No. 58: 4-[3-(4-chlorobenzyl)-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3,4- dihydroquinazolin-1 (2H)-yl]piperidine-1 -carbaldehyde No. 59: 4-{3-[3-(cyclopentyloxy)-4-methoxybenzyl]-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 72:4-[3-(3,4-dimethoxybenzyl)-6-(2-hydroxyethoxy)-2,4-dioxo-3,4- dihydroquinazolin-1 (2H)-yl]piperidine-1 -carbaldehyde No. 74: 4-[3-(3,4-dichlorobenzyl)-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 76:4-{3-[(6-chloropyridin-3-yl)methyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 78: 4-[3-(3-chloro-4-methoxybenzyl)-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 79:4-[3-(3,4-dimethoxybenzyl)-6-(2-fluoroethoxy)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 89: 2-[5-({6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 -formylpiperidin-4-yl)-2,4- dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxyphenoxy]acetamide No. 90: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(3-hydroxy-4-methoxybenzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 91:4-[3-(3,4-dimethoxybenzyl)-6-ethoxy-2,4-dioxo-3,4-dihydroquinazolin-1(2H)- yl]piperidine-1 -carbaldehyde No. 97: 4-[5,7-dichloro-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin- 1(2H)-yl]piperidine-1-carbaldehyde No. 102: 4-[7-chloro-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin- 1(2H)-yl]piperidine-1-carbaldehyde No. 108: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(3-fluoro-4-methoxybenzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 111: 4-[6-(difluoromethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 112: 4-[3-(3,4-dimethoxybenzyl)-6-(1-methylethoxy)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 114: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-methoxy-3-(1- methylethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 116: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-methoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 117: 4-{3-[3,5-bis(trifluoromethyl)benzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]- 2,4-dioxo-3,4-dihydroquinazolin-1 (2H)-yl}piperidine-1 -carbaldehyde No. 118: 4-[3-(3-ethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 124: 4-{3-[3-chloro-4-(2-methoxyethoxy)benzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 130: 4-[3-(3,4-diethoxybenzyl)-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo- 3,4-dihydroquinazolin-1 (2H)-yl]piperidine-1 -carbaldehyde No. 131:4-[3-(4-ethoxy-3-methoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 133; 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(4-methoxy-3-methylbenzy()-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 134: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4- (trifluoromethyl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 135: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4- (trifluoromethyl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 143: 4-{3-[4-(benzyloxy)-3-methoxybenzyl]-6-[2-fluoro-1 -(fluoromethyl)ethoxy]- 2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 145: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(3-methoxy-4-nitrobenzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 155: 4-[3-(4-ethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 158; 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[4-(morpholin-4-ylmethyl)benzyl]- 2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 160:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(4-(morpholin-4-yl)benzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 165: 4-[3-(biphenyl-4-ylmethyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo- 3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 166:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(methylsulphanyl)benzyl]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1 -carbaldehyde No. 167:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyridin-3-yl)benzyl)- 3,4-dihydroquinazolin-1 (2H)-yl}piperidine-1 -carbaldehyde No. 170: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(3-methoxy-4-methylbenzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 175: 2-t2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]acetamide No. 178: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(3-methoxy-4-propoxybenzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 183: 2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 - formylpiperidin-4-yl)-2,4-ciioxo-1,4-dihyclroquinazolin-3(2H)-yl}methyl)phenoxy]-N- methylacetamide No. 184: 2-[2-(cyclopentyloxy)-5-({6-t2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 - formylpiperidin-4-yl)-2,4-dioxo-1l4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N,N- dimethylacetamide No. 185: 2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 - formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N- methoxy-N-methylacetamide No. 186: 4-{3-[4-(cyclopentyioxy)-3-ethoxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 188;4-{3-[4-(cyclopentyloxy)-3-(1-methylethoxy)benzyl]-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 189: 4-{3-[4-(cyclopentyloxy)-3-propoxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 190: 4-{3-[4-(cydopentyloxy)-3-hydroxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 193: 4-{3-[4-(difluoromethoxy)-3-methoxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 194: 4-{3-[4-(difluoromethoxy)-3-ethoxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 200: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(thiophen-3-yl)- benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 201: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyridin-4-yl)benzyl)- 34-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 203: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[(1 -methyl-1 H-indol-6-yl)methyl]- 2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 206: 4-{3-[4-(cyclopropylmethoxy)-3-methoxybenzyl]-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No.207:2-[4-<{6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2f4- dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxyphenoxy]-N-methylacetamide No. 212: 4-{6-[2-fIuoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4-(1 H-pyrazol-1 - yl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 213:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyridin-2-yl)benzyl)- 3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 215:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(thiophen-2-yl)- benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 216: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(quinolin-7-ylmethyl)- 3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 218: 4-{5-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[(6-methoxynaphthalen-2- yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 223: 4-{3-[4-(1 H-benzimidazol-1-yl)benzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]- 2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 224: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[3-methoxy-4-(2- methylpropoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 226: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[3-methoxy-4-(tetrahydrofuran-3- yloxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 228:4-[3-{4-[(1-benzylpyrrolidin-3-yl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1- (fIuoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 230: 4-[3-(1-benzothiophen-5-ylmethyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 232: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4-(1- methylethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 233: 4-[3-(3,4-dimethoxybenzyl)-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]- 2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 234:4-t3-{4-[(1-acetylpyrrolidin-3-yl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 239: 4-[3-{4-[(4-fluorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 240: 4-[3-{4-[(4-chlorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 242: 4-t3-{4-[(3-chlorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 243: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(3-(thiophen-3- yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 245: 4-[3-(4-ethoxy-3-methoxybenzyl)-6-(2-hydroxyethoxy)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 246: 4-[3-{4-[2-(2,3-dihydro-1 H-indol-1-yl)-2-oxoethoxy]-3-methoxybenzyl}-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 250: 4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-methoxybenzyl}-6-t2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 251: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[3-methoxy-4-(2-oxo-2-(piperidin- 1-yl)ethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 254: 4-{3-[3-ethoxy-4-(thiophen-2-ylmethoxy)benzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 258: 4-[3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1 -(hydroxymethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 263: (2R)-2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 - formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]propanoic acid No. 264:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(1-methyl-3-(thiophen-2-yl)-1H- pyrazol-5-yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 270: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(5-methyl-1,2,4-oxadiazol-3- yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 275: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyrimidin-5- yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 276: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(1-methyl-3-phenyl-1H-pyrazol-5- yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 278: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-{[6-(1H-pyrazol-1- yl)pyridin-3-yl]methyl}-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 279: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-[(2-(thiophen-2- yl)pyrimidin-5-yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 280: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[4-(1 -methyl-1 H-pyrazol-3- yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 282: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[4-(3-methyl-1,2,4-oxadiazol-5- yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 283: [2-(cyclopentyloxy)-5-({6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 - formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]aceticacid No. 285:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(thieno[2,3-b]pyridin-2- ylmethyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 286: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[(6-phenylpyridin-3- yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 287: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[(6-(morpholin-4-yl)pyridin-3- yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 289: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-[(6-(thiophen-2- yl)pyridin-3-yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 292: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[(1 -methyl-5-phenyl-1 H-pyrazol-3- yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 294: 4-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo- 1,4-dihydroquinazolin-3(2H)-yl}methyl)biphenyl-2-carbonitrile No. 295:(2R)-2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- formylpiperidin-4-yl)-2,4-dioxo-1,4-clihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N- methylpropanamide No. 297: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(thiophen-2- yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 298: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[3-methoxy-4-(morpholin-4- ylmethyl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 299: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4-(piperidin-1 - ylmethyl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 300:4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 301:2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N- ethylacetamide No. 302: (2S)-2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 - formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]propanoic acid No. 305:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-methoxy-4-{[(3R)-2-oxo-1- phenylpyrrolidin-3-yl]oxy}benzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 306: 4-{3-[4-(cyclobutylmethoxy)-3-methoxybenzyi]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 307: 4-{3-[4-(benzyloxy)-3-methoxybenzyl]-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 308: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(4-hydroxy-3- methoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 309: 4-{3-[4-(cyclopropylmethoxy)-3-methoxybenzyl]-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 310: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[3-methoxy-4- (2-methylpropoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 311: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4- (1-methylethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 312: 4-[3-(4-ethoxy-3-methoxybenzyl)-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 315: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-{[6-(3- methoxyphenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 316: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-{[6-(2- fluorophenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 317: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-{[6-(4- fluorophenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 318: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-{[6-(4- methoxyphenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 319:4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[(6-(thiophen-2- yl)pyridin-3-yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 320: 4-{3-[3-ethoxy-4-(thiophen-2-ylmethoxy)benzyl]-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 321: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[4-(1 -methyl-1 H-pyrazol- 3-yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 322: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyrimidin-5- yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 323: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[(1 -methyl-3-(thiophen-2- yl)-1 H-pyrazol-5-yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1 (2H)-yl}piperidine-1 - carbaldehyde No. 324: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[3-methoxy-4-(2-oxo-2- (piperidin-1-yl)ethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 325: 4-[3-{4-[2-(2,3-dihydro-1 H-indol-1 -yl)-2-oxoethoxy]-3-methoxybenzyl}-7- fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)- yl]piperidine-1 -carbaldehyde No. 326: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(5-methyl-1,2,4- oxadiazol-3-yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 327: 4-[3-{4-[(3-chlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 328: 4-[3-{[6-(3,5-dichlorophenyl)pyridin-3-yl]methyl}-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 329: 4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)- 2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)biphenyl-2-carbonitrile No. 330: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4-(1 H-pyrazol- 1-yl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 331: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-{[6-(3- fluorophenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 332: 3-[5-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4- yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)pyridin-2-yl]benzonitrile No. 333:4-[3-(3,4-diethoxybenzyl)-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 334: 4-[3-{4-[(4-chlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 335: 4-{7-fluoro-6-[2-fluoro-1 -(fluorotnethyl)ethoxy]-3-t4-(morpholin-4- ylmethyl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 336: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-{[6-(1 H-pyrazol- 1-yl)pyridin-3-yl]methyl}-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 337: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(4-(morpholin-4-yl)- benzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1 -carbaldehyde No. 338: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(3-methoxy-4- propoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 339: 4-{3-[4-(1 H-benzimidazol-1 -yl)benzyl]-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 340: 5-({7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1-formylpiperidin-4-yl)- 2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxybenzonitrile No. 341: 3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 - formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-7-carbonitrile No. 342: 4-[3-(4-bromobenzyl)-7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 343:4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-(2-methoxyethoxy)benzyl}-7-fluoro-6- [2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 344: 4-{3-[4-(benzyloxy)benzyl]-7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 345: 4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-ethoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 349:4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-(2-fluoroethoxy)benzyl}-7-fluoro-6-[2- fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1 (2H)-yl]piperidine-1 - carbaldehyde No. 350:4-[3-{4-[(2-chloro-4-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2l4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 351:4-[3-{4-[(2,4-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 352: 4-[3-{4-[(2-chloro-6-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 353: 4-[3-{4-[(2,6-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 354: 4-[3-{4-[(2-chlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-t2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 355: 4-[7-fluoro-3-{4-[(2-fluorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3>4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 357: 2-[(3,4-dichlorobenzyl)oxy]-5-({7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]- 1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)benzonitrile No. 358: 4-[3-{4-[(3,4-dichlorophenoxy)methyl]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 360: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-t4-(2- phenylethyl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 362: 4-[3-{4-[(4,5-dichloro-2-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 369: 4-[3-{4-[(4-chlorophenoxy)methyl]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 371: 4-[3-{3-chloro-4-[(4-chlorobenzyl)oxy]-5-ethoxybenzyl}-7-fluoro-6-[2-fluoro- 1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 373:4-[3-{3-chloro-4-[(2,4-dichlorobenzyl)oxy]-5-ethoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 375: 4-[7-fluoro-3-{4-[(4-fluorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 376: 4-[3-{4-[(3,5-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 377: 4-[3-(4-{[4-chloro-3-(trifluoromethyl)benzyl]oxy}-3-methoxybenzyl)-7- fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)- yl]piperidine-1-carbaldehyde No. 379: 4-[3-{4-[(3-chlorophenoxy)methyl]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 380: 4-[3-{4-[(3,5-difluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 381: 4-{3-[4-(benzyloxy)-3-methoxybenzyl]-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 382: 4-[3-{4-[(3-chloro-5-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 383: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(3-methoxy-4-{[4- (trifluoromethyl)benzyl]oxy}benzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 384: 4-[3-{4-[(2,5-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 385: 4-{[4-({7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 -formylpiperidin-4- yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2- methoxyphenoxy]methyl}benzonitrile No. 385: 3-{[4-({7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 -formylpiperidin-4- yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2- methoxyphenoxy]methyl}benzonitrile No. 387:4-[3-{4-t(4-chloro-2-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 388:4-[3-{4-[1-(3,4-dichlorophenyl)ethoxy]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 389: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-{4-[(3-hydroxybenzyl)oxy]- 3-methoxybenzyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 390: 4-[7-fluoro-3-{4-[(3-fluorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 391:4-[3-{4-[(3,4-difluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 392: 4-{3-[4-(5,6-dichloro-1 H-benzimidazol-1-yl)-3-methoxybenzyl]-7-fluoro-6- [2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 393: 4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)- 2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenyl 3,4-dichlorobenzenesulphonate No. 394: 4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)- 2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxyphenyl3,4-dichlorobenzene- sulphonate No. 403: 3,4-dichloro-N-[4-({7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 - formylpiperidin-4-yl)-2,4-dioxo-1,4-clihydroquinazolin-3(2H)-yl}nnethyl)-2- methoxyphenyl]benzamide; in the form of the base or of an addition salt with an acid. 15. Compound corresponding to the general formula (I) in which — A represents an aryl group or a heteroaryl group; — R1 represents: ■ a hydrogen atom, ■ -C(O)R in which R is a hydrogen atom, a (C1-C6) alkoxy group, an aryl group, a (C3-C6) cycloalkyl group or a (C1-C6) alkyl group, the said alkyl optionally being substituted by: . one or more hydroxyl group(s), . a benzyloxy group, . a (C1-C6) alkoxy group, optionally substituted by an aryl, or . a (C3-C6) cycloalkyl group, ■ an optionally substituted (C1-C6) alkyl group; — R2 represents: ■ a hydrogen atom, ■ a halogen atom, ■ a cyano group, ■ a nitro group, ■ a (C1-C6) alkyl group optionally substituted by an -NH2 or else by an -NHC(O)Rb group, with Rb as defined below, ■ an -ORa group in which Ra represents: . a hydrogen atom, . a (C1-C6) alkyl group optionally substituted by one or more halogen atom(s), by one or more hydroxyl group(s), by an aryl group and/or by one or more cyano group(s), . a (C2-C6) alkynyl group, . an aryl group; — R3 represents: ■ a hydrogen atom, ■ a halogen atom, ■ a hydroxyl group, ■ a cyano group, ■ an -SCF3 group, ■ a nitro group, ■ an -S(O)0-2-alkyl group, an -S(O)0-2-heterocycloalkyl group, an -O-SO2-aryl group optionally substituted by one or more halogen atom(s); ■ an -alkylaminoalkyl or -cycloalkylaminoalkyl group, each optionally substituted on the end alkyl, ■ an optionally substituted sulphonamide group, ■ an aryl group or a heteroaryl group, the said group being monocyclic or polycyclic and in addition optionally being substituted by a (C1-C6) alkyl group, by one or more halogen atom(s) or by a (C1-C6) alkoxy group, ■ a heterocycloalkyl group optionally substituted by a (C1-C6) alkyl group, ■ a (C1-C6) alkyl group optionally substituted by: - one or more halogen atom(s), - an aryl group which can be substituted by one or more halogen atom(s) or by one or more hydroxyl group(s), - a heteroaryl group, - one or more hydroxyl group(s) which can be substituted by an aryl group itself optionally substituted by one or more halogen atom(s), or - a heterocycloalkyl group optionally substituted by a CO(O)Ra group or by a (C1-C6) alkyl group, with Ra as defined above, ■ a -C(O)NRbRc group, with Rb and Rc as defined below, ■ a -C(O)ORc group or an -O-C(O)ORc group, with Rc as defined below, ■ a (C1-C6) alkoxy group, optionally substituted by - an aminoalkyl group, - an aminocycloalkyl group, - a cycloalkyl group, - a heterocycloalkyl group, - a monocyclic or polycyclic heteroaryl group, - one or more hydroxyl group(s), - one or more halogen atom(s), - a (C1-C6) alkoxy group, - a -C(O)ORc group, with RC as defined below, - a -C(O)NRbRc group, with Rb and Rc as defined below, and/or - an aryl group, itself optionally substituted by one or more halogen atom(s), a cyano group, a (C1-C6) alkoxy group, an -O-haloalkyl group and/or a haloalkyl group, ■ an -O-cycloalkyl group, an -O-aryl group or an -O-heterocycloalkyl group, each optionally substituted by - an aryl group, itself optionally substituted by one or more halogen atom(s) or by a (C1-C6) alkyl group, - one or more halogen atom(s), and/or - a (C1-C6) alkyl group, which can itself be substituted by an aryl group, ■ an -NH-CO-NH-aryl group, an -NH-CO-NH-heteroaryl group or an -NH-CO- NH-(C1-C6) alkyl group, each optionally being substituted by one or more halogen atom(s), by a cyano group, by a nitro group, by one or more hydroxyl group(s) or by a (C1-C6) alkoxy group, ■ an -N-(C1-C6) alkyl group, it being possible for the (C1-C6) alkyl group to be substituted by one or more aryl group(s) optionally substituted by one or more halogen atom(s) and/or by an SO2 group, ■ an -NH-CO-aryl group or an -NH-CO-heteroaryl group, each optionally being substituted by one or more halogen atom(s); or else R3 forms, with A, a polycyclic heteroaryl group optionally substituted by a (C1-C6) alkoxy group or a (C1-C6) alkyl group optionally substituted by an aryl group which can itself be substituted by one or more halogen atom(s); — R4 represents a hydrogen atom or a (C1-C6) alkyl group; — Rb represents: . a hydrogen atom, . a (C1-C6) alkyl group optionally substituted by one or more halogen atom(s), by one or more hydroxyl, cyano, amino, heterocycloalkyl or (C1-C6) alkoxy group(s) or by an aryl group optionally substituted by one or more halogen atom(s), . a (C3-C6) cycloalkyl group, . a (C2-C6) alkynyl group, . a (C1-C6) alkoxy group, . an aryl group optionally substituted by one or more halogen atom(s); — Rc represents a hydrogen atom or a (C1-C6) alkyl group optionally substituted by one or more halogen atom(s); or then Rb and Rc form, together with the nitrogen atom to which they are attached, a polycyclic heteroaryl group or a heterocycloalkyl group; — m and n represent, independently of one another, the value 0, 1 or 2, it being understood that m+n<3; — p and p' represent, independently of one another, the value 1, 2 or 3, it being understood that, when p is greater than or equal to 2, then the R2 groups are on separate carbon atoms and can be different from one another and, when p' is greater than or equal to 2, then the R3 groups are on separate carbon atoms and can be different from one another; — q represents the value 0 or 2, it being understood that, when q = 0, then the nitrogenous heterocyclic group attached to the nitrogen situated in the 1 position of the 2,4-dioxo-1,2,3,4-tetrahydroquinazoline ring system is no longer bridged and is of the type: with R1, R4, m and n as defined above, — r represents the value 0 or 1; in the form of bases or of addition salts with acids; intended to treat at least one cardiovascular disease and/or to prevent the appearance of at least one cardiovascular disease. 16. Compound according to the preceding claim, characterized in that the cardiovascular diseases are chosen from (i) coronary diseases, (ii) diseases of the cardiac muscle, (iii) diseases of the heart valves, (iv) diseases of the pericardium, (v) diseases of the heart rhythm and diseases of cardiac conduction, and (vi) diseases of the vessels. 17. Compound according to either one of Claims 15 and 16, characterized in that the cardiovascular disease is chosen from myocardial infarction, in particular contractile cardiac dysfunction resulting from a myocardial infarction, diseases associated with reperfusion injuries of the cardiac and/or skeletal muscle, pulmonary hypertension, hepatic fibrosis, post-angioplasty arterial restenosis, with or without fitting a stent, atherosclerosis and its complications, cardiac insufficiency, dilated cardiopathy and myocarditis of viral and/or bacterial origin. 18. Compound according to one of Claims 15 to 17, characterized in that: — A is as defined in Claim 5; — q, m and n are as defined in Claim 6; — R2 is as defined in Claim 7, Claim 8 or Claim 9. 19. Compound according to one of Claims 15 to 17, characterized in that: A is a phenyl, R1 is a -C(O)R group in which R represents a hydrogen atom, q is equal to 0, n and m each have the value 1 and R2 represents -ORa, Ra being as defined in Claim 1 or Claim 2. 20. Compound according to one of Claims 15 to 17, characterized in that: A is a phenyl, R1 is a -C(O)R group in which R represents a hydrogen atom, q is equal to 0, n and m each have the value 1, p = 1 and R2 represents a methyl substituted by an -NH-CO-Rb group, Rb being as defined in Claim 1 or Claim 2. 21. Compound according to one of Claims 15 to 17, characterized in that: A is a phenyl, R1 is a -C(O)R group in which R represents a hydrogen atom, q is equal to 0, n and m each have the value 1, p is equal to 2, one of the R2 groups is -ORa, Ra being as defined in Claim 1 or Claim 2, and the other of the R2 groups is a halogen atom. 22. Compound according to one of Claims 15 to 17, characterized in that: the R2 group is in the 6 position of the 2,4-dioxo-1,2,3,4-tetrahydroquinazoline ring system and in that there may additionally be an R2 group, identical to or different from the said R2 group mentioned above, in the 7 position of the 2,4-dioxo-1,2,3,4- tetrahydroquinazoline ring system, the said compound of formula (I) being in the base, hydrate or solvate form, in the form of isomers or in the form of their mixtures. 23. Compound according to one of Claims 15 to 17 chosen from: No. 1: 2-{[3-(3,4-dimethoxybenzyl)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]oxy}propanenitrile No. 2: 1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-6-hydroxyquinazoline- 2,4(1 H,3H)-dione No. 3: {[1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]oxy}acetonitrile No. 4: 2-{[1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]oxy}propanenitrile No. 5: {[3-(3,4-dimethoxybenzyl)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]oxy}acetonitrile No. 6: {[3-(3,4-dimethoxybenzyl)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]oxy}acetonithle No. 11: 4-[3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo- 3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 12: 1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1- (fluoromethyl)ethoxy]quinazoline-2,4(1H,3H)-dione No. 13: 4-[3-(3,4-dimethoxybenzyl)-2,4-dioxo-6-(2,2,2-trifluoroethoxy)-3,4- dihydroquinazolin-1 (2H)-yl]piperidine-1 -carbaldehyde No. 14: 1-(1-acetylpiperidin-4-yl)-6-(2,2-difluoroethoxy)-3-(3,4- dimethoxybenzyl)quinazoline-2,4(1H,3H)-dione No. 16: 4-[6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1 (2H)-yl]piperidine-1 -carbaldehyde No. 20: N-{[3-(3,4-dimethoxybenzyl)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]methyl}acetamide No. 22:1-(1-acetylpiperidin-4-yl)-6-(aminomethyl)-3-(3,4- dimethoxybenzyl)quinazoline-2,4(1 H,3H)-dione hydrochloride No. 23: N-{[3-(3,4-dimethoxybenzyl)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]methyl}formamide No. 24: N-{[1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]methyl}formamide No. 25: N-{[1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-6-yl]methyl}acetamide No. 32:4-[6-(2,2-difluoroethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)- yl]piperidine-1-carbaldehyde No. 33: 4-[3-(3,4-dichlorobenzyl)-6-(2,2-difluoroethoxy)-2,4-dioxo-3,4- dihydroquinazolin-1 (2H)-yl]piperidine-1 -carbaldehyde No. 34:4-t3-(4-chlorobenzyl)-6-(2,2-difluoroethoxy)-2,4-dioxo-3,4- dihydroquinazolin-1 (2H)-yl]piperidine-1 -carbaldehyde No. 35: methyl 4-{[6-(2,2-difluoroethoxy)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4- dihydroquinazolin-3(2H)-yl]methyl}benzoate No. 36: 4-{[6-(2,2-difluoroethoxy)-1 -(1 -formylpiperidin-4-yl)-2,4-dioxo-1,4- dihydroquinazolin-3(2H)-yl]methyl}benzoicacid No. 37: 4-{[6-(2,2-difluoroethoxy)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4- dihydroquinazolin-3(2H)-yl]methyl}-N-(2-methoxyethyl)benzamide No. 38: 4-[3-(3,4-dimethoxybenzyl)-6-methyl-2,4-dioxo-3,4-dihydroquinazolin-1 (2H)- yl]piperidine-1 -carbaldehyde No. 39: 4-[6-(2,2-difluoroethoxy)-3-(3-hydroxy-4-methoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 40: 4-[6-(2,2-difluoroethoxy)-3-[3-(2-hydroxyethoxy)-4-methoxybenzyl]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 41: 4-[6-(2,2-difluoroethoxy)-3-(3-ethoxy-4-methoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yi]piperidine-1 -carbaldehyde No. 42: 4-[6-(2,2-difiuoroethoxy)-3-[4-methoxy-3-(2-methoxyethoxy)benzyl]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 43:4-[6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1 (2H)-yl]azepane-1 -carbaldehyde No. 47: 4-[6-(2,2-difluoroethoxy)-3-[3-(3-hydroxypropoxy)-4-methoxybenzyl]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 48: 4-[5-chloro-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)- yl]piperidine-1 -carbaldehyde No. 49: 4-{3-[3-(cyclopentyloxy)-4-methoxybenzyl]-6-(2,2-difluoroethoxy)-2,4-dioxo- 3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 50: 2-(5-{[6-(2,2-difluoroethoxy)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4- dihydroquinazolin-3(2H)-yl]methyl}-2-methoxyphenoxy)acetamide No. 51: 4-[6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-2(4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]-3-methylpiperidine-1-carbaldehyde No. 52:3-[6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]-8-azabicyclo[3.2.1]octane-8-carbaldehyde No. 55: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin- 1(2H)-yl}piperidine-1-carbaldehyde No. 56: 4-{3-[4-(cyclopentyloxy)-3-methoxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 57:4-[3-(3-chlorobenzyl)-6-[2-fluoro-1-{fluoromethyl)ethoxy]-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 58: 4-[3-(4-chlorobenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 59: 4-{3-[3-(cyclopentyloxy)-4-methoxybenzyl]-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 72: 4-[3-(3,4-dimethoxybenzyl)-6-(2-hydroxyethoxy)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 74: 4-[3-(3,4-dichlorobenzyl)-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 76: 4-{3-[(6-chloropyridin-3-yl)methyl]-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 78: 4-[3-(3-chloro-4-methoxybenzyl)-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 79:4-[3-(3,4-dimethoxybenzyl)-6-(2-fluoroethoxy)-2,4-dioxo-3,4- dihydroquinazolin-1 (2H)-yl]piperidine-1 -carbaldehyde No. 89: 2-[5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4- dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxyphenoxy]acetamide No. 90: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(3-hydroxy-4-methoxybenzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 91: 4-[3-(3,4-dimethoxybenzyl)-6-ethoxy-2,4-dioxo-3,4-dihydroquinazolin-1(2H)- yl]piperidine-1 -carbaldehyde No. 97: 4-[5,7-dichloro-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin- 1(2H)-yl]piperidine-1-carbaldehyde No. 102: 4-[7-chloro-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin- 1(2H)-yl]piperidine-1-carbaldehyde No. 108: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(3-fluoro-4-methoxybenzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 111: 4-[6-(difluoromethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1 -carbaldehyde No. 112: 4-[3-(3,4-dimethoxybenzyl)-6-(1-methylethoxy)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 114: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-methoxy-3-(1- methylethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 116: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-methoxybenzyl)-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 117: 4-{3-[3,5-bis(trifluoromethyl)benzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]- 2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 118: 4-[3-(3-ethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4- dihydroquinazolin-1 (2H)-yl]piperidine-1 -carbaldehyde No. 124: 4-{3-[3-chloro-4-(2-methoxyethoxy)benzyl]-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}pipericline-1 -carbaldehyde No. 130: 4-[3-(3,4-diethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo- 3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 131: 4-[3-(4-ethoxy-3-methoxybenzyl)-6-t2-fluoro-1 -(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 133: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(4-methoxy-3-methylbenzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 134: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4- (trifluoromethyl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 135: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4- (trifluoromethyl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 143: 4-{3-[4-(benzyloxy)-3-methoxybenzyl]-6-[2-fluoro-1 -(fluoromethyl)ethoxy]- 2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 145: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(3-methoxy-4-nitrobenzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 155: 4-[3-(4-ethoxybenzyl)-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3,4- dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 158: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[4-(morpholin-4-ylmethyl)benzyl]- 2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 160: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(4-(morpholin-4-yl)benzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 165: 4-[3-(biphenyl-4-ylmethyl)-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo- 3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 166: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[4-(methylsulphanyl)benzyl]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 167:4-{6-t2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyridin-3-yl)benzyl)- 3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 170:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-methoxy-4-methylbenzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 175:2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]acetamide No. 178: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(3-methoxy-4-propoxybenzyl)-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 183: 2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1-(1 - formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N- methylacetamide No. 184: 2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N,N- dimethylacetamide No. 185: 2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 - formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N- methoxy-N-methylacetamide No. 186: 4-{3-[4-(cyclopentyloxy)-3-ethoxybenzyl]-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 188: 4-{3-[4-(cyclopentyloxy)-3-(1-methylethoxy)benzyl]-6-t2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 189: 4-{3-[4-(cyclopentyloxy)-3-propoxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 190: 4-{3-[4-(cyclopentyloxy)-3-hydroxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 193: 4-{3-[4-(difluoromethoxy)-3-methoxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 194: 4-{3-[4-(difluoromethoxy)-3-ethoxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 200: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(thiophen-3-yl)- benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 201: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyridin-4-yl)benzyl)- 3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 203: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(1-methyl-1 H-indol-6-yl)methyl]- 2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 206: 4-{3-[4-(cyclopropylmethoxy)-3-methoxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 207:2-[4-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4- dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxyphenoxy]-N-methylacetamide No. 212:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4-(1H-pyrazol-1- yl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 213: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyridin-2-yl)benzyl)- 3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 215: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(thiophen-2-yl)- benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 216: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(quinolin-7-ylmethyl)- 3,4-dihydroquinazolin-1 (2H)-yl}piperidine-1 -carbaldehyde No. 218: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(6-methoxynaphthalen-2- yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 223: 4-{3-[4-(1 H-benzimidazol-1-yl)benzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]- 2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 224: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[3-methoxy-4-(2- methylpropoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 226: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[3-methoxy-4-(tetrahydrofuran-3- yloxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 228: 4-[3-{4-[(1 -benzylpyrrolidin-3-yl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoromethyl)6thoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 230: 4-[3-(1 -benzothiophen-5-ylmethyl)-6-[2-fluoro-1 -(fluorometrtyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 232: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4-(1 - methylethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 233: 4-[3-(3,4-dimethoxybenzyl)-7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxyj- 2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 234:4-[3-{4-[(1-acetylpyrrolidin-3-yl)oxy]-3-nriethoxybenzyl}-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 239:4-[3-{4-[(4-fluorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 240: 4-[3-{4-[(4-chlorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 242: 4-[3-{4-[(3-chlorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoramethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 243: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(3-(thiophen-3- yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 245: 4-[3-(4-ethoxy-3-methoxybenzyl)-6-(2-hydroxyethoxy)-2,4-dioxo-3,4- dihydroquinazolin-1 (2H)-yl]piperidine-1 -carbaldehyde No. 246: 4-[3-{4-[2-(2,3-dihydro-1 H-indol-1-yl)-2-oxoethoxy]-3-methoxybenzyl}-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 250: 4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 251: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4-(2-oxo-2-(piperidin- 1-yl)ethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 254: 4-{3-[3-ethoxy-4-(thiophen-2-ylmethoxy)benzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 258: 4-[3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1 -(hydroxymethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 263:(2R)-2-t2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- forrnylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]propanoic acid No. 264: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(1-methyl-3-(thiophen-2-yl)-1 H- pyrazol-5-yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 270: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(5-methyl-1,2,4-oxadiazol-3- yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 275: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyrimidin-5- yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 276: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(1-methyl-3-phenyl-1 H-pyrazol-5- yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 278:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-{[6-(1H-pyrazol-1- yl)pyridin-3-yl]methyl}-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 279:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[(2-(thiophen-2- yl)pyrimidin-5-yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 280:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(1-methyl-1H-pyrazol-3- yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 282: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(3-methyl-1,2,4-oxadiazol-5- yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 283: t2-(cyclopentyloxy)-5-({6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 - formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazoliri-3(2H)-yl}methyl)phenoxy]aceticacid No. 285: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-(thieno[2,3-blpyridin-2- ylmethyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 286: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-[(6-phenylpyridin-3- yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 287: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[(6-(morpholin-4-yl)pyridin-3- yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 289: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-[(6-(thiophen-2- yl)pyridin-3-yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 292: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(1 -methyl-5-phenyl-1 H-pyrazol-3- yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 294: 4-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo- 1,4-dihydroquinazolin-3(2H)-yl}methyl)biphenyl-2-carbonitrile No. 295: (2R)-2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 - formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N- methylpropanamide No. 297: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(thiophen-2- yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 298: 4-{6-[2-fluoro-1 -(f luoromethyl)ethoxy]-3-[3-methoxy-4-(morpholin-4- ylmethyl)benzyl]-2,4-clioxo-3,4-dihydroquinazolin-1(2H)-yl}pipericline-1-carbalclehyde No. 299: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[3-methoxy-4-(piperidin-1 - ylmethyl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 300: 4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1- (fiuoromethyl)ethoxy]-2I4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 301: 2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N- ethylacetamide No. 302: (2S)-2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1 -(fluoromethyl)ethoxy]-1 -(1 - formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]propanoic acid No. 305: 4-{6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(3-methoxy-4-{[(3R)-2-oxo-1 - phenylpyrrolidin-3-yl]oxy}benzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 306: 4-{3-[4-(cyclobutylmethoxy)-3-methoxybenzyl]-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 307: 4-{3-[4-(benzyloxy)-3-methoxybenzyl]-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 308: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(4-hydroxy-3- methoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 309: 4-{3-[4-(cyclopropylmethoxy)-3-methoxybenzyl]-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 310: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[3-methoxy-4- (2-methylpropoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 311: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4- (1-methylethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 312: 4-[3-(4-ethoxy-3-methoxybenzyl)-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 315: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-{[6-(3- methoxyphenyl)pyridin-3-yl]rnethyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 316:4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-{[6-(2- fluorophenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 317: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-{[6-(4- fluorophenyl)pyridin-3-yl]methyl}-2,4-dioxo-3I4-dihyclroquinazolin-1(2H)-yl}pipericline-1- carbaldehyde No. 318:4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-{[6-(4- methoxyphenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 319: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[(6-(thiophen-2- yl)pyridin-3-yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 320: 4-{3-[3-ethoxy-4-(thiophen-2-ylmethoxy)benzyl]-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 321: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[4-(1 -methyl-1 H-pyrazol- 3-yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 322: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyrimidin-5- yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 323: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[(1 -methyl-3-(thiophen-2- yl)-1H-pyrazol-5-yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 324: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[3-methoxy-4-(2-oxo-2- (piperidin-1 -yl)ethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1 (2H)-yl}piperidine-1 - carbaldehyde No. 325: 4-[3-{4-[2-(2,3-dihydro-1 H-indol-1 -yl)-2-oxoethoxy]-3-methoxybenzyl}-7- fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)- yl]piperidine-1-carbaldehyde No. 326: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-[4-(5-methyl-1,2,4- oxadiazol-3-yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 327: 4-[3-{4-[(3-chlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 328:4-[3-{[6-(3,5-dichlorophenyl)pyridin-3-yl]methyl}-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde i No. 329: 4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)- 2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)biphenyl-2-carbonitrile No. 330: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3-[4-(1 H-pyrazol- 1 -yl)benzyl]-3,4-dihydroquinazolin-1 (2H)-yl}piperidine-1 -carbaldehyde No. 331: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-{[6-(3- fluorophenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 332:3-[5-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4- yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)pyridin-2-yl]benzonitrile No. 333: 4-[3-(3,4-diethoxybenzyl)-7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 334: 4-[3-{4-[(4-chloroben2yl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 335: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(morpholin-4- ylmethyl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 336: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-{[6-(1 H-pyrazol- 1-yl)pyridin-3-yl]methyl}-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 337: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(4-(morpholin-4-yl)- benzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 338: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-(3-methoxy-4- propoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 339:4-{3-[4-(1H-benzimidazol-1-yl)benzyl]-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 340: 5-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)- 2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxybenzonitrile No. 341: 3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- formylpiperidin-y4-dioxo-1.2.3.SAtetrahydroquinazoline-7-carbonitrile No. 342: 4-[3-(4-bromobenzyl)-7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 343:4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-(2-methoxyethoxy)benzyl}-7-fluoro-6- [2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 344: 4-{3-[4-(benzyloxy)benzyl]-7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-2,4- dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 345: 4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-ethoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 349:4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-(2-fluoroethoxy)benzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 350:4-[3-{4-[(2-chloro-4-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 351: 4-[3-{4-[(2,4-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 352:4-[3-{4-[(2-chloro-6-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 353: 4-[3-{4-[(2,6-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihyclroquinazolin-1(2H)-yl]pipericline-1-carbaldehyde No. 354: 4-[3-{4-[(2-chlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 355: 4-[7-fluoro-3-{4-[(2-fluorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 357: 2-[(3,4-dichlorobenzyl)oxy]-5-({7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]- 1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)benzonitrile No. 358: 4-[3-{4-[(3,4-dich!orophenoxy)methyl]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 360: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4-(2- phenylethyl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 362: 4-[3-{4-[(4,5-dichloro-2-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 369: 4-[3-{4-[(4-chlorophenoxy)methyl]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 371: 4-[3-{3-chloro-4-[(4-chlorobenzyl)oxy]-5-ethoxybenzyl}-7-fluoro-6-[2-fluoro- 1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 373: 4-[3-{3-chloro-4-[(2,4-dichlorobenzyl)oxy]-5-ethoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 375: 4-[7-fluoro-3-{4-[(4-fluorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 376: 4-[3-{4-[(3,5-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 377: 4-[3-(4-{[4-chloro-3-(trifluoromethyl)benzyl]oxy}-3-methoxybenzyl)-7- fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)- yl]piperidine-1 -carbaldehyde No. 379: 4-[3-{4-[(3-chlorophenoxy)methyl]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 380: 4-[3-{4-f(3,5-difluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-t2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 381:4-{3-[4-(benzyloxy)-3-methoxybenzyl]-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 382:4-[3-{4-t(3-chloro-5-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2- fiuorc-1 -(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1 (2H)-y!]piperidine-1 - carbaldehyde No. 383: 4-{7-fluoro-6-[2-f!uoro-1 -(fluoromethyl)ethoxy]-3-(3-methoxy-4-{[4- (trifluoromethyl)benzyl]oxy}ben2yl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 384: 4-[3-{4-[(2,5-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-t2-fluoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 385: 4-{[4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4- yi)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2- methoxyphenoxy]methyl}benzonitrile No. 386: 3-{[4-({7-fluoro-6-[2-fluoro-1-(fiuoromethyl)ethoxy]-1-(1-formylpiperidin-4- yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2- methoxyphenoxy]methyl}benzonitrile No. 387: 4-[3-{4-[(4-chloro-2-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 388: 4-[3-{4-[1-(3,4-dichlorophenyl)ethoxy]-3-methoxybenzyl}-7-fluoro-6-[2- fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1- carbaldehyde No. 389: 4-{7-fluoro-6-[2-fluoro-1 -(fluoromethyl)ethoxy]-3-{4-[(3-hydroxybenzy!)oxy]- 3-methoxybenzyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde No. 390: 4-[7-fluoro-3-{4-t(3-fluorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fIuoro-1 - (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 391:4-[3-{4-[(3,4-difluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1- (fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde No. 392:4-{3-[4-(5,6-dichloro-1H-benzimidazol-1-yl)-3-methoxybenzyl]-7-fluoro-6- [2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1- carbaldehyde No. 393:4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)- 2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenyl 3,4-dichlorobenzenesulphonate No. 394: 4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)- 2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxyphenyl 3,4-dichlorobenzene- sulphonate No. 403:3,4-dichloro-N-[4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1- formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2- methoxyphenyrjbenzamide; A subject-matter of the present invention is the use of compounds of formula (I) in the base, hydrate or solvate form or in the form of their mixtures, as medicaments or for the preparation of medicaments intended for the treatment of at least one cardiovascular disease and/or to prevent the appearance of at least one cardiovascular disease.